Quantitative Modeling in Toxicology
Quantitative Modeling in Toxicology Editors KANNAN KRISHNAN D´epartement de sant´...
158 downloads
2298 Views
7MB Size
Report
This content was uploaded by our users and we assume good faith they have the permission to share this book. If you own the copyright to this book and it is wrongfully on our website, we offer a simple DMCA procedure to remove your content from our site. Start by pressing the button below!
Report copyright / DMCA form
Quantitative Modeling in Toxicology
Quantitative Modeling in Toxicology Editors KANNAN KRISHNAN D´epartement de sant´e environnementale et sant´e au travail, Ecole de sant´e publique & Facult´e de m´edecine, Universit´e de Montr´eal, Montr´eal, Canada MELVIN E. ANDERSEN Program in Chemical Safety Sciences, The Hamner Institutes for Health Sciences, Research Triangle Park, NC, USA
A John Wiley and Sons, Ltd., Publication
This edition first published 2010 C 2010 John Wiley & Sons Ltd Registered office John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, United Kingdom For details of our global editorial offices, for customer services and for information about how to apply for permission to reuse the copyright material in this book please see our website at www.wiley.com. The right of the author to be identified as the author of this work has been asserted in accordance with the Copyright, Designs and Patents Act 1988. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher. Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic books. Designations used by companies to distinguish their products are often claimed as trademarks. All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. The publisher is not associated with any product or vendor mentioned in this book. This publication is designed to provide accurate and authoritative information in regard to the subject matter covered. It is sold on the understanding that the publisher is not engaged in rendering professional services. If professional advice or other expert assistance is required, the services of a competent professional should be sought. The publisher and the author make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of fitness for a particular purpose. This work is sold with the understanding that the publisher is not engaged in rendering professional services. The advice and strategies contained herein may not be suitable for every situation. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of experimental reagents, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each chemical, piece of equipment, reagent, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. The fact that an organization or Website is referred to in this work as a citation and/or a potential source of further information does not mean that the author or the publisher endorses the information the organization or Website may provide or recommendations it may make. Further, readers should be aware that Internet Websites listed in this work may have changed or disappeared between when this work was written and when it is read. No warranty may be created or extended by any promotional statements for this work. Neither the publisher nor the author shall be liable for any damages arising herefrom. Library of Congress Cataloging-in-Publication Data Quantitative modeling in toxicology / editors, Kannan Krishnan, Melvin E. Andersen. p. ; cm. Includes bibliographical references and index. Summary: “In Quantitative Modeling in Toxicology leading experts outline the current state of knowledge on the modeling of dose, tissue interactions and tissue responses. Each chapter describes the mathematical foundation, parameter estimation, challenges and perspectives for development, along with the presentation of a modeling template. Additionally, tools and approaches for conducting uncertainty, sensitivity and variability analyses in these models are described”–Provided by publisher. ISBN 978-0-470-99809-0 (cloth) 1. Toxicology–Mathematical models. I. Krishnan, Kannan, 1961- II. Andersen, Melvin E. [DNLM: 1. Toxicology–methods. 2. Environmental Exposure–adverse effects. 3. Hazardous Substances–toxicity. 4. Models, Biological. 5. Toxicity Tests–methods. QV 602 Q13 2010] RA1199.4.M37Q36 2010 615.9001 5118–dc22 2009045991 A catalogue record for this book is available from the British Library. ISBN 978-0-470-99809-0 Typeset in 10/12pt Times by Aptara Inc., New Delhi, India. Printed and bound in Great Britain by CPI Antony Rowe, Chippenham, Wiltshire. The figure on the front cover, showing the “cusp catastrophe surface” for a biological feedback loop, illustrates the dynamic behavior for different selections of binding affinities. Steady-state values for the interacting proteins are plotted against respective binding affinities. The arrow indicates those sets of affinities where an abrupt, discrete transition would be observed, as expected for processes such as cellular differentiation. The region of the surface “under the fold” represents the parameter range where the system is bistable. The reader is referred to Chapter 10 for further discussion of this behavior.
Contents
Preface About the Editors About the Book List of Contributors
ix xi xiii xv
SECTION 1 INTRODUCTION 1
Quantitative Modeling in Toxicology: An Introduction Melvin E. Andersen and Kannan Krishnan
3
SECTION 2 PHYSIOLOGICALLY-BASED TOXICOKINETIC AND PHARMACOKINETIC (PBPK) MODELING 2
PBPK Modeling: A Primer Kannan Krishnan, George D. Loizou, Martin Spendiff, John C. Lipscomb and Melvin E. Andersen
21
3
Pharmacokinetic Modeling of Manganese – An Essential Element Andy Nong, Michael D. Taylor, Miyoung Yoon, and Melvin E. Andersen
59
4
Physiologically Based Modeling of Pharmacokinetic Interactions in Chemical Mixtures Sami Haddad, Robert Tardif, Jonathan Boyd, and Kannan Krishnan
5
Physiological Parameters and Databases for PBPK Modeling Douglas O. Johns, Elizabeth Oesterling Owens, Chad M. Thompson, Babasaheb Sonawane, Dale Hattis and Kannan Krishnan
83
107
SECTION 3 MODELING TOXICANT-TARGET INTERACTIONS 6
Modeling Cholinesterase Inhibition Charles Timchalk, Paul M. Hinderliter, and Torka S. Poet
137
vi
Contents
7
Modeling of Protein Induction and Dose-Dependent Hepatic Sequestration Andy Nong and Melvin E. Andersen
167
8
Bistable Signaling Motifs and Cell Fate Decisions Sudin Bhattacharya, Qiang Zhang, and Melvin E. Andersen
181
9
Ultrasensitive Response Motifs in Biochemical Networks Qiang Zhang, Sudin Bhattacharya, Courtney G. Woods, and Melvin E. Andersen
199
10 Gene and Protein Expression – Modeling Nested Motifs in Cellular and Tissue Response Networks Melvin E. Andersen, Qiang Zhang, and Sudin Bhattacharya 11 Modeling Liver and Kidney Cytotoxicity Kai H. Liao, Yei M. Tan, Harvey J. Clewell III, and Melvin E. Andersen
219
235
SECTION 4 MODELING TISSUE AND ORGANISM RESPONSES 12 Computational Model for Iodide Economy and the HPT Axis in the Adult Rat Jeffrey W. Fisher and Eva D. McLanahan 13 Two-Stage Clonal Growth Modeling of Cancer Rory B. Conolly and Melvin E. Andersen 14 Statistical and Physiological Modeling of the Toxicity of Chemicals in Mixtures Hisham A. El-Masri, Michael A. Lyons, and Raymond S.H. Yang 15 (Q)SAR Models of Adverse Responses: Acute Systemic Toxicity Mark T.D. Cronin, Yana K. Koleva, and Judith C. Madden
253
269
283
299
SECTION 5 MODEL APPLICATION AND EVALUATION 16 Modeling Exposures to Chemicals From Multiple Sources and Routes Panos G. Georgopoulos, Sastry S. Isukapalli, and Kannan Krishnan 17 Probabilistic Reverse Dosimetry Modeling for Interpreting Biomonitoring Data Yu-Mei Tan and Harvey J. Clewell III
317
353
Contents
18
Quantitative Modeling in Noncancer Risk Assessment Q. Jay Zhao, Lynne Haber, Melissa Kohrman-Vincent, Patricia Nance, and Michael Dourson
19
Application of Physiologically Based Pharmacokinetic Modeling in Health Risk Assessment Harvey J. Clewell III
20
Uncertainty, Variability, and Sensitivity Analyses in Simulation Models Sastry S. Isukapalli, Martin Spendiff, Panos G. Georgopoulos and Kannan Krishnan
21
Evaluation of Quantitative Models in Toxicology: Progress and Challenges Kannan Krishnan and Melvin E. Andersen
Index
vii
371
399
429
459
477
Preface
The goal of most toxicology studies is to help reach some conclusion about likely risks posed to humans or to other species from chemical exposures. Test results, both from in vivo and in vitro studies, require various forms of extrapolation to make risk predictions for specific exposures and in specific populations. Over the past 50 to 60 years, a variety of modeling tools have emerged that help in describing toxicological processes quantitatively and in making these extrapolations. These quantitative models have substantially improved our understanding of human exposure, pharmacokinetics, mode of action and toxic responses associated with chemicals. In recent years, toxicology, as true for other biological disciplines, has also been enriched by the new tools from genomic biology and by the increasing emphasis on computational systems biology for describing cell and tissue function. The opportunity now exists for toxicology to transition from a qualitative science cataloging responses in various animal species to a discipline capable of quantitatively describing key mechanistic processes that determine dose-response behaviors for animal and human responses. Quantitative modeling in toxicology includes approaches that simulate (i) exposure and disposition of chemicals in the body, (ii) biochemical interaction between toxic moiety and target tissues, (iii) molecular and cellular alterations emanating from the initial interactions; and (iv) adverse responses at the organ or organism level. Properly developed, these quantitative mechanistic models can provide unambiguous, testable statements of working hypotheses regarding chemical uptake, biochemical interactions, and the initiation and progression of toxicity in the exposed organism. Integration of quantitative tools within experimental design, data collection and analysis as well as risk assessment applications is more important than ever. Specifically, these tools are important (i) for conducting scientifically sound extrapolations of dosimetry and responses for risk assessment purposes, (ii) for refining/reducing animal use in toxicology studies by facilitating the development of new, novel and efficient experiments, and (iii) for creating a framework with which to integrate the various observations (exposure, dose, mechanism, response) at a quantitative level. Despite the growth in interest in these quantitative models in toxicology, there are few resources to serve as a guide in learning more about these tools. The two of us, along with other colleagues, have taught modeling courses at our respective institutions through lectures and computer demonstrations. In these courses, we have also felt the need for a concise overview of quantitative modeling in toxicology and began discussions leading to this book. Quantitative Modeling in Toxicology now brings together contributions from key scientists on the modeling of exposure, tissue dose, tissue interaction and toxicological responses. Chapters 2-5 describe the quantitative models of pharmacokinetics of individual chemicals
x
Preface
and mixtures. Chapters 6 through11 describe models for toxicant-target tissue interaction. Chapters 12 through 15 describe models for cellular, organ, and organism responses. The simulation models of toxic effects based on the toxicant-target interaction models and mode of action information are highlighted with specific examples. Finally, Chapters 16 through 21 present the approaches, tools and challenges regarding the application and evaluation of quantitative models for exposure and risk assessments. Based on the breadth of the material in these chapters, this book should serve as an initial reference for toxicologists and risk assessors who are interested in developing quantitative models for a better understanding of dose-response relationships. The process of simulation modeling requires writing computer code to represent the biological systems and the consequences of exposure. The models are written in a computer language and then solved by numerical integration. The examples throughout the book use a variety of commercial software, including ACSLC , BERKELEY MADONNAC , MATLABC , EXCELC and MEGenC . We do not endorse any particular software and did not require our contributors to use any particular software. In general, the source code developed in one language can be easily recoded into alternative language. Code for running various models in the book have been included in specific chapters and made available for download from the publisher. The text files for these models are intended to assist the interested reader in developing models for their own use or for use for instruction. We would appreciate comments from our readers about the value of these models for learning more about quantitative modeling in toxicology. Needless to say, the completion of this work was in large part due to our group of talented authors. Thanks to all! We also thank Richard Davies of Wiley for his enthusiasm and cooperation throughout this project as well as Michelle Gagn´e and Mathieu Valcke of Universit´e de Montr´eal for editorial assistance. KK and MEA
About the Editors . . .
Kannan Krishnan, PhD, DABT, FATS is Professor of Occupational and Environmental Health at Universit´e de Montreal and Director of the Inter-University Toxicology Research Center (CIRTOX), Montreal, Canada. An expert in the areas of PBPK modeling, chemical mixture toxicology and health risk assessment methods, Dr. Krishnan has held visiting scientist/faculty appointments at the Karolinska Institutet, Sweden (2004), Toxicology Excellence for Risk Assessment (TERA, Cincinnati, OH) (2007) and Environmental & Occupational Health Sciences Institute of UMDNJ-Rutgers University, NJ (2007). He received the Veylian Henderson Award of the Society of Toxicology of Canada (2000) and the SOT Board of Publications Award for the best paper in Toxicological Sciences (2003) for a land-mark publication on the PBPK modeling of metabolic interactions and health risk assessment of chemical mixtures. He was a significant contributor to the U.S. EPA report “Approaches for the Application of Physiologically Based Pharmacokinetic (PBPK) Models and Supporting Data in Risk Assessment” (2006) and IPCS/WHO guidance document “Characterization and application of PBPK models in support of risk assessment” (2010). Melvin Ernest Andersen, PhD, DABT, CIH, FATS is Director, Program in Chemical Safety Sciences at The Hamner Institutes for Health Research, Research Triangle Park, NC, U.S.A. He is reknown for his career contributions in developing quantitative models of the dosimetry and effects of drugs and toxic chemicals as well as applying these models in safety assessments and quantitative health risk assessments, Through short-courses in quantitative modeling in toxicology, Dr Andersen has trained several hundred toxicologists and risk assessors in quantitative modeling. An author or a co-author of 325 papers and 60 book chapters, he has received several awards for professional contributions; including the Herbert Stokinger Award (American Conference of Industrial Hygienists, 1988), the
xii
About the Editors . . .
Kenneth Morgareidge Award (International Life Sciences Institute, 1989), the George Scott Award (Toxicology Forum, 1993), and the Frank R. Blood (1982), Achievement (1984), and Arnold J. Lehman (2004) Awards from the Society of Toxicology. Recognized as a ‘highly cited’ scientist by the Institute for Scientific Information (June 2002), Dr. Andersen co-edited a 2005 book, “Physiologically Based Pharmacokinetics: Science and Applications”.
About the Book . . .
Quantitative modeling in toxicology is a must-read for those interested in computer simulation of the biological fate and effects of chemicals. It brings together a diverse group of experts in this area to provide the reader with the current state of knowledge regarding the modeling of dose, tissue interactions and tissue responses. Additionally, tools and approaches for model evaluation and application are described. Access to an electronic MODEL LIBRARY containing the source code for several dosimetry, toxicant interaction and toxicity models is included with the book in order to allow the interested reader to reconstruct the examples in the various chapters. This book will be of particular interest to graduate students, practicing toxicologists and risk assessors who are fascinated by the application of quantitative modeling approaches to simulate perturbations of biological systems upon exposure to xenobiotics.
List of Contributors
Melvin E. Andersen Program in Chemical Safety Sciences, The Hamner Institutes for Health Sciences, Research Triangle Park, NC, USA Sudin Bhattacharya Division of Computational Biology, The Hamner Institutes for Health Sciences, Research Triangle Park, NC, USA Jonathan Boyd C Eugene Bennett Department of Chemistry, West Virginia University, Morgantown, WV, USA Harvey J. Clewell III Center for Human Health Assessment, The Hamner Institutes for Health Sciences, Research Triangle Park, NC, USA Rory B. Conolly Integrated Systems Toxicology Division, National Health and Environmental Effects Research Laboratory, Office of Research and Development, US Environmental Protection Agency, Research Triangle Park, NC, USA Mark T.D. Cronin School of Pharmacy and Chemistry, Liverpool John Moores University, Byrom Street, Liverpool, England Michael L. Dourson
Toxicology Excellence for Risk Assessment, Cincinnati, OH, USA
Hisham A. El-Masri Integrated Systems Toxicology Division, National Health and Environmental Effects Research Laboratory, US EPA, Research Triangle Park, NC, USA Jeffrey W. Fisher
College of Public Health, University of Georgia, Athens, GA, USA
Panos G. Georgopoulos Computational Chemodynamics Laboratory, Environmental and Occupational Health Sciences Institute (EOHSI), Piscataway, NJ, USA Lynne T. Haber
Toxicology Excellence for Risk Assessment, Cincinnati, OH, USA
Sami Haddad D´epartement des sciences biologiques, Centre TOXEN, Universit´e du Qu´ebec a` Montr´eal, Montr´eal, Qu´ebec, Canada Dale Hattis Marsh Institute Center for Technology, Environment and Development, Clark University, Worcester, MA, USA
xvi
List of Contributors
Paul M. Hinderliter Center for Biological Monitoring and Modeling, Pacific Northwest National Laboratory, Richland, WA, USA Sastry S. Isukapalli Computational Chemodynamics Laboratory, Environmental and Occupational Health Sciences Institute (EOHSI), Piscataway, NJ, USA Douglas O. Johns National Center for Environmental Assessment, US Environmental Protection Agency, Research Triangle Park, NC, USA Melissa J. Kohrman-Vincent OH, USA
Toxicology Excellence for Risk Assessment, Cincinnati,
Yana K. Koleva School of Pharmacy and Chemistry, Liverpool John Moores University, Byrom Street, Liverpool, England Kannan Krishnan Groupe de recherche interdisciplinaire en sant´e et D´epartement de sant´e environnementale et sant´e au travail, Universit´e de Montr´eal, Montr´eal, Canada Kai H. Liao Drug Safety and Metabolism, Wyeth Research, Pearl River, NY, USA John Lipscomb National Center for Environmental Assessment, US Environmental Protection Agency, Cincinnati, OH, USA George Loizou Computational Toxicology Section, Health and Safety Laboratory, Buxton, United Kingdom Michael A Lyons Quantitative and Computational Toxicology Group, Colorado State University, Fort Collins, CO, USA Judith C. Madden School of Pharmacy and Chemistry, Liverpool John Moores University, Byrom Street, Liverpool, England Eva D. McLanahan Patricia M. Nance
College of Public Health, University of Georgia, Athens, GA, USA Toxicology Excellence for Risk Assessment, Cincinnati, OH, USA
Andy Nong The Hamner Institutes for Health Sciences, Research Triangle Park, NC, USA. Current address: Health Canada, Ottawa, Ontario, Canada Elizabeth Oesterling Owens Postdoctoral Fellow, Oak Ridge Institute for Science and Education, National Center for Environmental Assessment, US Environmental Protection Agency, Research Triangle Park, NC, USA Torka S. Poet Center for Biological Monitoring and Modeling, Pacific Northwest National Laboratory, Richland, WA, USA
List of Contributors
xvii
Babasaheb Sonawane National Center for Environmental Assessment, US Environmental Protection Agency, Washington, DC, USA Martin Spendiff Computational Toxicology Section, Health and Safety Laboratory, Buxton, United Kingdom Yu-Mei Tan Center for Human Health Assessment, The Hamner Institutes for Health Sciences, Research Triangle Park, NC, USA Robert Tardif Groupe de recherche interdisciplinaire en sant´e, D´epartement de sant´e environnementale et sant´e au travail, Universit´e de Montr´eal, Montr´eal Canada Michael D. Taylor
Environmental Science, Afton Chemical Corp., Richmond, VA, USA
Chad M. Thompson National Center for Environmental Assessment, U.S. Environmental Protection Agency, Washington, DC, USA; Present address: ToxStrategies, Houston, TX, USA Charles Timchalk Center for Biological Monitoring and Modeling, Pacific Northwest National Laboratory, Richland, WA, USA Courtney G. Woods Division of Computational Biology, The Hamner Institutes for Health Sciences, Research Triangle Park, NC, USA Raymond S. H. Yang Quantitative and Computational Toxicology Group, Colorado State University, Fort Collins, CO, USA Miyoung Yoon Division of Computational Biology, The Hamner Institutes for Health Sciences, Research Triangle Park, NC, USA Qiang Zhang Division of Computational Biology, The Hamner Institutes for Health Sciences, Research Triangle Park, NC, USA Q. Jay Zhao U.S. Environmental Protection Agency, Office of Research and Development, National Center for Environmental Assessment, Cincinnati, OH, USA
Section 1 Introduction
1 Quantitative Modeling in Toxicology: An Introduction Melvin E. Andersen1 and Kannan Krishnan2 1
2
The Hamner Institutes for Health Sciences, USA D´epartement de sant´e envrionnementale et sant´e au travail, University of Montreal, Canada
1.1 Introduction 1.1.1
Models and Modeling – Definitions
Models are simplified representations of a system with the intent of reproducing or simulating the structure, function or behavior of the system. Depending upon the goal, the models can be physical, conceptual, or mathematical. The mathematical models, also referred to as quantitative models, correspond to one or more equations whose solution provides the timespace evolution of the state variable (Bellomo and Preziosi, 1995). Quantitative modeling is, therefore, the process of developing mathematical descriptions of the interrelationships among input parameters in order to adequately simulate the system behavior (i.e., generate model output). The quantitative models can be classified in a number of ways. For example: r Discrete or continuous r Deterministic or stochastic r Empirical or mechanistic. A quantitative model is discrete if the state variable does not depend upon the time variable (Bellomo and Preziosi, 1995); the continuous or dynamic models describe the change in state variable over time. A model is deterministic if its outcome is a direct consequence of Quantitative Modeling in Toxicology C 2010 John Wiley & Sons, Ltd
Edited by Kannan Krishnan and Melvin E. Andersen
4
Quantitative Modeling in Toxicology: An Introduction
the initial conditions, not influenced by any random factors; it is stochastic or probabilistic when some or all features of the model capture a random behavior. The empirical or data based models correspond to equations that emulate the observed data. These models require no prior knowledge of the system but require that both the input and output be known a priori. An example of this kind of models is the one-compartmental pharmacokinetic model, which describes the relationship between the blood concentration at any time t (Ct ) as a function of initial concentration (Co ) and elimination rate (k): Ct = Co e−kt The mechanistic models are based on “first principles” or key mechanisms of the process of interest. Here, the compartments mimic system elements and the equations describe the quantitative relationship among system elements or key parameters to generate predictions of system behavior. Many simulation models in practice, however, may consist of mechanistic and empirical components. The motivation for the use of quantitative simulation models in toxicology is related to one or more of the following needs (Andersen, Clewell, and Frederick, 1995): r r r r r r r r r
Organize and codify facts and beliefs. Expose contradictions in existing data/beliefs. Explore implications of beliefs about the system. Expose serious data gaps. Predict response under new conditions. Predict parameter values for “inaccessible” parameters. Identify essentials of system structure. Provide representation of current state of knowledge. Suggest and prioritize new research.
In the follow section, a short review of chemical risk assessment is provided to help understand the motivation for developing quantitative systems modeling in toxicology.
1.1.2 Evolution of Chemical Risk Assessment To a large extent, the development of quantitative modeling tools in toxicology parallels the increasingly sophisticated understanding of modes of action of toxic chemicals in the body and the desire to apply this information to improve quantitative chemical risk assessment. In this regard, mode of action represents the nature of the initial interactions between a toxic compound and the biological system, and the steps that ensue from this interaction leading to adverse downstream consequences for the organism. Initially, little information on modes of action was available. In safety assessments in the 1950s for instance, animal toxicity test results were used to determine No-Observed Effect Levels (NOELs). The US Food and Drug Administration (FDA) derived acceptable daily intakes (ADIs) by dividing animal NOELs by 100 (Lehman and Fitzhugh, 1954). The factor of 100 consisted of two safety factors of 10 each, intended in a general way to account for (1) differences in sensitivity of humans compared to animals and (2) variation in sensitivity of individuals in a heterogeneous human population compared to more homogeneous sensitivity in inbred
Introduction
5
animal stains. These ADIs were usually established based on organ or organism level responses that were clearly adverse to health. An underlying premise in this approach was the existence of a threshold dose, that is, the belief that there were concentrations or exposure levels below which the risk of adverse health effects was zero. The dose measure for these evaluations was administered dose, for example, ppm in air or food or mg/kg for orally administered materials. The 1970s brought a focus on the biology of cancer and a shift of testing and research resources in toxicology toward chemical carcinogenesis (Albert, Train, and Anderson, 1977). Animal studies provided information of the incidence of tumors at specific doses in test animals, usually rats and mice. Two extrapolations were introduced: one predicted the shape of the dose-response curve at low levels of response; the second adjusted the expected responses for different species. The low dose extrapolation used a mathematical model of carcinogenesis, the linearized multistage (LMS) model. This model predicted some probability of increased cancer incidence at every dose, no matter how small. Interspecies extrapolation was calculated on a surface area adjustment for dose. This body surface extrapolation regarded humans as more sensitive to toxic responses than the smaller rodent species. The concept of dose was initially refined by toxicologists who borrowed methods from the field of clinical pharmacokinetics (PK) to assess the relationship between exposure, sometimes called administered dose, and the concentrations of active chemical/metabolites at target tissues. The initial emphasis on pharmacokinetic modeling in toxicology arose mainly due to the high doses used in many animal tests, doses at which capacity limited processes, that is, metabolism, tubular excretion in kidney, and so on, became saturated. Work with vinyl chloride carcinogenesis showed a better relationship between metabolized dose of this compound and liver cancer rather than a correspondence with inhaled concentration (Watanabe and Gehring, 1976). The 1980s provided other important developments that would shape the need for quantitative modeling tools. Among them were increasing use of in vitro cell systems for assessing chemical interactions in living cells and the first applications of molecular techniques emerging from the new field of molecular biology. Receptor-mediated toxicity, such as dioxin interactions with the Ah receptor, gained prominence. Another advance was the increasing sophistication applied to assessing how chemicals caused their effects – the mode of action of chemicals in biological systems. These contributions provided pressure to apply this growing information in some manner to improve the scientific basis of chemical risk assessment.
1.1.3
Risk Assessment Guidance
A seminal publication (NRC, 1983) proposed a set of consistent “inference guidelines” for use by federal regulatory agencies in the risk assessment process. Called “The Red Book,” because of the color of the cover, an emphasis was placed on the need to separate the scientific and the policy aspects of risk assessment. Risk assessment was defined as: “the use of the factual data base to define the health effects of exposures of individuals or populations to hazardous materials or situations.” It organized the risk assessment processes into four areas. Hazard identification is the determination of the effects of the chemical in
6
Quantitative Modeling in Toxicology: An Introduction
exposed animals or people. Dose-response assessment evaluates the exposure conditions under which these effects are observed. Exposure assessment estimates the amounts of the chemical present in the workplace, home, and general environment. The fourth component, risk characterization combines information on the exposure and dose-response assessment to estimate the risk level for specific individuals, groups, or populations. Various default methods are used in risk and safety assessments. These defaults are used to circumvent lack of detailed knowledge of the shape of the dose-response curve. In general, these policydriven defaults are designed to provide a conservative basis for estimating likely risks in exposed humans. This conservatism reflects an attempt to ensure adequate protection of members of the population in the absence of knowledge. The reliance on these defaults could be reduced by improved understanding of the shape of the dose-response curve in regions of low incidence. The major role of quantitative systems modeling in risk assessment is for enhancing dose-response assessment and in assisting in the various extrapolations, especially in understanding the biological factors that determine the shape of dose-response curves for adverse responses at low levels of incidence, that is, in regions of the dose-response curve where the probability of response in a population is small, and between animal species. The quantitative relationships among these biological factors are determinants of incidence-dose relationship for toxic responses. Mathematical models of various kinds can integrate this biological information to predict (calculate) incidence for various exposure situations. These models need to be developed in such a fashion to be concordant with biology and the chemistry of the compound in the biological system.
1.1.4
Quantitative Models in Risk Assessment
Both qualitative and quantitative inputs are required in the process of conducting safety/risk assessments. The qualitative studies are important for cataloging information about: (i) hazard, that is, the possible effects of a compound irrespective of exposure considerations; (ii) mode-of-action; (iii) progression, that is, the steps connecting initial interactions on to impaired function; and, (iv) susceptibility, that is, the inter-individual differences that may make any one person more affected by exposure than another (e.g., gender, age, genetics, pre-existing disease). Dose-response models were developed in the 1930s to assess responses in a population of animals treated with chemical, such as efforts to estimate the lethal dose in 50% of an exposed population (the LD50) or the effective dose for some response in 50% of the population, the ED50. Here a tolerance distribution depicted a quantal “either–or” response of individuals to chemical treatments. Incidence (number responding divided by number treated), either as a frequency distribution or as a cumulative response, was plotted against dose. In incidence-dose (ID) models, each member of the population has some dose sensitivity at which they respond to the test compound, and the “sensitivity” of individuals is considered to be distributed normally or log normally with tissue dose (Figure 1.1). In these analyses, the sensitivity of individuals and the variability in the population are estimated from the ID relationship, not from the underlying chemistry that describes delivery of chemical to target tissues or from the biology of the interactions of the chemical with specific cellular targets. This level of detail was unattainable in the 1930s; it is attainable in the twenty-first century.
Frequency
1.0
0.0
Cumulative
Frequency
7
Cumulative Probability
Introduction
Tissue Dose of Chemical
Figure 1.1 Biological responses were initially described by tolerance distributions within a population. Incidence-dose curves were generated by assuming that each individual in the population had some sensitivity or tolerance for expressing the biological responses. The frequency distribution for the response was the proportion of the population responding to a given tissue dose; the cumulative curve integrated the response from zero (no individual in the population had responded) to 1.0 (all members of the population had responded). In this figure, the distribution is represented as a log normal distribution, with skewing of the distribution towards high doses when plotted on a linear dose scale, as shown here. Andersen et al. (2005a), reprinted with permission from Elsevier. Copyright 2005.
Quantitative models have been developed to predict the relation between exposure and tissue dose (i.e., to describe the delivery of test molecule/metabolites to target tissues) and between tissue dose and tissue response (i.e., to describe the manner in which the molecular and cellular interactions of toxic compounds cause perturbations that are sufficiently large and sufficiently prolonged to lead to an adverse response). The broad categorization of these models breaks down into pharmacokinetic (PK) models for dosimetry and pharmacodynamic (PD) models for response. Pharmacokinetics has broadly been defined as what the body does to the compound; pharmacodynamics is what the compound does to the body. In order to be confident in the predictions/calculation from any model structure, these models themselves need to be as biologically realistic as possible without adding extraneous detail. Physiologically based (PB) models, such as physiologically based pharmacokinetic (PBPK) and physiologically based pharmacodynamic (PBPD) models, tend to be more firmly grounded in principles of biology and biochemistry (Reddy et al., 2005) than are conventional, compartmental models. Biologically based dose-response (BBDR) models predict expected incidence of adverse responses for varied exposure situations and, by their nature, combine PBPK and PBPD approaches. These model structures can provide important tools for improving risk and safety assessments. Starting in the 1980s there was considerable activity to create BBDR models for organism responses, including cancer and reproductive toxicity. These approaches had structures where dose led to alterations in cell growth, cell death, and mutation. Less detail was provided about the manner in which test chemicals altered cellular responses leading to the macroscopic changes in cell growth, differentiation, and mutation. Over the past decades with the growth of tools in cell and molecular biology, we now have the ability to query components of cellular, organ, and organism-level processes with exquisite detail, taking advantage of various new technologies, broadly referred to as “omics,” including components of genes, gene products, proteins, and various small molecules. This diverse
8
Quantitative Modeling in Toxicology: An Introduction
array of data, however, needs to be organized quantitatively to create information, that is, to discover how the parts of the system are organized and controlled both in time and in space to provide biological functions, and how chemical exposures may perturb these functions. In this regard, “systems approaches” represent the attempt to quantitatively organize information across multiple levels of biological organization to unravel the manner in which biological functions are produced from simpler molecular, cellular, and organ interactions. 1.1.5 Systems Approaches in Pharmacokinetics Compartments in PBPK models correspond to discrete tissues or to groupings of tissues with appropriate volumes, blood flows, and pathways for metabolism of test chemicals (Bischoff and Brown, 1966; Leung, 1991). Pertinent biochemical and physicochemical constants for metabolism and solubility are included in each compartment with routes of dosing described maintaining the proper relationship between the dosing site and the overall physiology of the portal of entry. The time-course behaviors of chemical throughout the body are then accounted for by equations that form the basis of the PBPK model and permit introduction of multiple routes, if necessary, for specific exposure situations. PBPK models have developed for a wide variety of compounds, associated with diverse toxicological outcomes (Reddy et al., 2005). PBPK modeling is an example of a systems approach applied at the level of cells, organs, and organisms to integrate the mechanisms of distribution and interactions of environmental chemicals and drugs in the body. Two chemical engineers, Drs Kenneth Bischoff and Robert Dedrick, who first incorporated engineering principles, physiology, chemistry, and biochemistry into a computer modeling platform to predict kinetics (Bischoff et al., 1971; Dedrick, 1973) are generally credited with being the pioneers in use of contemporary PBPK modeling. These PBPK models do integrate information across multiple levels of organization, especially when describing the interactions of compounds with molecular targets, processes that include reversible binding of ligands to specific receptors, for example, methotrexate (Bischoff et al., 1971) or dioxin (Leung et al., 1990) and the adduction of proteins or DNA by reactive parent chemicals or their metabolites in various tissues, for example, ethylene oxide (Krishnan et al., 1992) or acrylonitrile (Gargas et al., 1995). The goal in PBPK modeling is to integrate molecular, cellular, organ level, and organism-level processes to account for the time-courses of chemicals, metabolites, and bound complexes within multiple organs in the body. To a large extent, the main emphasis with these PBPK models is to account for the major determinants of the distribution and elimination of compounds without describing every physical chemical process involved in transport and storage of chemical in every tissue. Following the law of parsimony, making the model only as complex as possible for its intended use requires purposeful simplification in model construction. Increasing levels of detail in specific tissues can always be included in these models as more information becomes available on chemical disposition from specific experiments. In the early application of PBPK modeling with environmental chemicals, for instance, many examples were quickly discovered where the kinetics were of necessity linked to dynamics. With methylene chloride, a metabolite, carbon monoxide, binds heme proteins and this interaction had to be taken into consideration (Andersen et al., 1991). Other examples included dioxin inducing a dioxin-binding protein in liver (Leung et al., 1990; Kohn et al.,
Linking Doses and Response
9
1993), ethylene dichloride depleting glutathione, thereby altering conjugation rates with the parent compound (D’Souza, Francis, and Andersen, 1988), and trans-dichloroethylene acting as a suicide inhibitor to reduce rates of oxidative metabolism (Lilly et al., 1998). While adding a degree of complication to the PBPK description for these individual materials, the PBPK modeling approach was sufficiently versatile to accommodate these biological interactions and provide good descriptions of dose to target tissues for parent compounds and key metabolites. These models support calculation of measures of the concentrations of test chemicals and metabolites reaching target tissues in the body during various exposures (Gentry et al., 2002). They have been applied for both chemicals not normally found in the body (xenobiotics) and for chemicals found in the body that are toxic in conditions of excess or deficiency, such as the essential element, manganese (Nong et al., 2009). Risk assessment application has also required development of tools for variability, uncertainty, and sensitivity analysis (Allen, Covington, and Clewell, 1996; Clewell and Andersen, 1996; Clewell, 1995), and new technologies associated with Bayesian methods and Markov Chain Monte Carlo tools have appeared to assist in estimating parameters in these PBPK models. In addition, dose metrics derived from PBPK modeling are also commonly used in deriving benchmark values (Barton et al., 2000). These methods involve fitting a variety of empirical mathematical models to dose-response data to estimate a dose, with attendant confidence intervals, that is associated with predetermined benchmark response (BMR), for example, a 10% alteration in the target response (Allen, Covington, and Clewell, 1996).
1.2
Linking Doses and Response
To link exposure and outcome for toxic compounds, toxicology and risk assessment have focused on the exposure-dose-response relationship for the past 25 years (Figure 1.2). PBPK models provide greater detail on the steps up to tissue interactions, including binding of reactive molecules with cellular macromolecules or recognition of chemical structures by reversible binding of the xenobiotic to cellular receptors that regulate key cell signaling pathways. The measures of tissue dose that are more closely aligned with tissue responses are called dose metrics (Andersen, 1987). These measures are preferred as the basis for the dose-response portion of chemical risk assessment. The steps linking these dose metrics to
Figure 1.2 The Linear Exposure-Dose-Response Paradigm for Organizing Toxicology Research and Testing for Risk Assessment Applications as defined in the 1980s. Andersen et al. (2005b), reprinted with permission from Elsevier. Copyright 2005.
10
Quantitative Modeling in Toxicology: An Introduction
response are part of the pharmacodynamics (PD) of the response to chemical exposures. In this manner, dose metrics are the equivalent of a “biologically equivalent dose” (BED) and link active forms of the chemical at target tissues to the response of concern via the mode of action. Through the development of the PBPK modeling, tissue dose metrics have been linked with integrated cellular level responses, for example, cancer, cytotoxicity, and so on, to assist in risk assessments and guide various extrapolations (Clewell and Andersen, 1985). However, PD models have been more empirical, making use of simple effect compartments with responses correlated with blood or tissue concentrations of active chemical. Other PD approaches, called biologically based dose-response (BBDR) modeling, include two-stage clonal growth models for carcinogenesis and cell growth based models for developmental toxicology. These BBDR models were developed to assist with risk assessment (Moolgavkar and Luebeck, 1990; Leroux et al., 1996; Whitaker, Tran, and Portier, 2003). In these descriptions, adverse endpoints are a function of compound-related alterations in cell replication, apoptosis, and mutation rates. In general, the parameters in the BBDR models have not yet been described with respect to the effects of chemicals on specific cellular signaling pathways or the interactions among signaling pathways. 5-Fluorouracil (5-FU) is arguably the best example of a BBDR model for developmental toxicity where tissue concentrations are linked to enzyme inhibition, impaired nucleotide synthesis, altered DNA synthesis, and, finally, developmental anomalies (Lau et al., 2001; Setzer et al., 2001). As in all response models, a challenge with 5-FU is the difficulty in first providing an adequate description of the underlying biology that is being affected by the compound. The problem in describing biology is a particular issue for development where processes and structures are changing rapidly and consecutive developmental landmarks are critically dependent on completion of earlier steps.
1.2.1 Systems Biology and Dose-Response Assessment As noted earlier, PBPK models represent a “systems approach” to the physiological and biochemical levels. The ability to apply more integrated systems approaches to tissue response modeling has been seriously impeded by limited knowledge before the expansion of methods in cell molecular biology over the past two decades. These systems biology approaches integrate diverse data across various “omic” technologies and biological organization to understand how these various components lead to specific biological functions. Today, these high throughput, broad coverage technologies – such as, genomics, transcriptomics, proteomics, and metabonomics – are generating molecular “parts lists” for the components of cells, tissues, organs, and all the way to the organism level. In a perspective in Science at the turn of the millennium, Lander and Weinberg (2000) discussed the implications of the information generated by “genomics” technologies in providing a more complete understanding of biology: The long-term goal is to use this information to reconstruct the complex molecular circuitry that operates within the cell – to map out the network of interacting proteins that determines the underlying logic of various cellular biological functions including cell proliferation, responses to physiologic stresses, and acquisition and maintenance of tissue-specific differentiation functions. A longer term goal, whose feasibility remains unclear, is to create mathematical models of these biological circuits and thereby predict these various types of cell biological behavior.
Linking Doses and Response
11
Current initiatives in computational systems toxicology emphasize an iterative process, with recurrent steps through laboratory experiments and computer modeling, to create an understanding of the manner in which the components of biological systems are organized in order to produce these circuit elements that regulate biological function. Perturbations of these biological processes by environmental stressors, including chemicals and drugs, can lead to adverse responses (toxicity), restoration of normal function to a compromised tissue (drug efficacy), or control of biological processes, such as occurs with use of hormonal therapies in post-menopausal women. Computational systems biology is now an intense area of activity providing key information for understanding cell behavior. Some of these approaches were highlighted in the focused series of papers in Nature in 2002 (Kitano, 2002; Surridge, 2002). More recent contributions outline contributions of computational systems biology to understanding the circuitry controlling biological responses and stress pathways (Alon, 2006, 2007). Toxicology and pharmacology are disciplines at the interface of chemistry/pharmacokinetics (primarily embedded in the vertical component from exposure to perturbation) and biology/pharmacodynamics (primarily captured by the horizontal chain from inputs to normal biological function – Figure 1.3). With the rapid advances in quantitative understanding of many biological processes and responses to perturbations, toxicology modeling can focus more directly on the underlying biology rather than simply the perturbations
Figure 1.3 The Maturing Exposure-Dose-Response Paradigm for Toxic Responses is related to Perturbations of the Normal Control Processes in the Cell by Toxicant Exposures. Low doses are largely without functional consequences; intermediate doses activate adaptive stress responses with attendant homeostatic controls; and, high enough doses lead to overt toxicity. Increasing dose leads to progress through several dose-dependent transitions. Andersen et al. (2005b), reprinted with permission from Elsevier. Copyright 2005.
12
Quantitative Modeling in Toxicology: An Introduction
following chemical exposure. When the exposure-dose-response is recast with intersection of chemical perturbation with normal biology, toxicity and efficacy become situated at the intersection of chemical action with the underlying biology. We are now moving to a second-generation of systems approaches in PK and PD modeling. This new initiative will include simulation models with increasingly detailed descriptions of biology derived from new technologies coupled with the expansion of current modeling tools that focus on signaling pathways affected by chemical exposures and drug treatments.
1.2.2 Circuits, Networks and Signaling Motifs and Toxicity Cells consist of multiple interacting modules, with various feedback controllers. These control modules have been primarily examined through detailed experimental work prokaryote cell systems. These simplified signaling circuits have been described by mathematical models to capture the behavior of the control networks. Using the variety of tools from molecular biology, simple prokaryotic cells have in some cases been engineered with specific circuit elements, including, biological oscillators, switches, amplifiers, and so on. These artificial constructs then can be queried by laboratory experiments and the results used to construct detailed models for the underlying circuitry controlling these behaviors (Hasty, McMillen, and Collins, 2001, 2002; Guet et al., 2002; McMillen et al., 2002; Tyson et al., 2003). Computational models have evaluated the protein networks within cells, the control of these networks by the component circuitry, and uncovered the logic of cellular responses affected by these networks (Davidson et al., 2002; Ferrell, 2002; Alm and Arkin, 2003). Among these control processes are activation of latent networks, silencing of active networks, and modulation of network function. The circuitry is regulated by various input signals to the cells. Input signals, including endogenous compounds, such as hormones and various exogenous compounds, are capable of activating cell signaling networks to modulate both control circuitry and affect downstream genetic networks. Cell cycle control has been extensively modeled in eukaryotic organisms and represents a generic process that is common across biological organisms (Tyson, 1999; Tyson et al., 2003). Progress in understanding similar common signaling themes (Ray, Adler, and Gough, 2004; Schlessinger, 2004) has increased the appreciation of the manner in which modular components are used to achieve and control a host of cellular outputs/functions. Xenobiotics have effects on tissues in biological systems through two general processes – receptor-mediated recognition of the three-dimensional structure of the compound – or stress pathways, where the cells respond to chemical reactivity and stress through negative feedback control processes to maintain homeostasis. These interactions perturb cell circuits and modulate cellular functions. This classification of response pathways is especially relevant for so-called receptor-mediated toxicants that interact in the body with specific endogenous receptors. Receptor-mediated toxicants have the potential to cause toxicity by mimicking endogenous signaling molecules, leading to over-stimulation of natural circuits. Alternatively, compounds of this class may cause toxicity because they are competitive inhibitors of natural receptor-mediated functions. Competitive inhibitors can bind with endogenous receptors, but cause failure of activation of important circuits in the presence of normal signals. Inhibitory compounds with a receptor-mediated mode of action can lead to diseases associated with deficiencies of signaling molecules and circuit activation.
Linking Doses and Response
13
The report from the National Academy of Sciences, Scientific Frontiers of Developmental Toxicity and Risk Assessment (NRC, 2000), outlined the suite of known intercellular signaling motifs and their roles that these pathways play in development. This suite of signaling pathways represents potential targets that could lead to toxic responses if they are sufficiently perturbed by chemical exposures, that is, adverse responses could ensue if these pathways were inhibited or over-stimulated at times during development. 1.2.3
Modeling Cellular Response Pathways
Cell signaling pathway model code is similar to the sets of ordinary differential equations used in most PBPK models. There are some new challenges because the low copy number of genes, transcripts, and proteins may require stochastic simulation. Despite these difficulties, several mammalian signaling pathways have been modeled – including platelet derived growth factor (PDGF) pathway (Bhalla, Ram, and Iyengar, 2002) in mouse 3T3 cells and tumor necrosis factor-alpha (TNF-α) signaling through the nuclear factor kappa B (NF-κB) pathway in mouse fibroblasts (Hoffmann et al., 2002; Cho et al., 2003). The equations in these models represent groups of reactions within a cell and require estimation of multiple parameters in the biochemical steps embedded within the signaling networks. Models based on series of differential equations have also been augmented by Boolean approaches that use on-off logic to increase the model coverage on intracellular reactions, without necessarily increasing the numbers of parameters that have to be estimated for all the protein–protein interactions involved in the signaling networks (Bolouri and Davidson, 2002). The huge diversity of cellular responses and interactions can be broken down and categorized in a much smaller set of functional circuits – positive and negative feedback, feed-forward loops, and so on. While there are many discrete signaling modules within any cell, the process of careful modeling of prototype circuits that allows dissection and modeling of individual signaling modules should eventually encourage a modular approach to understanding more integrated biological pathways (Hartwell et al., 1999). Progress in applications of these modeling strategies in toxicology and risk assessment is likely to come from model development for a series of prototype compounds. These compounds would be selected based on knowledge of the key signaling pathways with which they interact. The computational systems biology models of the response pathway could then focus on the circuits giving rise to pathway function, allowing improved mechanistic understanding of the dose-response behavior of the circuit serving as a primary focus of model development. The increasing focus on cell response pathways for toxicity testing (NRC, 2007) is likely to spur greater interest in computational systems biology for evaluating the dose response for perturbations and for activation of adaptive responses. Along with a fairly large group of modern computational biologists, Alon (2006) has emphasized the pattern of recurring motifs and commonality of motif functions that are present in larger scale networks. Nonlinear processes associated with positive feedback, double negative feedback, negative feedback homeostasis, and coherent and incoherent feed-forward loops are increasingly being analyzed using engineering principles to understand cell function and how the intrinsic cell circuitry is designed to achieve specific functions (Alon, 2007). A course on computational systems biology and dose-response modeling at The Hamner Institutes for Health Sciences has outlined the key ideas and focused on both numerical simulation and on understanding the nonlinear dynamics that are the basis of complex
14
Quantitative Modeling in Toxicology: An Introduction
Figure 1.4 The mitogen-activated protein kinase (MAPK)cascade generates nonlinear dose relationships for cellular responses. This signaling motif has three sequential kinase partners – MAP kinase kinase kinase (MAPKKK), MAP-kinase kinase (MAPKK), and MAP kinase (MAPK). The steepness of dose response increases through each component of the cascade. Reprinted with permission from Huang et al. Copyright 1996, National Academy of Sciences, USA.
cellular responses to chemical and environmental stressors (http://www.thehamner.org/ education-and-training/current-course-offerings.html). Cell response modeling, more than PBPK or PBPD simulation models, has created increasing attention on the characteristics of nonlinear dynamics rather than on numerical solution of series of differential equations (Strognatz, 1994). Key topics for cell signaling include ultrasensitivity (Ferrell and Machleder, 1998; Ferrell, 2002), bistability (Xiong and Ferrell, 2003), and the use stochastic differential equation solvers that account for noise and randomness in cellular reactions that involve small numbers of participating molecules (Kaern et al., 2005; Gillespie, 1976). One ubiquitous ultrasensitive motif in eukaryotes is the mitogen-activated protein kinase (MAPK) cascade (Johnson and Lapadat, 2002) that participates in a variety of cell response pathways (Figure 1.4). Through activation of the sequential kinase components, these motifs generate ultrasensitive behaviors, with equivalent for steepness for Hill-curves with n-values of greater than 5.0 for the MAPK itself (Huang and Ferrell, 1996). These ultrasensitive motifs coupled through positive feedback produce bistability, that is, true switches, in cellular response behaviors (Xiong and Ferrell, 2003). A common discussion among the community working on quantitative modeling of complex responses is whether the models should be built bottom-up (focusing on the initial interactions and going on to adverse responses) or top-down from the adverse consequences at the organism level and piecing the path back to uncover the key portions of the toxic response. Increasingly, it appears that real progress in quantitative modeling of toxic responses is likely to arise from a middle-out approach, where the primary responder is the cell, with model structures focusing on how cells respond to perturbations and how excessive perturbations cause cascades of cellular pathway activation, for example,
Acknowledgment
15
anti-oxidant stress, up-regulation of anti-oxidant response genes, inflammation, and, finally, apoptosis (Nel et al., 2006). The field of quantitative systems modeling for toxicology and risk assessment is emerging as a critical area for informing risk and safety assessment with environmental chemicals and drugs. Zhang et al. (2009), for instance, have examined dose-response relationships for reactive intermediates where liver concentration of reactive metabolites from Phase I enzymes is controlled by feed-forward activation of phase II and phase III enzymes. Feed-forward homeostatic control can produce complex, and in some cases, hormetic dose response. Integration of biomedical engineering concepts with the biology of cell signaling should provide theoretical justification for dose-response curves with a wide variety of shapes and allow consideration of dose-dependent transitions as key components of dose-response assessment strategies (Slikker et al., 2004).
1.3
Summary
Quantitative modeling in toxicology dates back to the development of dose-response methods for estimating effective doses using probit analyses for quantal responses. Major advances increased our ability to understand dose to tissues through pharmacokinetic (PK), and, especially, physiologically based pharmacokinetic (PBPK) modeling. PBPK models have spurred growth of sensitivity, variability, and uncertainty analysis; they forced development of statistical tools for assessing goodness-of-fit of models to diverse data sets; and they instigated strategies for using measures of internal dose in risk assessment through linkage with benchmark dose (BMD) models. Response modeling matured more slowly due to lack of detailed understanding of the biological processes leading to organism level responses. Response models for cytotoxicity, cancer, and developmental toxicity have focused on cell level responses and relied on admixtures of mechanistic and empirical structures. Models for precursor responses related to chemical adduction of protein and DNA and enzyme inhibition retained more fidelity with the chemistry of test compounds and the biology of the precursor interactions. Looking forward, rapid development are expected in continued expansion of PBPK models at the organism, organ, and cell levels, and in computational systems biology modeling of intra- and intercellular signaling, leading to more biologically relevant dose-response models for cell and tissue level responses. Other advances in bioinformatics and high data content methodologies will drive new dose-response modeling approaches that organize genomic results on the basis of the classification of gene families affected by chemical treatment (see for example, Thomas et al., 2007; Andersen et al., 2008) that are more difficult to predict. It is hoped that the chapters and examples in this volume will spur further development of quantitative modeling in toxicology and continue the improvement of chemical risk assessment by encouraging quantitative, biological modeling approaches for toxicology and for risk assessment decision making.
1.4
Acknowledgment
This chapter draws heavily from two other contributions by the senior author: Andersen, Conolly, Gaido, and Thomas (2005b) and Andersen and Hanneman (2002).
16
Quantitative Modeling in Toxicology: An Introduction
References Albert, R.E., Train, R.E., and Anderson, E. (1977) Rationale developed by the Environmental Protection Agency for the assessment of carcinogenic risks. J. Natl. Cancer Inst., 58, 1537–1541. Allen, B.C., Covington, T.R., and Clewell, H.J. (1996) Investigation of the impact of pharmacokinetic variability and uncertainty on risks predicted with a pharmacokinetic model for chloroform. Toxicology, 111, 289–303. Alm, E. and Arkin, A.P. (2003) Biological networks. Curr. Opin. Struct. Biol. 13, 193–202. Alon, U. (2006) An Introduction to Systems Biology: Design Principles of Biological Circuits, Chapman & Hall/CRC Press, Boca Raton, FL. Alon, U. (2007) Network motifs: theory and experimental approaches. Nat. Rev. Genet., 8, 450–461. Andersen, M.E. (1987) Tissue dosimetry in risk assessment: what’s the problem here any way? Drinking Water Health, 8, 8–23. Andersen, M.E., and Hanneman, W.H. (2002) Exposure-Dose-Response: A Molecular Perspective, in Cellular and Molecular Toxicology (eds J. Vanden Heuvel, W.F. Greenlee, and G. Perdew), Elsevier Press. Andersen, M.E., Clewell, H.J. III, and Frederick, C.B. (1995) Applying simulation modeling to problems in toxicology and risk assessment – a short perspective. Toxicol. Appl. Pharmacol., 133, 181–187. Andersen, M.E., Dennison, J.E., Thomas, R.S., and Conolly, R.B. (2005a) New directions in incidence-dose modeling. Trends in Biotechnology, 23, 122–127. Andersen, M.E., Conolly, R.B., Gaido, K.W., and Thomas, R.S. (2005b) Dose-response modeling in the systems biology era. Reproductive Toxicology, 19, 327–337. Andersen, M.E., Clewell, H.J. III, Gargas, M.L., et al. (1991) Physiologically based pharmacokinetic modeling with dichloromethane, its metabolite, carbon monoxide, and blood carboxyhemoglobin in rats and humans. Toxicol. Appl. Pharmacol., 108, 14–27. Andersen, M.E., Clewell, H.J. III, Bermudez, E., et al. (2008) Genomic signatures and dose dependent transitions in nasal epithelial responses to inhaled formaldehyde in rats. Toxicol. Sci., 105, 368–383. Barton, H.A., Deisinger, P.J., English, J.C., et al. (2000) Family approach for estimating reference concentrations/doses for series of related organic chemicals. Toxicol. Sci., 54, 251–261. Bellomo, N. and Preziosi, L. (1995) Modeling Mathematical Methods and Scientific Computation. CRC Press, Boca Raton, FL. Bhalla, U.S., Ram, P.T., and Iyengar, R. (2002) MAP kinase phosphatase as a locus of flexibility in a mitogen-activated protein kinase signaling network. Science, 297, 1018–1023. Bischoff, K.B. and Brown, R.H. (1966) Drug distribution in mammals. Chem. Eng. Prog. Symp. Ser., 62, 33–45. Bischoff, K.B., Dedrick, R.L., Zaharko, D.S., and Longstreth, J.A. (1971) Methotrexate pharmacokinetics. J. Pharm. Sci., 60, 1128–1133. Bolouri, H. and Davidson, E.H. (2002) Modeling transcriptional regulatory networks. Bioessays, 24, 1118–1129. Cho, K.-H., Shin, S.-Y., Lee, H.-W., and Wolkenhauer, O. (2003) Investigations into the analysis and modeling of the TNF-α-mediated NF-κB-signaling pathway. Genome Res., 13, 2412–2422. Clewell, H.J. (1995) The application of physiologically based pharmacokinetic modeling in human health risk assessment of hazardous substances. Toxicol. Lett., 79, 207–217. Clewell, H.J. and Andersen, M.E. (1996) Use of physiologically based pharmacokinetic modeling to investigate individual versus population risk. Toxicology, 111, 315–329. Clewell, H.J. III and Andersen, M.E. (1985) Risk assessment extrapolations and physiological modeling. Toxicol. Ind. Health, 1, 111–131. D’Souza, R.W., Francis, W.R., and Andersen, M.E. (1988). A physiologic model for tissue glutathione depletion and increased resynthesis following ethylene dichloride exposure. J. Pharmacol. Exp. Ther., 245, 563–568. Davidson, E.H., Rast, J.P., Oliveri P, et al. (2002) A genomic regulatory network for development. Science, 295, 1669–1678. Dedrick, R.L. (1973) Animal scale-up. J. Pharmacokinet. Biopharm., 1, 435–461.
References
17
Ferrell, J. E. Jr. and Machleder, E.M. (1998) The biochemical basis of an all-or-none cell fate switch in Xenopus oocytes. Science, 280, 895–898. Ferrell, J.E. Jr. (2002) Self-perpetuating states in signal transduction: positive feedback, doublenegative feedback and bistability. Curr. Opin. Chem. Biol., 6, 140–148. Gargas, M.L., Andersen, M.E., Teo, S.K.O., et al. (1995) A physiologically-based dosimetry description of acrylonitrile and cyanoethyleneoxide in the rat. Toxicol. Appl. Pharmacol., 134, 185–194. Gentry, P.R., Covington, T.R., Andersen, M.E., and Clewell, H.J. (2002) Application of a physiologically-based pharmacokinetic model for isopropanol in the derivation of an RfD/RfC. Regul. Toxicol. Pharmacol., 36, 51–68. Gillespie, D.T. (1976) A general method for numerically simulating the stochastic time evolution of coupled chemical reactions. J. Computational Phys, 22, 403–434. Guet, C.C., Elowitz, M.B., Hsing, W., and Seibler, S. (2002) Combinatorial synthesis of genetic networks. Science, 296, 1466–1470. Hartwell, L.H., Hopfield, J.J., Leibler, S., and Murray, A.W. (1999) From molecular to modular cell biology. Nature, 402, C47–C52. Hasty, J., McMillen, D., and Collins, J.J. (2002) Engineered gene circuits. Nature, 420, 224–230. Hasty, J.F., Isaacs, F., Dolnik, M., et al. (2001) Designer gene networks: towards fundamental cellular control. Chaos, 11, 207–220. Hoffmann, A., Levchenko, A., Scott, M.L., and Baltimore, D. (2002) The IkB-NF-kB signaling module: temporal control and selective gene activation. Science, 298, 1241–1245. Huang, C.-Y. and Ferrell, J.E. (1996) Proc. Natl. Acad. Sci.USA, 93, 10078–10083. Johnson, G.L. and Lapadat, R. (2002) Pathways mediated by ERK, JNK, and p38 protein kinases. Science, 298, 1911. Kaern, M., Elston, T.C., Blake, W.J., and Collins, J.J. (2005) Stochasticity in gene expression: from theories to phenotypes. Nat. Rev. Genet., 6, 451–464. Kitano, H. (2002) Computational systems biology. Nature, 420, 206–210. Kohn, M.C., Lucier, G.W., Clark, G.C., et al. (1993) A mechanistic model of the effects of dioxin ongene expression in the rat liver. Toxicol. Appl. Pharmacol., 120, 138–154. Krishnan, K., Gargas, M.L., Fennell, T.R., and Andersen, M.E. (1992) A physiologically-based description of ethylene oxide dosimetry in the rat. J. Toxicol. Ind. Health 8, 121–140. Lander, E.S. and Weinberg, R.A. (2000) Genomics: journey to the center of biology. Science, 287, 1777–1782. Lau, C., Mole, M.L., Copeland, M.F., et al. (2001) Toward a biologically based doe-response model for developmental toxicity of 5-fluorouracil in the rat: acquisition of experimental data. Toxicol. Sci., 59, 37–48. Lehman, A.J. and Fitzhugh, O.G. (1954) 100-fold margin of safety. Assoc. Food Drug Off. U.S.Q. Bull., 18, 33–35. Leroux, B.G., Leisenring, W.M., Moolgavkar, S.H., and Faustman, E.M. (1996) A biologically-based dose–response model for developmental toxicology. Risk Anal., 16, 449–458. Leung, H.W. (1991) Development and utilization of physiologically based pharmacokinetic models for toxicological applications. J. Toxicol. Environ. Health, 32, 247–267. Leung, H.W., Paustenbach, D.J., Murray, F.J., and Andersen, M.E. (1990) A physiologically based pharmacokinetic description of the tissue distribution and enzyme inducing properties of 2,3,7,8tetrachlorodibenzo-p-dioxin in the rat. Toxicol. Appl. Pharmacol., 103, 399–410. Lilly, P.D., Thorton-Manning, J., Gargas, M.L., et al. (1998) Kinetic characterization of CYP2E1 inhibition in vivo and in vitro by the chloroethylenes. Arch. Toxicol., 72, 609–621. McMillen, D., Kopell, N., Hasty, J., and Collins, J.J. (2002) Synchronizing genetic relaxation oscillators by intercell signalling. PNAS 999, 679–684. Moolgavkar, S.H. and Luebeck, G. (1990) Two-event model for carcinogenesis: biological, mathematical and statistical considerations. Risk Anal., 10, 323–341. Nel, A., Xia, T., Madler, L., and Li, N. (2006) Toxic potential of materials at the nanolevel. Science, 311, 622–627. Nong, A., Taylor, M., Clewell, H.J. III et al. (2009) Manganese tissue dosimetry in rats and monkeys: accounting for dietary and inhaled Mn with physiologically based pharmacokinetic modeling. Toxicol. Sci., 108, 22–34.
18
Quantitative Modeling in Toxicology: An Introduction
NRC (National Research Council) (1983) Risk Assessment in the Federal Government: Managing the Process, National Academies Press, Washington, DC. NRC (National Research Council) (2000) Scientific Frontiers in Developmental Toxicology and Risk Assessment, National Academies Press, Washington, DC. NRC (National Research Council) (2007) Toxicity Testing in the 21st Century. A Vision and a Strategy, National Academies Press, Washington, DC. Ray, L.B., Adler, E.M., and Gough, N.R. (2004) Common signaling pathways. Science, 306, 1505 Reddy, M.B., Yang, R.S.H., Clewell, H.J. III and Andersen, M.E. (eds) (2005) Physiologically Based Pharmacokinetics: Science and Applications, John Wiley & Sons, Inc., Hoboken, NJ. Schlessinger, J. (2004) Common and distinct elements in cellular signaling via EGF and FGF receptors. Science, 306, 1506–1507. Setzer, R.W., Lau, C., Mole, M.L., et al. (2001) Toward a biologically based doe-response model for developmental toxicity of 5-fluorouracil in the rat: a mathematical construct. Toxicol. Sci., 59, 49–58. Slikker, W. Jr., Andersen, M.E., Bogdanffy, M.S., et al. (2004) Dose-dependent transitions in mechanisms of toxicity. Toxicol. Appl. Pharmacol. 201, 203–225. Strognatz, S. (1994) Nonlinear Dynamics and Chaos: With Application to Physics, Biology, Chemistry, and Engineering, Westview Press, Boulder, CO. Surridge, C. (2002) Nature insight: computational biology. Nature, 420, 205. Thomas, R.S., Allen, B.C., Nong, A., et al. (2007) A method to integrate benchmark dose estimate with genomic data to assess the functional effects of chemical exposure. Toxicol. Sci., 98, 240–248. Tyson, J.J. (1999) Models of cell cycle control. J. Biotechnol., 71, 239–244. Tyson, J.J., Chen, K.C., and Novak, B. (2003) Sniffers, buzzers, toggles and blinkers: dynamics of regulatory and signaling pathways in the cell. Curr. Opin. Cell Biol., 15, 221–231. Watanabe, P.G. and Gehring, P.J. (1976) Dose-dependent fate of vinyl chloride and its possible relationship to oncogenicity in rats. Environ. Health Perspect., 17, 145–152. Whitaker, S.Y., Tran, H.T., and Portier, C.J. (2003) Development of a biologicallybased controlled growth and differentiation model for developmental toxicology. J. Math. Biol., 46, 1–16. Xiong, W. and Ferrell, J.E. Jr. (2003) A positive-feedback-based bistable ‘memory module’ that governs a cell fate decision. Nature, 426, 460–465. Zhang, Q., Pi, J., Woods, C.G., and Andersen, M.E. (2009) Phase I to II cross-induction of metabolizing enzymes: a feed forward control mechanism for potential hormetic responses. Toxicol. Appl. Pharmacol., 237, 345–356.
Section 2 Physiologically-based toxicokinetic and pharmacokinetic (PBPK) modeling
2 PBPK Modeling: A Primer Kannan Krishnan1 , George D. Loizou2 , Martin Spendiff 2 , John C. Lipscomb3 , and Melvin E. Andersen4 1
D´epartement de sant´e environnementale et sant´e au travail, Groupe de recherche interdisciplinaire en sant´e (GRIS), Universit´e de Montr´eal, Canada 2 Computational Toxicology Section, Health and Safety Laboratory, United Kingdom 3 National Center for Environmental Assessment, US Environmental Protection Agency, USA 4 Division of Computational Biology, The Hamner Institutes for Health Research, USA
2.1 Introduction Pharmacokinetic models are quantitative descriptions of the time-course behavior of chemicals in biological matrices (e.g., blood, urine, exhaled air, tissues). The pharmacokinetic models can be developed either based on fitting to the experimental data (often referred to as “data based” or compartmental models) or based on the critical determinants of absorption, distribution, metabolism, and excretion (ADME). The later is the basis of physiologically based pharmacokinetic (PBPK) (alternatively referred to as physiologically based toxicokinetic) models. The mathematical formulation and implementation of “data based” pharmacokinetic models have been described in detail in several monographs (e.g., Notari, 1987; Heinzel, Woloszczak, and Thomann, 1993; Rowland and Tozer, 1995; Kwon, 2001). PBPK models, the focus of this chapter, refer to mathematical descriptions of the uptake and disposition of chemicals based on quantitative interrelations among the critical determinants of these processes (i.e., physiological processes, metabolic and excretory processes, absorption, and tissue solubility phenomena). The literature on PBPK models dates back to the research works of Haggard (1924), Teorell (1937a, 1937b), Kety (1951), Mapleson (1963), Riggs (1970) and Fiserova-Bergerova (1975) on antineoplastics, anesthetics, and other pharmaceuticals. Since the early 1980s, PBPK models have been developed for a Quantitative Modeling in Toxicology C 2010 John Wiley & Sons, Ltd
Edited by Kannan Krishnan and Melvin E. Andersen
22
PBPK Modeling: A Primer
number of environmental chemicals of toxicological interest and are being increasingly explored for use in improving the dose-response relationships (reviewed in Krishnan and Andersen, 2001, 2007; Clewell, Andersen, and Barton, 2002; Reddy et al., 2005; Lipscomb and Ohanian, 2006; USEPA, 2006). This chapter provides a beginner-level description of the quantitative aspects of PBPK models and their implementation. The role of in silico and in vitro methods for developing PBPK models in data-poor situations is also discussed.
2.2
Model Structure and Purpose
The development of PBPK models typically starts with a definition of the problem such that the capability and complexity of the resulting model can be determined appropriately. The intended use of a PBPK model may be for the conduct of in vitro to in vivo extrapolation, high dose to low dose extrapolation, animal to human extrapolation or route to route extrapolation of the tissue dose of a chemical. The level of detail relates not only to the compartments (e.g., whole body, target tissue, or intracellular concentrations) but also to the chemical forms that are tracked within the model (e.g., parent chemical and/or metabolite(s)). Accordingly, a conceptual representation, that is, a diagrammatic description of the compartments and interconnections among them, is developed. The conceptual model requires an understanding of the anatomical and physiological characteristics of the species, as well as the pathways of ADME of the chemicals and/or its metabolite(s). Lumping or splitting approaches can be used to identify those tissues that need to be represented individually in the PBPK models (Clewell and Clewell, 2008). Here, statistical approaches for evaluation of model structure may be of relevance, in addition to the fundamental considerations of biology and mode of action (see Chapter 20, this volume). Generally, the approach to PBPK model building is one of striking the balance between model parsimony and biological plausibility. In this regard, parsimony refers to the choice of a model structure that has minimal but necessary elements that together adequately describe the pharmacokinetics of a chemical (Krishnan and Andersen, 1994). In other words, model complexity is increased only when it is required for explaining the behavior contained in the data. In PBPK models, increments in complexity generally involve the addition of mathematical representations of mechanisms that are thought to represent the system behavior. The necessity for representing a particular organ or tissue as a separate compartment is determined by its relevance to toxicity, mode-of-action, uptake, and pharmacokinetics of the chemical under study. The most common criteria for the selection and definition of a compartment are related to significant role of: (a) relevant metabolizing enzyme activities within an organ or tissue, and (b) the solubility of a chemical within an organ or tissue. The liver is an example of the former and the adipose compartment for lipophilic chemicals is an example of the latter. Figure 2.1 shows the conceptual representations of the PBPK models for selected chemicals. In these particular examples, the model compartments together represent ≈91% of body mass, with the remaining 9% corresponding to the mass of the skeletal/structural components. The slowly and rapidly perfused compartments are assumed to be “kinetically homogeneous” since a chemical would be well mixed, assuming venous equilibration (i.e., the free tissue concentration and the venous concentration exiting the tissue are equal), and
Model Structure and Purpose (a)
23
(b) Exhaled Chemical
Inhaled Chemical
Alveolar Space Lung Blood
Inhaled Chemical
Exhaled Chemical
Lungs
Fat
Fat Binding
Poorly Perfused Tissues
Poorly Perfused Tissues
Venous blood
Liver
Brain Metabolism and Binding
Testes
Arterial blood
Metabolism and Binding
Richly Perfused Tissues
Metabolism and Binding
Metabolism
Other Richly Perfused Tissues Metabolism and Binding
Liver
(c)
Metabolism and Binding
I.V.
Blood
(d)
Fat
Inhalation
TCDD
Exhalation
Lungs & arterial blood
TCDD
Biotransformation
Poorly perfused Tissues
Rapidly perfused tissue
TCDD
TCDD
Perirenal fat Richly perfused Tissues
Subcutaneous fat
TCDD
TCDD
Working muscle
Liver Ah-TCDD Ah
Pr-TCDD
Resting muscle
Pr TCDD
TCDD
Metabolism
Liver Biotransformation
Figure 2.1 (a) Conceptual representation of a PBPK model for (a) styrene, (b) ethylene oxide, (c) 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD; Pr, protein; Ah, Ah receptor) and (d) toluene. Adapted with permission from Ramsey and Andersen (1984), Krishnan et al. (1992), Andersen, Mills, and Gargas (1993), and Jonsson and Johanson (2001). ((a) and (d) reprinted with permission from Elsevier, (b) reprinted with permission from SAGE Publications Ltd, (c) reprinted with permission from Wiley-Blackwell.
24
PBPK Modeling: A Primer
have a similar disposition or “time constant” (i.e., blood flow rate divided by the product of partition coefficient and tissue mass) within each individual compartment (Krishnan and Andersen 1994). It is also very common for fat depots such as perirenal, epididymal, and omental fat to be grouped and represented as a single “fat” compartment. This simplification is justified in cases of small molecular weight compounds, which predominately exhibit perfusion-limited kinetics. While lumping or splitting the compartments, the following fundamental tenets should be observed: 1. The sum total of tissue and organ compartment masses should be within the body mass of the organism; and 2. the total blood flow (i.e., cardiac output) in the model should be equal to the sum of the flows to the tissue compartments of the model in order to maintain the mass balance of the chemical at all times.
2.3
Mathematical Representation
A summary of frequently used mathematical representations in PBPK models is provided in Table 2.1, along with the symbols and abbreviations used in equations presented in this chapter. A list of some fundamental measures and units relevant to PBPK modeling is provided in Table 2.2. 2.3.1 Calculating the Rate of Change in the Compartments The rate of change in the amount of chemical in tissues is essentially proportional to the concentration difference, as defined by Fick’s first law: dAt/dt ∝ ∆C
(2.1)
In the above equation, ∆C refers to the input-output difference in chemical concentration (i.e., Cin – Cout ). Replacing the ∝ sign in the above equation with the = sign necessitates the introduction of a proportionality constant, k. Therefore, Equation 2.1 becomes: dAt/dt = k(Cin − Cout )
(2.2)
The constant, k, corresponds to the membrane permeability coefficient, which can be represented as PAQt /(PA + Qt ), where PA = permeation area cross product and Qt = tissue blood flow rate. Accordingly, when the PA of a chemical is very large compared to Qt , k approximates to Qt . On the other hand, when the PA is small compared to Qt (i.e., membrane diffusion is the factor limiting chemical movement into and out of the tissue compartment), then k ≈ PA. For small molecular weight compounds, blood flow rather than the membrane diffusion is the limiting factor (Figure 2.2a), such that: dAt (2.3) = Qt(Ca − Cvt ) dt However, for high molecular weight compounds dAt/dt is frequently calculated as a function of the rate of change in the tissue blood (vascular) subcompartment and cellular matrix subcompartment (Figure 2.2b). The rate of change in the amount of chemical in
Mathematical Representation
25
Table 2.1 Mathematical representation of ADME in PBPK models. Toxicokinetic process
Examples of PBPK mathematical descriptions
1. Absorption Pulmonary Dermal Oral Intravenous 2. Distribution Protein binding Diffusion limited tissue distribution Perfusion limited tissue distribution
Ca =
Qp · Ci nh + Qc · Cv Qc + Qp/Pb Csk Csk = K p · S Cai r − + Qsk · Ca − Ps:a Ps:b
dAsk dt dAo = K o · Do · e−ko ·t dt Cv =
K z+
n t
Qt ·Cvt
Qc
n · β · Kd · C f Cb = 1 + Kd · C f Ct dAt = P At · Cvt − dt Pt dAt = Qt · (Ca − Cvt ) dt
3. Metabolism First order Second order Saturable process 4. Excretion Urinary Pulmonary
dAmet = K f · Cvt · Vt = C L int · Cvt dt dAmet = K s · Cvt · Vt · Ccf dt Vmax · Cvt dAmet = dt K m + Cvt Tm dAr c = GF R · Cp dt Kt + Cp Ca + (0.3 · Ci nh ) C x = 0.7 · Pb
Abreviations: Qc , cardiac output (liters.h−1 ); Qp , alveolar ventilation rate (liters.h−1 ); Qt , blood flow to tissue “t” (liters.h−1 ); Qf , blood flow to fat (liters.h−1 ); Ql , blood flow to liver (liters.h−1 ); Qp , blood flow to poorly perfused tissues (liters.h−1 ); Qr , blood flow to richly perfused tissues or rest of body (liters.h−1 ); C, Concentration (mg/l). Subscripts: a, arterial blood; alv, alveolar air; b, bound; cf., cofactor in tissue “t”; f , free; inh, inhaled air; p, plasma; pr, binding protein; sk, skin; t, tissue “t”; v, mixed venous blood; vf , venous blood leaving fat; vl, venous blood leaving liver; vp, venous blood leaving poorly perfused tissues; vr, venous blood leaving richly perfused tissues (or rest of body); vt, venous blood leaving tissue “t”; x, exhaled air; V, Volume (liters); A, Quantity. Subscripts: rc, renal compartment; met, metabolized; o, oral absorption; CLint , Intrinsic clearance (liters.h−1 ); GFR, Glomerular filtration rate (liters.h−1 ); Kd , dissociation constant (mg/liter); Kf , first-order metabolism rate constant (h−1 ); Km , Michaelis constant (mg/l); Ko , oral absorption rate constant (h−1 ); Kp , skin permeability coefficient rate constant (cm × 10−2 .h−1 ); Ks , second-order metabolism rate constant (liters·mg−1 h−1 ); Kt , Apparent Michaelis–Menten constant with respect to secretary carrier (mg/l); Kz , Input via intravenous dosing; nβ, binding maximum; PAt , Permeation area cross product for tissue “t” (liters.h−1 ); Pb , blood : air partition coefficient; Pl , liver: blood partition coefficient; Pr , richly perfused (or rest of body):blood partition coefficient; Ps : a , skin : air partition coefficient; Ps : b , skin : blood partition coefficient; Pt , tissue : blood partition coefficient; S, Exposed skin surface area (cm.h−1 × 10−2 ); t, Elapsed time (h); Tm , Apparent maximum transport of the carrier system (mg.h−1 ); V max , Maximal velocity of enzymatic reaction (mg.h−1 ).
26
PBPK Modeling: A Primer Table 2.2 Some measures and units of relevance to PBPK modeling. Measures
Units
Quantity Volume Weight Area Concentration Time Administered (applied) dose Area under the curve (AUC)
µg, mg, kg ml, l g, kg cm2 , m2 µg/ml, mg/la , ppm min, h, day mg/kg mg/l × hr
a
mg/l (air) = ppm × molecular weight/24 450
cellular matrix is equal to the product of the diffusion constant and the net flux from the vascular compartment: Ct dAcm = PAt Cvt − (2.4) dt Pt The rate of change in the vascular (i.e., tissue blood) sub-compartment equals the sum of the net flux from blood flow plus the net flux from cellular matrix: Ct dAtb − Cvt = Q t (Ca − Cvt ) + PAt (2.5) dt Pt So, if diffusion from the vascular compartment to cellular matrix is slow with respect to total tissue blood flow, then Equations 2.4 and 2.5 are necessary. However, if the blood flow is slow compared to diffusion, then tissues are described as homogeneous, well mixed compartments, such that the rate of change is described using a single equation (Equation 2.3) (i.e., cellular matrix + tissue blood or Equations 2.4 + 2.5). When there is metabolism and other clearance processes operative in a given tissue, additional terms are included within Equations 2.3–2.5. The rate of change as per Equations 2.3–2.5 is calculated in terms of amount per unit time (e.g., mg/h); therefore, the next step is to determine the amount of chemical in the tissue at any time, t. The differential equations presented above are all ordinary differential equations, that is, they consist of differentials of dependent variables with respect to an independent variable. Here the dependent variable is the amount and the independent variable is the time. The time-dependent incremental change in the resulting value of the dependent variable at the end of a simulation period should be added to the initial or starting value, such that the new value of the dependent variable at the end of each time interval can be obtained. Obviously, the computer then needs to track and maintain a record of the solved values of the dependent variable during a simulation exercise. The general principle underlying the solution for the first order ordinary differential equations used in PBPK models is reflected by the following strategy: Current value = Previous value + (slope × dt)
(2.6)
Mathematical Representation
27
(a) Qt · Cvt Out
Qt · Ca In
Tissue
(b) Cell + interstitial fluid Qt ·Cvt Out
Qt · Ca Vascular
In
Figure 2.2 Schematic of a tissue compartment. Qt is tissue blood flow rate, Ca is arterial blood concentration, Cvt is the concentration of the chemical in the venous blood leaving tissue.
Consider a situation where arterial blood with a concentration of 5 µg/l enters an adipose tissue compartment at the flow rate of 0.4 l/unit time. The influx here would be 5 µg/l × 0.4 l/unit time = 2 µg/unit time. The blood, flowing out at the same rate, let’s say contains a concentration of 0.05 µg/l. The output here equals 0.05 µg/l × 0.4 l/ unit time = 0.2 µg/ unit time. The rate of change in the adipose tissue compartment (dAt/dt) then equals: Input (2 µg/unit time) – Output (0.2 µg/unit time) = 1.8 µg/unit time. The calculation of the rate of change should be done for very small units of time or simulation period (alternatively referred to as the integration interval, dt). At the beginning of a simulation period, say the amount of chemical in the compartment is zero. In that case, the amount in the tissue would become 0 µg + [(1.8 µg/unit time) × dt] = 1.8 µg at the end of one unit time or one integration interval. This process yields the amount in tissue, which is divided by the volume of the tissue compartment to obtain the concentration in the tissue, which in turn is used as the basis to derive the free concentration of chemical leaving the tissue. The integration, or the determination of numerical solution, for the differential equations used in PBPK models can be obtained using different algorithms (i.e., step-by-step procedures). For a generic differential equation of the following form: dy = f(t, y) dt
(2.7)
at any time t = t0 , y = y0 , the derivative is f (t0 , y0 ); the true solution (value) of the y at t = t0 + ∆t can be expressed by an infinite series as follows: f (t0 + ∆t) = f (t0 ) + f (t0 ) ∆t +
1 1 1 f (t0 ) ∆t 2 + f (t0 ) ∆t 3 + f (t0 ) ∆t 4 + · · · 2 6 24 (2.8)
A number of algorithms are useful for solving the differential equations used in PBPK models (e.g., Euler, Gear, Runge–Kutta routines, and predictor-corrector methods) (Gear 1971; Rideout 1991; Haddad, Pelekis, and Krishnan, 1996). Of the commonly used
28
PBPK Modeling: A Primer Ca =
QpCi + QcCv Q Qc + p Pb:a
V C dAt = Ql (Ca − Ccl ) − max vl dt K m + Cvl
dAr = Qr (C a − Cvr ) dt
t
Al = ∫ dAl
t
Ar = ∫ dAr
0
0
Cl =
Al Vl
Cr =
C vl =
Cl Pl
Ar Vr
C vr =
Cr Pr
Cv =
Qr Cvr + Ql Cvl Qc
Figure 2.3 Illustration of the calculation of mixed venous blood concentration in PBPK models (abbreviations defined in Table 2.1).
algorithms, the Euler method takes the first term of the derivatives (Equation 2.8) for the increments in integration, and therefore the error associated with Euler method arises from the negligence of the rest of the terms and is proportional to ∆t2 . The Runge–Kutta method, on the other hand, takes four terms in approximating the integration update. The associated error then is proportional to or of the same order as ∆t5 . In other words, the higher the order of the error, the more accurate would the integration method be. Let’s examine the derivation of solution and the integration mechanics, using a simple PBPK model. Figure 2.3 shows the equations and interconnections in a two compartmental PBPK model (liver and rest of body). Here, to compute the mixed venous concentration, Cv , the venous blood concentration leaving the two compartments is needed (Cvl , Cvr ). To compute Cvl and Cvr , in turn, the concentrations in the respective tissues are required (Cl , Cr ) in addition to the knowledge of the tissue: blood partition coefficients. The tissue concentrations in turn can be calculated knowing the amount in tissues, Al and Ar , which result from the integration of the differential equations in each of these tissues (dAt/dt). In order to solve the two differential equations (one for each compartment), we need the arterial blood concentration, Ca , as well as the tissue blood flow rate (Ql , Qr ). Ca , in turn, can be calculated with knowledge of several input parameters along with that of mixed venous concentration, Cv , thus establishing a loop-type calculation within the PBPK model (Haddad, Pelekis, and Krishnan, 1996). The solution to the differential equations then becomes key to the computational implementation of these models. In this example, for initial conditions of n = 0, f = 0, Cl = 0, Cr = 0 and Ci = 45 µg/l, the differential equations can be written as follows (Note that the simplification is the result of the use of all the numerical values of constants in the equations): fl (Cl , Cr ) =
1.0301Cl dCl = −114.270Cl − + 81.1640Cr + 128.629Ci dt 1.10713Cl + 59.04 (2.9)
Mathematical Representation
fr (Cl , Cr ) =
dCr = 4.7517Cl − 4.9145Cr + 17.1419Ci dt
29
(2.10)
For the above problem, the solution based on Euler method is obtained as follows: (2.11) Cln+1 = Cln + fln Cln , Crn ∗ ∆t Crn+1 = Crn + frn (Cln , Crn ) ∗ ∆t
(2.12)
For the fourth-order Runge–Kutta integration method, the updates are calculated as follows: k1 = fl (Cln , Crn ) ∗ ∆t
(2.13)
l1 = fr (Cln , Crn ) ∗ ∆t
(2.14)
1 1 k2 = fl Cln + k1 , Crn + l1 ∗ ∆t 2 2
(2.15)
1 1 l2 = fr Cln + k1 , Crn + l1 ∗ ∆t 2 2
(2.16)
1 1 n n k3 = fl Cl + k2 , Cr + l2 ∗ ∆t 2 2
(2.17)
1 1 n n l3 = fr Cl + k2 , Cr + l2 ∗ ∆t 2 2
(2.18)
k4 = fl Cln + k3 , Crn + l3 ∗ ∆t
(2.19)
l4 = fr Cln + k3 , Crn + l3 ∗ ∆t
(2.20)
and updates at each iteration using the Runge–Kutta method are obtained as follows: Cln+1 = Cln +
1 (k1 + 2k2 + 2k3 + k4 ) 6
(2.21)
1 (l1 + 2l2 + 2l3 + l4 ) 6
(2.22)
Crn+1 = Crn +
The solution obtained with Euler integration is presented in Box 2.1, while the step-bystep solution obtained with Runge–Kutta procedure is depicted in Box 2.2, for the first two integration intervals. The results of integration obtained with these two methods, for this particular case, are very close to each other as summarized in Table 2.3.
30
PBPK Modeling: A Primer
Box 2.1: Solution by Euler method At n = 1, t = n∗ dT = 0.001 fl(0, 0) = - 114.270∗ 0 + 81.1640∗ 0 - 1.0301∗ 0(1.0713∗ 0 + 59.04) + 128.629∗ 45 = 5788.3 Cl(n=1) = Cl(n=0) + dT∗ fl = 0 + 0.001 ∗ 5788.3 = 5.7883 fr(0, 0) = 4.7517∗ 0 - 4.9145∗ 0 + 17.7419∗ 45 = 798.386 Cr(n=1) = Cr(n=0) + dT∗ fr = 0 + 0.001 ∗ 798.386 = 0.7984 n = 2, t = n∗ dT = 0.002 fl(5.7883, 0.7984) = - 114.270∗ 5.7883 + 81.1640∗ 0.7984 - 1.0301∗ 5.7883/(1.0713∗ 5.7883 + 59.04) + 128.629∗ 45 = 5191.59 Cl(n=2) = Cl(n=1) + dT∗ fl = 5.7883 + 0.001 ∗ 5191.59 = 10.9799 fr(5.7883, 0.7984) = 4.7517∗ 5.7883 - 4.9145∗ 0.7984 + 17.7419∗ 45 = 821.966 Cr(n=2) = Cr(n=1) + dT∗ fr = 0.7984 + 0.001 ∗ 821.966 = 1.6204
Box 2.2: Solution by Runge–Kutta method n = 1, n∗ dT = 0.001 kl = fl(Cl, Cr)∗ dT = fl(0,0)∗ 0.001 = 5.7883 l1 = fr(Cl, Cr)∗ dT = fr(0,0)∗ 0.001 = 0.798386 fl(0,0)=-114.270∗ 0 + 81.1640∗ 0 - 1.0301∗ 0/(1.0713∗ 0 + 59.04) + 128.629∗ 45 =5788.3 fr(0,0)=4.7517∗ 0 - 4.9145∗ 0 + 17.7419∗ 45 = 798.386 k2 = fl(Cl+k1/2, Crl1/2)∗ dT = fl(0+5.7883/2, 0+0.798386/2) = 5.48994 l2 = fr(Cl+k1/2, Cr+l1/2)∗ dT = fr(0+5.7883/2, 0+0.798386/2 = 0.810176 fl(2.89415, 0.399193)=-114.270∗ 2.89415 + 81.1640∗ 0.399193 - 1.0301∗ 2.89415/(1.0713∗ 2.89415 + 59.04) + 128.629∗ 45 =5489.94 fr(2.89415, 0.399193)=4.7517∗ 2.89415 - 4.9145∗ 0.399193 + 17.7419∗ 45 = 810.176 k3 = fl(Cl+k2/2, Crl2/2)∗ dT = fl(0+5.48994/2, 0+0.810176/2) = 5.50747 l3 = fr(Cl+k2/2, Cr+l2/2)∗ dT = fr(0+5.48994/2, 0+0.810176/2) = 0.809438 fl(2.74497, 0.405088)=-114.270∗ 2.74497 + 81.1640∗ 0.405088 1.0301∗ 2.74497/(1.0713∗ 2.74497 + 59.04) + 128.629∗ 45 =5507.47 fr(2.74497, 0.405088)=4.7517∗ 2.74497- 4.9145∗ 0.405088+ 17.7419∗ 45 = 809.438 k4 = fl(Cl+k3, Crl3)∗ dT = fl(0+5.50747, 0+0.809438) = 5.22458 l4 = fr(Cl+k3, Cr+l3)∗ dT = fr(0+5.50747, 0+0.809438) = 0.820577
Mathematical Representation
31
fl(5.50747, 0.809438)=-114.270∗ 5.50747+ 81.1640∗ 0.8094381.0301∗ 5.50747/(1.0713∗ 5.50747+ 59.04) + 128.629∗ 45 =5224.58 fr(5.50747, 0.809438)=4.7517∗ 5.50747- 4.9145∗ 0.809438+ 17.7419∗ 45 = 820.577 Cl(n=1) = Cl(0)+(k1+2∗ k2+2∗ k3+k4)/6 = 0 + (5.7883 + 2∗ 5.48994 + 2∗ 5.50747 + 5.22458)/6 = 0 + 5.50128 = 5.50128 Cr(n=1) = Cr(0)+(l1+2∗ l2+2∗ l3+l4)/6 = 0 + (0.798386 + 2∗ 0.810176 + 2∗ 0.809438 + 0.820577)/6 = 0 + 0.809698 = 0.809698 n = 2, n∗ dT = 0.002 kl = fl(Cl, Cr)∗ dT = fl(5.50128,0.809698)∗ 0.001 = 5.2253 l1 = fr(Cl, Cr)∗ dT = fr(5.50128,0.809698)∗ 0.001 = 0.820547 fl(5.50128,0.809698)=-114.270∗ 5.50128 + 81.1640∗ 0.809698 - 1.0301∗ 5.50128/(1.0713∗ 5.50128 + 59.04) + 128.629∗ 45 =5225.3 fr(5.50128,0.809698)=4.7517∗ 5.50128 - 4.9145∗ 0.809698 + 17.7419∗ 45 = 820.547 k2 = fl(Cl+k1/2, Crl1/2)∗ dT = fl(5.50128+5.2253/2, 0.809698+ 0.820547/2) = 4.96002 l2 = fr(Cl+k1/2, Cr+l1/2)∗ dT = fr(5.50128+5.2253/2, 0.809698+ 0.820547/2= 0.830945 fl(8.11394, 1.21997)=-114.270∗ 8.11394 + 81.1640∗ 1.21997 1.0301∗ 8.11394 /(1.0713∗ 8.11394 + 59.04) + 128.629∗ 45 = 4960.02 fr(8.11394, 1.21997)= 4.7517∗ 8.11394 - 4.9145∗ 1.21997 + 17.7419∗ 45 = 830.945 k3 = fl(Cl+k2/2, Crl2/2)∗ dT = fl(5.50128+4.96002/2, 0.809698+ 0.830945/2) = 4.9756 l3 = fr(Cl+k2/2, Cr+l2/2)∗ dT = fr(5.50128+4.96002/2, 0.809698+ 0.830945/2) = 0.830289 fl(7.98129, 1.22517)=-114.270∗ 7.98129+ 81.1640∗ 1.225171.0301∗ 7.98129/(1.0713∗ 7.98129+ 59.04) + 128.629∗ 45 =4957.6 fr(7.98129, 1.22517)=4.7517∗ 7.98129- 4.9145∗ 1.22517 + 17.7419∗ 45 = 830.289 k4 = fl(Cl+k3, Crl3)∗ dT = fl(5.50128+4.9756, 0.809698+0.830289) = 4.72407 l4 = fr(Cl+k3, Cr+l3)∗ dT = fr(5.50128+4.9756, 0.809698+ 0.830289) = 0.840109 fl(10.4769, 1.63999)=-114.270∗ 10.4769+ 81.1640∗ 1.639991.0301∗ 10.4769/(1.0713∗ 10.4769+ 59.04) + 128.629∗ 45 =4724.07 fr(10.4769, 1.63999)=4.7517∗ 10.4769- 4.9145∗ 1.63999+ 17.7419∗ 45 = 840.109 Cl(n=2) = Cl(1)+(k1+2∗ k2+2∗ k3+k4)/6 = 5.50128 + (5.2253 + 2∗ 4.96002 + 2∗ 4.9756 + 4.72407)/6 = 5.50128 + 4.9701 = 10.4714 Cr(n=2) = Cr(1)+(l1+2∗ l2+2∗ l3+l4)/6 = 0.809698 + (0.820547 + 2∗ 0.830945 + 2∗ 0.830289 + 0.840109)/6 = 0.809698 + 0.830521 = 1.64022
32
PBPK Modeling: A Primer
Table 2.3 Summary of integration results obtained for Equations (2.9) and (2.10), using Euler and fourth order Runge–Kutta algorithms. Time
Cl (µg/l) Euler
0 0.001 0.002 0.003 0.004 0.005 0.006 0.007 0.008 0.009 0.01
0 5.788 10.979 15.644 19.845 23.635 27.063 30.172 32.998 35.576 37.934
Cr (µg/l)
Runge–Kutta
Euler
Runge–Kutta
0 5.501 10.471 14.969 19.047 22.751 26.123 29.200 32.014 34.595 36.968
0 0.798 1.620 2.463 3.323 4.2 5.090 5.992 6.904 7.825 8.754
0 0.809 1.640 2.489 3.354 4.233 5.124 6.027 6.939 7.859 8.787
2.3.2 Calculating the Concentration of Chemical Leaving the Tissues In the “venous equilibration-type” PBPK models, the chemical concentration in venous blood leaving the tissue is considered to be in equilibrium with the chemical in tissue. In this case then, if the tissue:blood partition coefficient (Pt ) is 10, it would imply that the affinity of the chemical towards the tissue is 10 times greater than that for the blood. In other words, the concentration of chemical leaving the tissue compartment to enter the venous blood pool, that is, Cvt , will be equal to one tenth of the tissue concentration. Notationally, Cvt = Ct /Pt . So the greater the tissue:blood partition coefficient, the greater the concentration in a given tissue and the smaller the contribution of the tissue to the mixed venous pool. In calculating Cvt , binding to tissue proteins and blood proteins should be accounted for, as applicable (Chapter 7). 2.3.3 Calculating the Arterial and Venous Blood Concentrations The arterial blood concentration, following inhalation exposures, has been calculated based on the mass balance equation for the combined lung tissue-alveolar air compartments as shown in Box 2.3. The algebraic equation for computing arterial blood concentration shown in Box 2.3 is based on the specification that the loss of chemical from the air is balanced by an identical gain in the pulmonary (arterial) blood (Ramsey and Andersen, 1984). Box 2.3: Calculation of Arterial Blood Concentration During Inhalation Exposures (Parameters and Variables are Defined in Table 2.1) Conceptual model: Qp · Cinh Qc · Cv v
Qp · Calv Qc · Ca
Mathematical Representation
33
Quantitative descriptions leading to computation of arterial blood concentration: Q p Cinh + Q c Cv = Q p Calv + Q c Ca Q c Ca − Q c Cv = Q p Cinh − Q p Calv Calv =
Ca Pb
Q c Ca − Q c Cv = Q p Cinh − Q p
Ca Pb
Ca = Q p Cinh + Q c Cv Pb Qp Ca Q c+ = Q p Cinh + Q c Cv Pb
Q c Ca + Q p
Ca =
Q p Cinh + Q c Cv Q Q c + Pbp
The mixed venous blood concentration, resulting from the pooling of the venous blood exiting various tissue compartments (Figure 2.4), is not a simple, arithmetic average of the Cvt of the various tissues. Rather, it is a weighted average of the free concentrations of chemicals originating from the tissues. This is due to the fact that the fraction of cardiac output flowing through the tissues differs from one tissue to another (e.g., liver = 0.25, fat = 0.09, slowly perfused tissues = 0.15, and richly perfused tissues = 0.51 in the rat); therefore, the weighted average is calculated as follows: Cven = (0.25 × Cvl ) + (0.09 × Cvf ) + (0.15 × Cvs ) + (0.51 × Cvr )
2.3.4
(2.23)
Calculating the Rate of Metabolism
The rate of the amount of chemical metabolized in liver or other metabolizing tissues can be computed as per the nature of the metabolic reaction. Accordingly, it may be calculated using the first order, second order or saturable descriptions as shown below: dAmet = K f Cvt Vt dt dAmet = K s Cvt Vt Ccf dt Vmax Cvt dAmet = dt K m + Cvt
(2.24) (2.25) (2.26)
In all the above cases, dAmet /dt has units of mg/h (or quantity per time). Whereas the first order reaction suggests that the amount metabolized per unit time increases (or decreases)
34
PBPK Modeling: A Primer Ql · Cvl (Liver)
Qf · Cvf (Fat)
Qc · Cv
Qr · Cvr (Richly perfused tissues)
Qp · Cvp (Poorly perfused tissues) n
∑Q ⋅C t
Cv =
vt
t =1
Qc
Figure 2.4 Functional representation of a two-compartmental PBPK model for a volatile organic chemical. All symbols and abbreviations are defined in Table 2.1.
in direct relation to the input variable (i.e., free concentration of chemical), the second order reaction suggests that it is a function of both cofactor as well as the substrate. The saturable reaction, on the other hand, implies that the reaction is essentially first order at low concentrations of the substrates, and it approaches zero order after a certain high concentration (which exceeds the K m for the reaction). Box 2.4 depicts the relationship between the metabolism rate and hepatic clearance, on the basis of the venous equilibration model. Other types of physiological descriptions of liver metabolism, such as the parallel tube model and the distributed sinusoidal perfusion model, may also be used, depending upon the objective of the study (Liu and Pang, 2006). Conjugation reactions are often described as a second order process (Equation 2.25) with respect to the concentration of the cofactor and the chemical (D’Souza, Francis, and Andersen, 1988; Krishnan et al., 1992). Alternatively, descriptions based on a ping-pong mechanism have also been used successfully (Csanady et al., 1996).
Box 2.4: Quantitative Description of Hepatic Clearance for a Well-Stirred Model of Liver (Refer to Table 2.1 for the Definition of Parameters and Variables) Conceptual model: Ql Cvl
Liver
CLint
Cvl
Ql Ca
Computer Implementation
35
Quantitative description of hepatic clearance: Amount in = amount out + amount metabolized Vmax · Cvl Q l · Ca = Q l · Cvl + Km As CLh = Q l · ⎡
⎛
Ca − Cvl Ca
and Cvl =
Q l · Ca Ql +
Vmax Km
⎞⎤
⎜ Q l · Ca ⎟ ⎥ ⎢ ⎟⎥ ⎢ Ca − ⎜ ⎝ ⎢ Vmax ⎠ ⎥ ⎢ ⎥ Ql + ⎢ Km ⎥ ⎥. CLh = Q l · ⎢ ⎢ ⎥ Ca ⎢ ⎥ ⎢ ⎥ ⎢ ⎥ ⎣ ⎦
⎛ Simplifying,
⎜ CLh =Q l · ⎜ ⎝1 −
⎛
⎞ Vmax + − Q Q l⎟ ⎜ l Km ⎟ Rewriting, CLh = Q l · ⎜ ⎝ Vmax ⎠ Ql + Km since
⎞ ⎟ Ql ⎟ Vmax ⎠ Ql + Km
Vmax Km CLh = Vmax Ql + Km Ql ·
or
Vmax Q l · CLint = CLint , CLh = , Km Q l + CLint
For high clearance (CLint Q l ) CLint ≈ Ql CLh = Q l · Q l + CLint
For low clearance (CLint Q l ) CLint CLh = Q l · ≈ CLint Q l + CLint
2.4 Computer Implementation This section describes the implementation of PBPK models using an open-source model equation generator, MEGen. The following description is based on MEGen Version 0.3.0.16788 (http://xnet.hsl.gov.uk/megen/). However, it is emphasized that MEGen captures just one approach to the computational representation and implementation of the model building process. MEGen comprises two main components: an electronic database of species-specific anatomical and physiological parameters for the most commonly used species in toxicological research, and a PBPK model equation generator (Figure 2.5). MEGen enables a user to describe physiology, biology, and toxicology in order to output a set of mathematical equations that emulate the information supplied by the user and which
36
PBPK Modeling: A Primer MATLAB®
Database acslXtreme®
Equation Generator
XML MCSim
Berkeley Madonna®
Figure 2.5
Overview of MEGen and the model generation process.
constitute a PBPK model. Collation and storage of the most commonly used species-specific anatomical and physiological parameters, such as organ and tissue masses and blood flow rates, into an electronic database provide a means of readily and rapidly accessing these data. Further, by merging the database with the equation generator it would be possible for the software to interrogate and retrieve pertinent data for use within the model during the model building process. The PBPK functional forms are merged, in the form of mathematical markup language (MathML), into an extensible markup language (XML) document. The resulting mathematics can be translated and imported into a number of modeling packages where the equations can be solved and the output visualized (Figure 2.5). The current version of MEGen can generate code for Berkerley Madonna (www.berkeleymadonna.com), acslXtreme version 2.4 (www.acslXtreme.com), and MATLAB (www.mathworks.com), which are commercial available packages, and MCSim (http://fredomatic.free.fr/), which is freely available. In addition, MEGen provides a schematic diagram of a built model along with a corresponding table listing the value, units, source, origin, and reference for each parameter specified (Figure 2.6). The diagrams and tables can be exported directly into documents prepared in standard word processors, providing a clear, transparent, and auditable trail as well as error-free, auditable numerical code. Generated code is designed to be robust to modification outside of MEGen due to the presence of a number of check functions. One example of this is an expression to ensure that mass balance is preserved. Manual alterations to code can create inconsistencies in the equations, leading to predictions that do not correspond to the modeling assumptions. By inserting a check function that calculates the quotient of mass delivered and amount present in the compartments as well as the amount excreted, it is possible to plot this function over time. The mass balance check function should be used after every manual alteration made to the model code. Building such check functions into code generated using MEGen increases the chances of trapping errors in the code that may subsequently be manually adjusted. In the Berkeley Madonna code this function is expressed as: rel = IF(dose > 0)THEN mass/dose ELSE 1
Computer Implementation
Figure 2.6
37
Model documentation by MEGen.
The IF statement prevents division by zero when dose = 0. In practice, this is only likely to occur before exposure (usually at time = 0). 2.4.1
A PBPK Model for β-Chloroprene
Implementation is illustrated in this section, which includes a selection of screenshots taken from MEGen during the construction of a male Syrian Golden hamster model for simulation of exposure to β-chloroprene. The physiological, biochemical, and physicochemical parameters were taken from the paper by Himmelstein et al. (2004). It is not a comprehensive step-by-step guide, although the selection of screenshots should convey the intuitive nature of the approach. Table 2.4 lists the parameters used to build the model; they were either determined experimentally by Himmelstein et al. (2004), taken by Himmelstein et al. from Brown et al. (1997), or are default assumptions in MEGen. Clicking “database” or “model” menu options on the home page provides access to the PBPK database and model equation generator, respectively. Clicking on “model” and then “load” leads to a page where the model builder wizard can be run. In addition to obtaining help by clicking “Help” on the drop down menu, assistance and information text is available on various pages. The left-hand pane contains links to different steps of the model building process. The transparent box is a “floating menu” which allows models to be saved at various stages of the model building process, initiation of the building process, editing, and verification of a model structure (validation) and the generation of model code for export. Model building is initiated by clicking “Begin” at the bottom right-hand corner; alternatively, clicking “Labeling” in the left-hand pane of the model builder wizard home page
38
PBPK Modeling: A Primer
Table 2.4 Parameters used to build model for β-chlorpyrene in MEGen. Parameter
Symbol
Value
Molecular mass (g/mol) Body mass (kg) Proportion of vascularized tissue (body mass) Cardiac allometric constant (l/h/kg) Cardiac allometric exponent Respiratory allometric exponent Blood:air partition coefficient
RMM BW VT QCC CAE RAE Pba
88.53 0.11 0.91 30 0.75 0.75 9.3
Metabolism (Oxidative, Liver) Michaelis constant (mg/l) Maximum rate of metabolism (scaled to body mass) (mg/h)
KM V max C
Gas exchange Proportion of dead space (not involved in gas exchange) Respiratory allometric constant (l/h/kg)
DS QPC
0.3 30
c
Partition coefficient Slowly perfused Richly perfused Adipose Liver
Pspda Prpda Pfaa Plia
5 8.2 130.1 10.5
a
Tissue blood flow as a fraction of cardiac output Slowly perfused blood flow Richly perfused blood flow Adipose blood flow Liver blood flow
QspdC Qrpd QfaC QliC
0.15 0.07 0.183
Tissue volume as a fraction of body mass Slowly perfused mass Richly perfused mass Adipose mass Liver mass
V spdC V rpd V faC V liC
0.75 — 0.07 0.04
0.118 4.28
Reference c b c a c c a
a a
a
a a a
a d a a
b d b b
a
Himmelstein et al. (2004). Brown et al. (1997). Default assumption in MEGen. d Calculated by difference by MEGen. b c
opens the labeling page. A title and description of the model can be entered here. A simple PBPK model comprising a slowly and richly perfused compartment, represented by the schematic on the right-hand side, is the starting point of the model building process. As organs and tissue compartments are defined discretely they are removed from the aggregated compartments and the schematic diagram is updated accordingly. The aggregated compartments are reduced by the same mass and blood perfusion rate as the newly defined discrete compartment in order to maintain mass and blood flow balance. Clicking on “Exposure routes” or “next” in the bottom right-hand corner links to the “Exposure Routes” page (Figure 2.7). At the time of writing, MEGen had dermal, inhalation, and intravenous routes available. An example of how the schematic diagram is updated to include a gas exchange
Figure 2.7
Configuration of exposure routes in MEGen.
40
PBPK Modeling: A Primer
compartment when the inhalation route is enabled is illustrated in Figure 2.7. Clicking “Next” in the bottom right-hand corner or “Metabolism” in the left-hand panel links to the page where metabolism can be ascribed to, and enabled for, any chosen organ or tissue compartment. The schematic is updated to include a compartment in which metabolism can take place. In this example the diagram displays the liver compartment. Any number of enzymes, which contribute to metabolism, can be described. Clicking on “Functions” in the left-hand pane links to the “Functions” page. The appropriate form or “dose metric” of the chemical leading to a biological response is selected on this page. For example, the “peak” value or “areaunder-the-curve” of the venous or exhaled concentration of chemical or the rate or amount metabolized may be selected. Clicking “Compartments” in the left-hand pane or “Next” at the bottom right hand corner loads the compartments page (Figure 2.8). More compartments may be defined discretely by enabling the required compartment. In the example shown in Figure 2.8 adipose, stomach, and gut compartments have been enabled. Another example of an in-built check function is demonstrated in Figure 2.8. The correct anatomical location of organs and tissues such as the stomach and gut, which send blood to the liver by pouring blood into the hepatic portal vein, are enforced in MEGen. Likewise, when enabled the lung would appear separately from the gas exchange compartment and have the same configuration of arterial input and venous output as seen for liver, adipose, richly perfused, and so on. This is because the lung has two circulations, the pulmonary circulation that perfuses the alveoli, and the bronchial circulation that provides nutrients and gas exchange for the conducting airways. The bronchial circulation is part of the systemic circulation and receives about 2% of the cardiac output from the left side of the heart. Many PBPK models published in the literature, which describe a lung compartment for the estimation of tissue dosimetry, do not separate the bronchial and pulmonary circulations (e.g., Csanady et al., 2003; Himmelstein et al., 2004). Clicking on “Animal” in the left-hand pane links to the animal selection page. The anatomical and physiological parameters for a number of animal species and their gender are available in the database. Selection of an animal species imposes a filter during interrogation and retrieval of model parameters from the database, so that only those parameters corresponding to that animal species can be selected. Clicking on “Chemical” in the left-hand pane links to the chemical selection page. Chemical specific data such as partition coefficients can also be stored in the database. The specification of a chemical imposes an additional filter to further limit the interrogation and retrieval of chemical-specific data from the database. Clicking on “Configuration” links to the “Configuration” page where on–off time points for exposure may be configured. Each enzyme that contributes to the metabolism of the chemical is named on this page. In the case of β-chloroprene a general name such as “oxidative” may be entered to describe cytochrome P450 enzyme mediated oxidative metabolism. In addition, an abbreviation may be entered such as “2E1” if the specific isoenzyme catalyzing the metabolism of the chemical is known. This information provides labels that will appear in the code that is generated once the model is completed and also provides the name “Oxidative metabolism,” in this case, for the header on the data entry page for metabolism (Figure 2.9). Clicking on “Data” in the left-hand pane links to the page where model parameters can be selected (Figure 2.9). Model parameters such as body mass, organ and tissue masses, blood perfusion rates, partition coefficients, and metabolic rate constants are entered on the “Data” page. Clicking
Figure 2.8
Additional compartment selection in MEGen.
Figure 2.9
Model parameter input in MEGen.
Computer Implementation
43
the “Root” header allows entry of the molecular mass of the chemical, the body mass of the animal, proportion of vascularized tissue, and blood:air partition coefficients. If allometric equations are used to estimate cardiac output then the cardiac allometric constant and exponent may be entered. The default allometric exponents for biological flow rates are 0.75 (Ings, 1990). The respiratory allometric constant or alveolar ventilation rate is entered under the “Gas exchange” header (Figure 2.9). Clicking on “Edit” allows selection of a datum (Figure 2.10). An “Edit datum” dialog box appears. Clicking the cylinder symbol initiates a search of the PBPK database. If the datum does not appear in the database the datum may be entered manually by clicking the fountain pen nib symbol. Clicking the cylinder brings up another dialog box with a datum selected from the database. In this example, the blood:air partition coefficient for β-chloroprene in the Golden Syrian Hamster is available (Figure 2.11). In addition to the parameter value, the animal species, sex, chemical, and source of the datum are displayed. Also, the ticked boxes indicate that filters for animal species and chemical are enabled. Clicking “Select” retrieves the datum, which is then incorporated into the model. A summary information page, for the selected datum, appears by clicking the information button, “i” to the left of the “Select” button in the dialog box. The partition coefficient, organ mass, and perfusion rate are retrieved by interrogating the database or entering the value directly as described for each compartment. The appropriate units for the metabolic rate constants, K M and V max may be selected from a drop down menu obtained after clicking the “Oxidative” header. Clicking “Finish” in the left-hand pane links to the “Build Complete” page. The model is considered “valid,” which, in this specific context, implies that all the required parameters and configurations have been successfully entered (Figure 2.12). A validation report on model structure may be viewed by clicking “View validation report.” The validation report provides an overview of the model. It lists the compartments, exposure, and elimination routes. When a datum is missing from a specific compartment it is highlighted along with instructions to rectify the problem. When clicking “generate code” an XML document is created, which is populated by the built model. The PBPK functional forms are merged, in the form of MathML, into the XML document (see the folder entitled LOIZOU in the QMT Model Library). For the computer codes of PBPK models written in Bekeley Madonna and Microsoft Excel, ACSL, and MATLAB the reader is referred to the MODEL LIBRARY folders for Chapters 3, 4, 5, 7, and 11 (e.g., manganese, 2,3,7,8-TCDD, chloroform and mixtures of volatile aromatic hydrocarbons). A list of toxicologically important chemicals for which PBPK models have been developed in one or more species is provided in Table 2.5. For further mathematical treatment of PBPK models, parameter estimation methods, as well as their evaluation and use in risk assessment, the reader is referred to Gerlowski and Jain (1983), Clark, Setzer, and Barton (2004), Reddy et al. (2005), Lipscomb and Ohanian (2006), Chiu, Barton, and Dewoskin (2007), Krishnan and Andersen (2007) and Chapter 21. Whereas Chapter 5 of this volume discusses physiological parameters and databases for PBPK modeling, the following sections highlight current progress and challenges regarding the integration of in vitro and in silico approaches within PBPK models, to facilitate their rapid development in data-poor situations.
Parameter selection in MEGen.
Cylinder
Figure 2.10
Fountain pen nib
Figure 2.11
Searching the database in MEGen.
Figure 2.12
MEGen model completion screenshot.
Computer Implementation
47
Table 2.5 List of environmental chemicals for which PBPK models have been developed in one or more speciesa . Acetone Acrylamide Acrylic acid Acrylonitrile & cyanoethylene oxide Aldicarb Allyl chloride Amyl methyl ether (tert) & tert-amyl alcohol Arsenic
Dichloroethane (1,2-) Dichloroethylene (1,1-; 1,2) Dichloromethane Dichlorophenoxyacetic acid (2,4-) Dieldrin Diethylether Difluoromethane
Methyl mercury Methyl tertiary-butyl ether Methylene chloride Methylene dianiline (4,4 -)
Diisopropylfluorophosphate
Benzene Benzo(a)pyrene Benzoic acid Bisphenol A Bromide Bromochloromethane Bromodichloromethane Bromoform Bromotrifluoromethane
Dimethyl sulfate Dioxane (1,4-) Dioxins Ethanol Ethyl acrylic acid Ethylbenzene Ethylene dibromide Ethylene dichloride Ethylene glycol and its metabolite Ethylene glycol mono butyl ether & intermediates Ethylene oxide Fluazifop-butyl Fluoride
Naphthalene & naphthalene oxide n-Hexane n-Hexane Nickel Nicotine Nitropyrene Octamethylcyclotetrasiloxane Paraoxon Parathion PCBs
Butadiene (1,3-) and metabolites Butanol (tertiary) Butoxyacetic acid (2-) Butoxyethanol (2-) and metabolites Butyl compounds (n-butyl acetate, n-butanol, n-butyraldehyde, n-butyric acid) Carbon tetrachloride
Chlordecone Chlorfenvinphos Chloride Chloro(1-)-1,1difluoroethane Chloro(2-)-1,1,1,2tetrafluoroethane Chlorobenzene Chloroethane Chlorofluorohydrocarbons
Formaldehyde
Furans
Methylethylketone Methylmetacrylate Mirex
p-chlorobenzotrifluoride Pentachloroethane Pentafluoroethane Phthalates (diethylhexyl-; dibutyl-; monobutyl-) Polychlorotrifluoroethylene
Glycol ethyl ether acetate Glycol monomethyl ether Heptafluoropropane Hexachlorobenzene
Propylene glycol methyl ether & propylene glycol methyl ether acetate Pyrene Styrene Tetrachloroethane (1,1,1,2-) Tetrachloroethane (1,1,2,2-)
Hexachlorobutadiene
Tetrachloroethylene
Hexachloroethane Hexanedione (2,5-) Hexanemethyldisiloxane
Tetrachorobenzyltoluene Toluene Toluene diamine (Contined)
48
PBPK Modeling: A Primer
Table 2.5 (Continued) Chloroform
Hydroquinone
Chloromethane Chloropentafluorobenzene Chloroprene (β-) Chlorpyrifos Chromium Cyclohexane DDE Decane Diazinon Dibromochloromethane Dibromoethane (1,2-) Dibromomethane Dichloro(1,1-)-1fluoroethane Dichlorodiphenylsulfone (p-p -)
Iodide Iron Isofenphos Isoflurane Isopropanol Isopropene Lead Lindane Malathion Manganese Methanol Methoxyacetic acid (2-) Methoxyethanol (2-)
a
Trichloroethylene and its metabolites Trichlorofluoromethane Trichloropropane (1,2,3-) Trifluoroethane Trifluoroiodomethane Trifluralin Trimethyl-2-pentanol (2,4,4-) Trimethylbenzene (1,2,4-) Vinyl acetate Vinyl chloride Vinyl fluoride Xylene Zinc
Methyl chloroform
Based on compilations by Krishnan and Andersen (2008).
2.5 In silico Methods for PBPK Modeling Limited advances have been made regarding the development of in silico methods, particularly qualitative and quantitative structure–activity relationship (QSAR) models for parameterizing PBPK models (B´eliveau and Krishnan 2003). An advantage of QSARs is that the impact of number and nature of the molecular fragments on the pharmacokinetics of chemicals (within the valid application domain) under untested scenarios can be generated. As such, these could be useful as a tool for screening-level evaluation and for planning limited key pharmacokinetic studies in vivo. The in silico approaches for estimating tissue:air, blood:air and tissue:blood partition coefficients may be one of the following types: empirical, mechanistic, and semi-empirical (B´eliveau and Krishnan, 2003). The empirical methods relate the partition coefficients to structural features or physicochemical properties of chemicals through a mathematical function, whereas the mechanistic approaches allow the use of information on the mechanisms (i.e., solubility and binding) in computing the parameters. In this regard, the tissue:blood PCs of volatile organic chemicals, for which macromolecular binding in tissue and blood is negligible, have been estimated from n-octanol:water PCs or vegetable oil:water PCs (Po : w ) as follows (Poulin and Krishnan, 1995):
Pt =
(Po:w × Fnlet ) + Fwet (Po:w × Fnleb ) + Fweb
(2.27)
In silico Methods for PBPK Modeling
49
Table 2.6 The content (volume/volume) of neutral lipid and water equivalents of major tissues in humans and rats (Poulin, Beliveau, and Krishnan, 1999). Water equivalent
Neutral lipid equivalent
Tissues
Rat
Human
Rat
Human
Blood Fat Liver Muscle
0.842 0.121 0.717 0.747
0.821 0.151 0.740 0.757
0.002 0.853 0.042 0.011
0.004 0.798 0.047 0.037
where Fnlet = fractional volume of neutral lipid equivalents in tissue, calculated as the sum of neutral lipids plus 0.3 × phospholipid content, Fwet = fractional volume of water equivalents in tissue, calculated as the sum of tissue water content plus 0.7 × phospholipid content, Fnleb = fractional volume of neutral lipid equivalents in blood, calculated as the sum of neutral lipids plus 0.3 × phospholipid content, and Fweb = fractional volume of water equivalents in blood, calculated as the sum of tissue water content plus 0.7 × phospholipid content. The physicochemical properties in the above equation, in turn, can be obtained with the use of QSARs, and integrated with tissue-specific water and lipid composition data (Table 2.6). Poulin and Theil (2000, 2002) demonstrated the applicability of the above algorithm to predict the tissue:plasma partition coefficients and volumes of distribution of pharmaceuticals, with the consideration of protein binding, as follows: Pvow · Vnlt + 0.3 · V plt + 1 · Vwt + 0.7 · V plt f up · f ut Pvow · Vnlp + 0.3 · V plp + 1 · Vwp + 0.7 · V plp
(2.28)
where: Pvow = vegetable oil:water PC; V = total volume fraction; nl = neutral lipids; pl = phospholipids; t = tissue; p = plasma; fup = unbound fraction in plasma; and fut = unbound fraction in tissue. More recent re-formulations of this algorithm, accounting for the differential behavior in acidic and neutral phospholipids, have been published (Box 2.5). Such in silico approaches for predicting maximal velocity and the Michaelis constant for metabolic reactions in animals and humans are not available yet (B´eliveau and Krishnan, 2003). The limited QSARs developed to date have characterized the fragment-specific values related to intrinsic clearance of volatile organic chemicals (e.g., Table 2.7). The in silico approaches, or algorithms, have been integrated within PBPK models to automatically generate pharmacokinetic predictions based on molecular structure information (B´eliveau et al., 2005; B´eliveau and Krishnan, 2005; Kamgang, Peyret, and Krishnan, 2008).
50
PBPK Modeling: A Primer
Table 2.7 Fragment Specific Contributions toward Po : a and Pw : a as well as Intrinsic Clearance [CLint (l/h/µmol P450)]. Fragments
Log Po : a
Log Pw : a
Log CLint
CH3 CH2 CH C C C H (on ) Br Cl F AC H AC
0.354 0.441 0.377 −0.354 0.197 0.134 0.174 0.776 0.136 3.729 −0.19.0
−3.76E–2 −0.223 −0.477 −1.49 −1.94 0.555 0.622 0.468 0.229 0.650 −0.062 4
1.552 0.514 7.83E–2 −0.871 0.591 0.383 1.00 0.522 −7.646 1.535
From B´eliveau et al. (2005).
Box 2.5: Algorithms for Calculation of Tissue:Plasma Partition Coefficients for Pharmaceuticals (Rodgers, Leahy, and Rowland, 2005; Rodgers and Rowland, 2006) Tissue:plasma PC for weak bases
Ka AP− T · 10 pK a− p HI W 1 + 10 pK a− p HIW · fIW + Ptp = f EW + 1 + 10 pK a− p H p 1 + 10 pK a− p H p Pow · f NL + (0.3 · Pow + 0.7) · f NP + . 1 + 10pKa−pHp Tissue:plasma PC for acids, neutrals, and zwitterions Ptp = f EW +
X · f IW Pow · f NL + (0.3 · Pow + 0.7) · f NP + + KaPR · [PR]T Y Y
where: f = fractional tissue volume; EW = extracellular water; IW = intracellular water; NL = neutral lipids; NP = neutral phospholipids; PR = dominant binding protein; AP= acidic phospholipids; T = tissue; Ka = association constant; pKa = acid dissociation constant; X = 1 for neutrals; (1 + 10pKa – pHIW for monoprotic bases; 1 + 10pHIW-pKa for monoprotic acids; 1 + 10pHIW-pKaACID +10pKABASE-pHIW for zwitterions); Y = 1 for neutrals; (1 + 10pKa-pHp for monoprotic bases; 1 + 10pHp+pKa for monoprotic bases; 1 + 10pHIW-pKaACID + 10pKABASE-pHIW for zwitterions).
2.6 In vitro-Derived Metabolic Parameters for PBPK Models The development of PBPK models, especially those for the human, is complicated by many factors. For humans, ethical constraints limit the exposure to known or suspected toxicants.
In vitro-Derived Metabolic Parameters for PBPK Models
51
Substance availability for scarce and otherwise untested and expensive products may limit the amount of substance available for in vivo testing. Especially in these circumstances, in vitro test systems offer an alternative means of characterizing metabolism. In vitro systems have been used to develop and extrapolate clearance values useful in designing pharmacokinetic and toxicologic studies with test animals, and similar studies with human preparations have been used to develop data considered when estimating safe “first in human” doses for testing of drugs in development. In vitro test systems offer several distinct advantages over in vivo systems in metabolic studies. There are several methodological considerations that must be undertaken when designing, conducting and evaluating data from in vitro systems for the purpose of extrapolating metabolic rate constants. Among these are the choice of the in vitro test system, the methods to quantify metabolic rate constants, data and methods to quantify the amount of enzyme in the intact liver, data to extrapolate in vitro metabolic rate constants to the intact liver, and allometric scaling of extrapolated metabolic rate constants for use in parameterizing PBPK models. 2.6.1
Choosing the In Vitro System
The choice of system and method require careful consideration, with advantages and drawbacks inherent in each. Choosing the in vitro test system requires some basic considerations. Some of the available test systems include tissue slices, isolated cells in primary suspension culture, isolated and plated cells, subcellular fractions (cytosol, microsomal protein, etc.), purified enzymes, recombinantly expressed enzymes, and so on. If characterizing the metabolites without regard to metabolism rate constants, tissue slices may be acceptable; for determining the enzymes responsible for metabolism, recombinant systems represent a good choice. However, to get results best suited to the species of interest, the isolated hepatocyte in suspension culture may represent the best option. When the metabolism of the compound has not been determined (it is not known which enzyme is responsible), the use of plated cells should be avoided, due to the shift in enzymology (selective down-regulation of some enzymes). Further, distribution of substance in an inhomogeneous system may complicate the understanding of substrate availability in the cell. To the extent possible, binding of the substrate to components of the system other than the enzyme or metabolic system should be taken into account. For example, protein binding in vitro may be different from that in vivo, resulting in differential availability to the metabolic systems studied in vitro and for which predictions will be made in vivo. The use of recombinantly expressed enzymes presents some often under-appreciated complications. These systems typically use an expression vector such as bacteria to express a cloned and inserted human gene encoding a drug metabolizing enzyme. When isolated in microsomal protein (especially), these enzymes reside in a lipid matrix that is different in composition and physicochemical properties from that of the human. Further, differences in co-enzymes, such as oxidoreductases, between the two species may also result in different observed catalytic properties of the enzyme (Remmel and Burchell, 1993), although amino acid sequence may be identical. When the enzymology is known, then subcellular preparations offer a cost effective and readily available consideration. These preparations can be easily made in the laboratory or procured from commercial services. The availability of samples from multiple human organ donors offers a means to estimate population variability, within some constraints.
52
PBPK Modeling: A Primer
2.6.2 Quantifying Metabolic Rate Constants PBPK models are populated with values for metabolic rate constants, typically expressed as units of mg/h. The expression of in vitro-derived metabolic rate constants is typically in units of pmol/min/mg subcellular fraction (e.g., microsomal protein; MSP), pmol/min/pmol of a given enzyme, or pmol/min/106 hepatocytes. It is important to consider the expression of enzyme in the in vitro system. Up until recently, metabolic rate constants have usually been expressed as rate per time per milligram MSP, most often without regard to considerations such as inter and intraspecies differences in the MSP content of the responsible enzyme (e.g., pmol CYP2E1/mg MSP). This is a primary concern when extrapolating metabolic rate constants for substrates metabolized by a specific (single) form of an enzyme. Recent advances in quantitative models adapted to 96-well plate reading quantitation have enabled near high-throughput quantitation of CYP forms (Snawder and Lipscomb, 2000). These methods have also been applied to MSP from other species, increasing the reliability of interspecies comparisons of metabolic rate constants derived in vitro. Species differences in enzyme expression have been demonstrated to be one basis for quantitative metabolic differences between species. The combination of well-controlled in vitro metabolic rate constant determination and determination of the responsible enzyme concentration in subcellular preparations can result in increased understanding of interspecies differences in chemical metabolism. Recently, in vitro studies to determine metabolic rate constants for the CYP2E1-mediated metabolism of chloroform in rats and humans demonstrated remarkable species similarity in the specific activity of CYP2E1 for chloroform (pmol/min/pmol CYP2E1) between rats and humans (Lipscomb et al., 2003, 2004). The determination of metabolic rate constants for CYP enzymes usually assumes saturable metabolism, but exceptions have been noted for some forms (e.g., CYP3A forms). For saturable reactions, K m and V max values are derived via conventional methods. The extrapolation of V max values is a relatively straightforward process, whereas the extrapolation of K m values is somewhat more challenging. 2.6.3 Enzyme Quantitation Studies Because the ultimate mediator of xenobiotic biotransformation is the enzyme, the extrapolation of data (i.e., metabolic rate constants) derived in vitro requires quantitative data on enzyme distribution. Regardless of the preparation involved, the goal is the same – to determine the amount of enzyme present per individual (organism). Because most PBPK models are constructed around the assumption that metabolism occurs primarily, if not solely, in the liver, then this is the initial target for extrapolation of enzyme quantity. This is of more direct importance for studies conducted with subcellular preparations than with isolated hepatocytes. Studies with MSP are typical of studies with cytosol and will be used here as an example. The units of expression of original metabolic rate constants determine the methods and data required for extrapolation. When V max is expressed only per milligram MSP, and there are no data to determine the identity of the enzymes involved, or when the substrate is metabolized by multiple enzymes (e.g., multiple CYP forms), then optimal units of measurement may be those expressed per milligram MSP. Here, the most important laboratory measurement may
In vitro-Derived Metabolic Parameters for PBPK Models
53
Table 2.8 Physiologic and biochemical parameters important for scaling in vitro clearance valuesa . Parameter
Parameter value
Scaling factor
0.25 kg 4.5 g/kg BW 1.35 × 108 cells/g liver 45 mg/g liver
11 g 1.5 × 109 cells 500 mg MSP
70 kg 2.6 g/kg BW 99 × 106 cells/g livere 34 mg/g livere
1 820 g 1.8 × 1011 cells 61,880 mg MSP
b
RAT Body Weight Liver Weight Hepatocellularity MSP Yield HUMANc, d Body Weight Liver Weight Hepatocellularity MSP Yield a
Adapted from Lipscomb and Poet (2008). Source: Houston (1994); presented for a Standard Rat Weight (SRW) of 250 grams; values from published literature. c Human values adapted from typical PBPK values. d Cardiac output = 5200 ml/min, liver blood flow = 25% cardiac output; Body weight = 70 kg; liver mass = 0.026 BW (Brown et al., 1997). e Source: Barter et al. (2007). b
be that describing the amount of MSP per gram liver. Barter et al. (2007) have presented the results of a meta analysis of laboratory data demonstrating that a general consensus value for the amount of MSP per gram human liver might be 32 mg/gram. Biological values for the amount of human liver per body mass are available and are already used in PBPK modeling for the purpose of predicting liver dosimetry. For example, if liver comprises 0.026 of body mass, then a 70 kg human will have a liver mass of 1800 grams. Values for mice are not readily available, but Houston and colleagues have developed a value of 55 mg MSP/gram rat liver, and this value has been widely used in the in vitro to in vivo extrapolation of clearance values in drug development. However, when the enzymology or a reaction is known, especially when the reaction is catalyzed by a single form (e.g., CYP2E1), then data on the MSP content of that enzyme become important. There are multiple studies that have presented the distribution of CYP forms to human MSP (e.g., Shimada et al., 1994; Snawder and Lipscomb, 2000). To extrapolate metabolic rate constants expressed per unit enzyme (e.g., pmol/min/pmol CYP2E1), then combining data sets describing the distribution of enzyme to MSP and describing the distribution of MSP to intact liver can and have been combined. This approach was employed by Lipscomb et al. (2004) to examine the population variability of metabolic rate constants for trichloroethylene oxidation in humans, and more recently to examine the age and population variability of chloroform oxidation in humans (USEPA, 2005). Mathematically, these approaches are demonstrated below. Table 2.8 provides some quantitative data useful in the IVIVE of V max values for application in PBPK modeling. 2.6.4
Extrapolation of V max values
Once V max has been determined and appropriate protein (enzyme) recovery data are located, extrapolation to the intact organism is accomplished, followed by scaling for incorporation
54
PBPK Modeling: A Primer
into PBPK models. When V max is determined and expressed as specific activity (turnover number), for example, pmol/min/pmol microsomal enzyme, then the extrapolation to intact liver is constructed as: pmol/min/pmol enzyme × pmol enzyme/mg MSP × mg MSP/gram liver × gram liver/organism = pmol/min/liver (2.29) When V max is determined and expressed as pmol/min/ mg MSP, then the extrapolation to intact liver is constructed as: pmol/min/mg MSP × mg MSP/gram × gram liver/organism = pmol/min/liver When V max is determined and expressed as pmol/min/106 hepatocytes, then the extrapolation to intact liver is constructed as: pmol/min/106 hepatocytes × hepatocellularity (e.g. 99 × 106 cells/gram human liver) × gram liver/organism = pmol/min/liver (2.30) The final step in extrapolation of in vitro-derived metabolic rate constants is scaling for inclusion in the model code for the PBPK model. Once extrapolated to units of “pmol/min/liver,” this is equivalent to pmol/min/animal; this value is then adjusted by formula weight and by scaled body weight, as demonstrated below. Because PBPK models include V max as a value scaled to body weight, typically body weight raised to the 0.75 power, this must also be taken into account. Once V max is expressed per whole body (e.g., mg/hour), body weight (not the V max value) is raised to the exponential power. Using an in vitro-derived metabolic rate of 175 mg/h (per 70-kg human) as an example, the following demonstrates the scaling for incorporation in PBPK modeling. While other exponential powers of body weight may be used, this example is typical, in that it uses body weight raised to the 0.75 power. (70 kg)0.75 = 24.2 kg 175 mg/h/24.2 kg = 7.23 mg/h/kg
(2.31) (2.32)
The V max C value would be 7.23 mg/h/kg 2.6.5 Extrapolation of K m Values The extrapolation of V max values has been accomplished for several compounds, but the extrapolation of K m values has not received so much attention. Most often, PBPK models are constructed so that K m values (as substrate concentration) are expressed as concentration in venous blood at equilibrium with liver. This construction seems to be based on reasoning that substrate in the aqueous phase of liver will be at equilibrium with the concentration of substrate in blood. The implicit assumption seems to be that these concentrations will be not only in equilibrium, but will be equivalent. There are other considerations and approaches to the extrapolation of K m values derived in vitro, and these differ for volatile and non-volatile compounds, and for lipophilic and hydrophilic compounds. For volatile compounds for which K m values are reported as concentration in headspace, these concentrations may be adjusted to represent concentration in either the biological component (i.e., hepatocytes) of the incubation system or concentration in the incubation system. The
References
55
latter is appropriate when the incubation system can be deemed a valid representation of the functional characteristics of the intact liver. Once this has been accomplished, the concentration in the representative phase of the incubation system can be multiplied by the value of the liver:blood partition coefficient used in the model to adjust the concentration so that it is expressed in units of concentration in venous blood at equilibrium with liver tissue (Mazur et al., 2007). The same considerations, except for consideration of partitioning from headspace into incubation system, apply to non-volatile compounds. It may be reasoned that for hydrophilic compounds little, if any, adjustment from in vitro K m values may be necessary when incorporating those values into PBPK models. For lipophilic compounds, some accounting for partitioning into the enzymatic fraction of the incubation system should be considered. Finally, differences between protein binding in the in vitro system and in vivo should be taken into account. Differential protein binding can significantly affect the free fraction of substrate available for metabolism (Lipscomb and Poet, 2008). While protein binding can affect metabolic rates, when V max values are derived in vitro under saturating conditions, it may be reasoned that protein binding may have a greater impact on K m values than on V max values. Clearly, the extrapolation of K m values has received far less attention that the extrapolation of V max values.
2.7
Concluding Remarks
This chapter provided a beginner-level description of the mathematical representation and computation implementation of PBPK models. The model codes in the QMT Model Library should facilitate structured learning of PBPK modeling. Other chapters in this book provide ample examples and model codes for describing protein binding and induction, diffusion-limited uptake, hepatic sequestration, metabolite kinetics, metabolic interactions, GSH depletion by reactive metabolites, and so on. Also, examples in this volume describe the role of probabilitic analyses and Bayesian approaches in PBPK modeling as well the tools and approaches for the conduct of specialized analyses (variability, uncertainty, and sensitivity) (Chapters 17 and 20). Progress to-date and challenges associated with the documentation, evaluation, and validation of PBPK models and other quantitative models in toxicology are discussed in Chapter 21.
Acknowledgements The authors thank Thomas Peyret and Katia Sokoloff of Universit´e de Montr´eal for their assistance with the preparation of this chapter.
References Andersen, M.E., Mills, J.J., and Gargas, M.L. (1993) Modeling receptor-mediated processes with dioxin: Implications for pharmacokinetics and risk assessment. Risk Anal., 13, 25–36. Barter, Z.E., Bayliss, M.K., Beaune, P.H., et al. (2007) Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: Reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Current Drug Metabolism, 8 (1), 33–45.
56
PBPK Modeling: A Primer
B´eliveau, M. and Krishnan, K. (2003) In silico approaches for developing physiologically based pharmacokinetic (PBPK) models, in Alernative Toxicology Methods (eds H. Salem and S. Katz), CRC Press, NY, pp. 479–532. B´eliveau, M. and Krishnan, K. (2005) A spreadsheet program for modeling quantitative structurepharmacokinetic relationships for inhaled volatile organics in humans. SAR QSAR Environ. Res., 16, 63–77. B´eliveau, M., Lipscomb, J., Tardif, R., and Krishnan, K. (2005) Quantitative structure-property relationships for interspecies extrapolation of the inhalation pharmaconkinetics of organic chemicals. Chem. Res. Toxicol., 18, 475–485. Brown, R.P., Delp, M.D., Lindstedt, S.L., et al. (1997) Physiological parameter values for physiologically based pharmacokinetic models. Toxicol. Ind. Health, 13, 407–484. Chiu, W.A., Barton, H.A., and Dewoskin, R.S. (2007) Evaluation of physiologically based pharmacokinetic models for use in risk assessment. Journal of Applied Toxicology, 27, 218–237. Clark, L.H., Setzer, R.W., and Barton, H.A. (2004) Framework for evaluation of physiologically-based pharmacokinetic models for use in safety or risk assessment. Risk Anal., 24, 1697–1717. Clewell, H.J., Andersen, M.E., and Barton, H.A. (2002) A consistent approach for the application of pharmacokinetic modeling in cancer and noncancer risk assessment. Environmental Health Perspectives, 110, 85–93. Clewell, R.A., Clewell, H.J. 3rd (2008) Development and specification of physiologically based pharmacokinetic models for use in risk assessment. Regulatory Toxicology and Pharmacology, 50 (1), 129–143. Csanady, G.A., Kessler, W., Hoffmann H.D., and Filser, J.G. (2003) A toxicokinetic model for styrene and its metabolite styrene-7,8-oxide in mouse, rat and human with special emphasis on the lung. Toxicol. Lett., 138, 75–102. Csanady, G.A., Kreuzer, P.E., Baur, C., and Filser, J.G. (1996) A physiological toxicokinetic model for 1,3-butadiene in rodents and man: blood concentrations of 1,3-butadiene, its metabolically formed epoxides, and of haemoglobin adducts - relevance of glutathione depletion. Toxicology, 113, 300–305. D’Souza, R.W., Francis, W.R., and Andersen, M.W. (1988) Physiological model for tissue glutathione depletion and decreased resynthesis after ethylene dichloride exposures. J. Pharmacol. Exp. Ther., 245, 563–568. Fiserova-Bergerova, V. (1975) Mathematical modeling of inhalation exposure. J. Combust. Toxicol., 32, 201–210. Gear, C.W. (1971) Numerical Initial Value Problems in Ordinary Differential Equations, PrenticeHall, Englewoods Cliffs, NJ. Gerlowski, L.E. and Jain, R.K. (1983) Physiologically based pharmacokinetic modeling: principles and applications. Journal of Pharmaceutical Sciences, 72, 1103–1127. Haddad, S., Pelekis, M., and Krishnan, K. (1996) A methodology for solving physiologically based pharmacokinetic models without the use of simulation softwares. Toxicol. Lett., 85, 113–126. Haggard, H.W. (1924) The absorption, distribution and elimination of ethyl ether. Analysis of the mechanism of the absorption and elimination of such a gas or vapor as ethyl ether. J. Biol. Chem., 59, 753–770. Heinzel, G., Woloszczak, R., and Thomann, P. (1993) TopFit, Version 2.0 : Pharmacokinetic and Pharmacodynamic Data Analysis System for the PC (ed. G. Fischer), VCH Publishers, Stuttgart/New York. Himmelstein, M.W., Carpenter, S.C., Evans, M.V., et al. (2004) Kinetic modeling of beta-chloroprene metabolism: II. The application of physiologically based modeling for cancer dose response analysis. Toxicol. Sci., 79, 28–37. Houston, J.B. (1994) Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem. Pharmacol., 47, 1469–1479. Ings, R.M.J. (1990) Interspecies scaling and comparisons in drug development and toxicokinetics. Xenobiotica, 20, 1201–1231. Jonsson, F. and Johanson, G. (2001) Bayesian estimation of variability in adipose tissue blood flow in man by physiologically based pharmacokinetic modeling of inhalation exposure to toluene. Toxicology, 157, 177–193.
References
57
Kamgang, E., Peyret, T., and Krishnan, K. (2008) An integrated QSPR-PBPK modelling approach for in vitro–in vivo extrapolation of pharmacokinetics in rats. SAR QSAR Environ. Res., 19, 669–680. Kety, S.S. (1951) The theory and application of the exchange of inert gas at the lungs. Pharmacol. Rev., 3, 1–41. Krishnan, K. and Andersen, M.E. (1994) Physiologically based pharmacokinetic modeling in toxicology, in Principals and Methods of Toxicology (ed. A.W. Hayes), Raven Press Ltd., New York, pp. 149–188. Krishnan, K. and Andersen, M.E. (2001) Physiologically based pharmacokinetic modeling in toxicology, in Principles and Methods of Toxicology (ed. A.W. Hayes), Taylor & Francis, Philadelphia, PA, pp. 193–241. Krishnan, K. and Andersen, M.E. (2007) Physiologically based pharmacokinetic modeling in toxicology, in Principles and Methods of Toxicology (ed. A.W. Hayes), Taylor & Francis, New York, pp. 193–241. Krishnan, K., Gargas, M.L., Fennell, T.R., and Andersen, M.E. (1992) A physiologically-based description of ethylene oxide dosimetry in the rat. Toxicol. Ind. Health, 8, 121–140. Kwon, Y. (2001) Handbook of Essential Pharmacokinetics, Pharmacodynamics, and Drug Metabolism for Industrial Scientists, Kluwer Academic/Plenum Publishers, New York. Lipscomb, J.C. and Ohanian, E.V. (eds.) (2006) Toxicokinetics and Risk Assessment, Informa Healthcare, New York, NY, 361 pp. Lipscomb, J.C. and Poet, T.S. (2008) In vitro measurements of metabolism for application in pharmacokinetic modeling. Pharmacology and Therapeutics, 118, 82–103. Lipscomb, J.C., Teuschler, L.K., Swartout, J., et al. (2003) The Impact of Cytochrome P450 2E1dependent Metabolic Variance on a Risk Relevant Pharmacokinetic Outcome in Humans. Risk Analysis, 23, 1221–1238. Lipscomb, J.C., Barton, H., Tornero-Velez, R., et al. (2004) The metabolic rate constants and specific activity of human and rat cytochrome P450 2E1 toward chloroform. J. Toxicol. Envtl. Hlth. (Part A), 67, 537–553. Liu, L. and Pang, K.S. (2006) An integrated approach to model hepatic drug clearance. Eur. J. Pharm. Sci., 29, 215–230. Mapleson, W.W. (1963) An electric analog for uptake and elimination in man. J. Appl. Physiol., 18, 197–204. Mazur, C.S., Kenneke, J.F., Tebes-Stevens, C., et al. (2007) In vitro metabolism of the fungicide and environmental contaminant trans-bromuconazole and implications for risk assessment. J. Toxicol. Envtl. Health, 70, 1241–1250. Notari, R.E. (1987) Biopharmaceutics and Clinical Pharmacokinetics : An Introduction, Marcel Dekker, New York. Poulin, P. and Krishnan, K. (1995) An algorithm for predicting tissue : blood partition coefficients of organic chemicals from n-octanol : water partition coefficient data. J. Toxicol. Environ. Health, 46, 117–129. Poulin, P. and Theil, F.P. (2000) A priori prediction of tissue : plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. J. Pharm. Sci., 89, 16–35. Poulin, P. and Theil, F.P. (2002) Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanismbased prediction of volume of distribution. J. Pharm. Sci., 91, 129–156. Poulin, P., Beliveau, M., and Krishnan, K. (1999) Mechanistic animal replacement approaches for predicting pharmacokinetics of organic chemicals, in Toxicity Assessment alternatives: Methods, Issues, Opportunities (eds H. Salem and S.A. Katz), Humana Press Inc., Totowa, NJ, pp. 115– 139. Ramsey, J.C. and Andersen, M.E. (1984) A physiologically-based description of the inhalation pharmacokinetics of styrene in rats and humans. Toxicol. Appl. Pharmacol., 73, 159–175. Reddy, M., Yang, R.S., Clewell, H.J. III and Andersen, M.E. (2005) Physiologically Based Pharmacokinetic Modeling : Science and Applications. John Wiley & Sons, Inc., New Jersey. Remmel, R.P. and Burchell, B. (1993) Validation and use of cloned, expressed human drugmetabolizing enzymes in heterologous cells for analysis of drug metabolism and drug-drug interactions. Biochem. Pharmacol., 46, 559–566.
58
PBPK Modeling: A Primer
Rideout, V.C. (1991) Mathematical and Computer Modeling of Physiological Systems, Prentice-Hall, New York. Riggs, D.S. (1970) The Mathematical Approach to Physiological Problems: A Critical Treatise, MIT Press, Cambridge, MA. Rodgers, T., Leahy, D., and Rowland, M. (2005) Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J. Pharm. Sci., 94, 1259–1276. Rodgers, T. and Rowland, M. (2006) Physiologically based pharmacokinetic modelling 2: Predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J. Pharm. Sci., 95, 1238–1257. Rowland, M. and Tozer, T.N. (1995) Clinical Pharmacokinetics : Concepts and Applications, Williams & Wilkins, Baltimore. Shimada, T., Yamazaki, H., Mimura, M., et al. (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japaneses and 30 Caucasions. J. Pharmacol. Exp. Ther., 270, 414–423. Snawder, J.E. and Lipscomb, J.C. (2000) Interindividual variance of cytochrome P450 forms in human hepatic microsomes: correlation of individual forms with xenobiotic metabolism and implications in risk assessment. Regul. Toxicol. Pharmacol., 32, 200–209. Teorell, T. (1937a) Kinetics of distribution of substances administered to the body. I. The extravascular modes of administration. Arch. Int. Pharmacodyn., 57, 205–225. Teorell, T. (1937b) Kinetics of distribution of substances administered to the body. II. The intravascular modes of administration. Arch. Int. Pharmacodyn., 57, 226–240. USEPA (United States Environmental Protection Agency) (2005) Use of Physiologically Based Pharmacokinetic Models to Quantify the Impact of Human Age and Interindividual Differences in Physiology and Biochemistry Pertinent to Risk: Final Report for Cooperative Agreement. EPA 600/R-06-014A. USEPA (United States Environmental Protection Agency) (2006) Approaches for the application of physiologically based pharmacokinetic (PBPK) models and supporting data in risk assessment. EPA 600/R-05/043A.
3 Pharmacokinetic Modeling of Manganese – An Essential Element Andy Nong1 , Michael D. Taylor2 , Miyoung Yoon1 , and Melvin E. Andersen1 1
The Hamner Institutes for Health Sciences, USA 2 Afton Chemical Corp., USA
3.1 Introduction The past 20 years have witnessed the expansion of PBPK modeling for many compounds and the use of these models to support extrapolations required in risk assessment, including extrapolations from high to low doses, across routes of exposure and for different animal species, from the test animal to humans (Reddy et al., 2005; Chapter 19). Most of these successes were with exogenous compounds that lack active processes for controlling uptake, retention, and elimination. Essential elements participate in multiple biological pathways that conserve concentrations at low levels and may enhance their elimination at higher intake levels. Manganese is an essential metal that is obtained from the diet. Recommended dietary intakes are about 3 mg/day in an adult, but only a small percentage of the ingested manganese is taken into the body systemically. Manganese deficiency leads to a failure to thrive, congenital abnormalities, impaired reproductive performance, ataxia, and defects in lipid and carbohydrate metabolism. Despite its essentiality, inhalation of high levels of manganese dust and fumes in occupational settings, the intake of drinking water with high concentrations of manganese, or the inability to adequately excrete manganese via the bile lead to neurotoxicity in humans. The target tissues for manganese neurotoxicity are mid-brain structures such as the striatum and globus pallidus, which influence motor control, and which accumulate manganese in conditions where intake chronically exceeds elimination. Neurotoxicity generally arises Quantitative Modeling in Toxicology C 2010 John Wiley & Sons, Ltd
Edited by Kannan Krishnan and Melvin E. Andersen
60
Pharmacokinetic Modeling of Manganese – An Essential Element
over a prolonged period and results from accumulation of excess manganese in these tissues and impairment of function of dopaminergic and γ -aminobutyric acid (GABA)-containing structures. A Parkinson’s Disease-like condition known as manganism has been observed after prolonged (>2 years) inhalation of high concentrations (>1 mg/m3 ) of manganesecontaining dusts in occupational settings such as mining. More subtle neurological effects, such as subclinical deficits in fine motor control, have been reported in workers with chronic inhalation to lower concentrations (0.5–1 mg/m3 ) of manganese in other occupational settings such as smelting. Neurological effects have also been reported in human populations that consumed water or food with total manganese intakes by these routes of more than 10 mg/day, received manganese intravenously as a constituent in total parenteral nutrition (TPN) solutions, or in individuals with impaired clearance of manganese because of liver disease (Aschner and Aschner, 2005). The finding of similar neurological effects following high dose oral, inhalation, or parenteral exposure to manganese, or when hepatobiliary clearance of this metal is impaired, indicates that the dose to target tissue in the central nervous system is the critical determinant for manganese toxicity, regardless of route. Thus, the risk assessment challenge with manganese is to identify inhaled and ingested doses that do not alter target tissue concentrations to levels associated with neurotoxicity while ensuring adequate intake for normal function, including adequacy during critical times of manganese incorporation into tissues during early life-stage growth and development (Andersen et al., 2010). To do this, an understanding of the biological processes that control manganese movement to brain and its retention in brain and other target tissues is necessary. The integration of these characteristics for manganese uptake and persistence was possible with the PBPK models described in this chapter. Previous essential element models were developed for zinc (Foster et al., 1979; Miller, Krebs, and Hambidge, 2000) and copper (Cartwright and Wintrobe, 1964; Harvey et al., 2005). These models captured the control of these essential elements under normal and deficient dietary conditions. Compartmental (or mammillary) structure and linear exchange models distribute the elements to different tissues and cellular components. With manganese, a linear PK model was adapted to describe decreased gastrointestinal manganese uptake and increased hepatobiliary elimination seen with rising manganese dietary levels (Teeguarden et al., 2007a, 2007b, 2007c). However, linear compartmental exchange rates were unable to capture the kinetic data for inhalation exposure to manganese in which tissue concentrations at higher inhaled manganese increased within weeks to steady state and decreased rapidly to basal levels after cessation of exposure (Nong et al., 2008). A different model structure was required that had limited tissue stores of manganese capable of avidly binding manganese at low dietary intake that filled quickly on higher concentration exposures (Nong et al., 2009). Key components of the current model structure include: (1) saturable tissue binding, (2) variable percentage uptake from diet depending on daily manganese intake, (3) inducible biliary excretion, and (4) asymmetric tissue diffusion behaviors in tissue that have proportionately higher than average tissue manganese, such as mid-brain targets. With these processes included in the PBPK description, it is possible to examine the relative role of different processes in controlling tissue manganese concentrations over a broad range of intake concentrations from levels of deficiency to levels that can lead to toxicity. This chapter provides background on the development of the PBPK model for manganese, shows several examples of using main elements of the published model for examining PK
Processes Included In the PBPK Model for Manganese
61
behaviors for different exposure conditions, discusses extension of the modeling from the adult to other life stages, and outlines the risk assessment challenges in applying the PBPK model to assist in setting reference concentrations (RfCs) or references doses (RfDs) for this essential element.
3.2 3.2.1
Processes Included In the PBPK Model for Manganese Tissue Binding
The overall PBPK model schematic for manganese is made up of tissues with some maximal binding capacity for manganese (Figure 3.1). The manganese concentrations in various tissues represent a combination of free manganese and manganese bound to tissue
Inhaled Mn QP Lung & Nose
QC
Olfactory ka
B + Mnf
Mnb kd
kout
QBrn
Brain Blood kin
kin
kout
Striatum
kout Cerebellum
ka
B + Mnf
Arterial blood
Venous blood
kin
ka
Mnb
B + Mnf
kd
Mnb kd
Rest of body
Qbody
ka
B + Mnf
Mnb kd
Liver
QLiv
ka
B + Mnf
Mnb kd
Diet
Bile
Figure 3.1 Final manganese PBPK model structure (adapted from Nong et al., 2009). Tissue storage is based on binding rate constants (ka, kd) and regional brain manganese sequestration is determined by influx/efflux diffusional constants (kin, kout).
62
Pharmacokinetic Modeling of Manganese – An Essential Element
constituents. Tissue binding likely represents incorporation of manganese into various cytosolic macromolecules and into constituents within subcellular organelles, including mitochondria. While the binding sites are diverse, representing various intracellular pools, the binding is described with a maximal binding capacity per tissue and a single dissociation constant. The amount bound in a tissue is determined by association and dissociation processes between free manganese and the pool of binding sites, as noted in Equation 3.1. Mnfree + Bfree,tissue ← → Mnbound
(3.1)
The provision of a maximal binding capacity in each tissue allows a limited ability of each tissue to sequester manganese; saturation of the binding capacity with increasing exposure concentrations leads to differential increases of free manganese in certain tissues depending on this capacity. Free manganese is likely to be the form more closely associated with toxicity. The tissue binding processes are described by association and dissociation rate constants, ka and kd. The tissue dissociation constant (Kd) would be the ratio of the dissociation and association rate constants, that is, Kd = kd/ka. The change of amount of free manganese in the liver with time (dAliver / dt) includes loss due to binding and increased dissociation of bound manganese: dAliver = Q liv (Cart − Cvl ) + kdliver × ABliver − kaliver × Bliv dt ×Aliver − R Abile + kDiet
(3.2)
In addition to the binding between manganese and the tissue constituents (Bliv ), there is also uptake from the diet (kDiet), elimination to bile (RAbile ), and terms for manganese entering and leaving the liver in blood. The venous effluent concentration depends on the free manganese concentration in tissue divided by the tissue partition coefficient. The rate of change of the amount of bound manganese in liver (ABliver ) over time is then calculated as the difference in the rates of binding and the rates of dissociation from the bound complex: dABliver (3.3) = −kdliver × ABliver + kaliver × Bliv × Afree dt The rate constants for the association and dissociation processes are the main driving components for the exchange between free and bound forms of manganese. The maximal binding capacity (Bmax ) in each tissue regulates the storage capacity of the tissue for bound manganese: Bliv = Bmax,liv − Abound
(3.4)
The rate constants for these dissociation processes are small, indicating relatively slow exchange of manganese between bound and free pools (Figure 3.1). 3.2.2 Tissue Uptake/Accumulation Preferential increases of manganese in some brain regions compared to other tissues such as the liver were observed in several studies where rats were exposed to manganese by inhalation (Dorman et al., 2006a). Preferential tissue accumulation was achieved in the
Processes Included In the PBPK Model for Manganese
63
model by including asymmetric diffusion from tissue blood into tissue and back. Such asymmetries could arise from the presence of metal transporters with differential activity for efflux and intake in specific cells. With diffusion-limited tissue uptake, tissues have to be described with two compartments – tissue itself and tissue blood. Uptake from striatal blood to striatal tissue is described with a diffusional clearance (kin); the reverse direction from striatum to striatal blood was also described with a diffusional clearance (kout), but the two-diffusional clearances, kin and kout, have different values. Thus, the rate of change in amount of free manganese in the brain blood compartment with time (dABrBd / dt) depends on blood flow and diffusion from blood to brain and from brain back to blood, as shown in Equation 3.5. dABrBd = Q brn (Cart − Cvbr ) + koutstr × Astr − kinstr × ABrBd dt
(3.5)
In the striatal tissue (str), the rate of change of free manganese over time depends on the diffusion of manganese into and out of the tissues and the binding and release of manganese from the tissue binding capacity, as shown in Equation 3.6. dAstr = −koutstr × Astr + kinstr × ABrBd + kdstr × ABstr − kastr × Bstr × Astr dt
(3.6)
The diffusional clearance terms are likely to account for manganese movement across the blood–brain barrier into brain tissue (Moos and Morgan, 2000; Crossgrove et al., 2003; Yokel, Crossgrove, and Bukaveckas, 2003). Equations describing the binding of manganese to saturable tissue stores are similar to those for the liver. Simulated brain concentrations include amounts in tissue (free plus bound) and the contribution of blood in the brain compartment, assumed to be 3% of the tissue by weight (Brown et al., 1997). Basal tissue concentrations were used to provide initial estimates for tissue Bmax . 3.2.3
Calibrating Dietary Uptake and Biliary Elimination
Dorman and colleagues (2001a, 2001b, 2004) have collected extensive data on tissue concentrations in rats and monkeys exposed to manganese by diet and inhalation, and have evaluated the relationship between dietary manganese and increases in tissue manganese concentrations following inhalation exposures. Several studies were conducted with rats receiving diets containing 2, 10, or 100 ppm manganese. After maintenance on the diet for 13 weeks, analyses included both steady-state tissue manganese concentrations and elimination kinetics for an intravenous tracer dose of 54 MnCl2 (Dorman et al., 2001a). These studies were critical for setting dietary uptake and biliary excretion parameters. Initial calibration of the PBPK model consisted of adjusting daily manganese dietary intake (F DietUp ) and biliary elimination (kelim ) to correspond with the observed steadystate tissue concentrations in rats fed defined daily diets containing 2, 10, or 100 ppm manganese (Dorman et al., 2001a). Initial calibration also consisted of adjusting fractional gastrointestinal absorption (fdietup) and biliary manganese excretion (kbile ) rate based on the dietary levels. Since the processes controlling uptake and elimination of manganese are dose dependent (Teeguarden et al., 2007a), specific model parameters were defined for each diet. The biliary manganese excretion rate was fitted to be consistent with the tracer elimination kinetics following an intravenous (iv) injection of 54 Mn (Figure 3.2). These
64
Pharmacokinetic Modeling of Manganese – An Essential Element (a)
Total 54Mn Radioactivity (kBq)
30 25 20 15 10 5 0 0
20
40
60
80
100
60
80
100
60
80
100
Days
(b)
Total 54Mn Radioactivity (kBq)
30 25 20 15 10 5 0 0
20
40 Days
(c)
Total 54Mn Radioactivity (kBq)
30 25 20 15 10 5 0 0
20
40 Days
Figure 3.2 Simulation of the whole body 54 Mn elimination at different dietary concentrations: (a) 2, (b) 10, and (c) 100 ppm. Manganese dietary uptake and biliary excretion are calibrated to data from Dorman et al., 2001a. The curves represent model predictions and the symbols with standard errors represent data (8 rats/diet). Reprinted with permission from supplementary materials of Nong et al., 2009.
Processes Included In the PBPK Model for Manganese
65
biphasic tracer curves indicate that the relative amount of free manganese in the body increases slightly with increasing dietary intake and this increase is adequately captured by the manganese model with saturable binding within all the tissues in the body. Fractional gastrointestinal absorption was then determined in correspondence with the steady-state tissue manganese concentrations for each dietary level (Figure 3.3). Preliminary fits were (a) 5
Concentration (µg/g))
4
3
2
1
0 10
30
50
70
90
70
90
Days
(b)
Concentration (µg/g)
2.0
1.5
1.0 ` 0.5
0.0 10
30
50 Days
Figure 3.3 Manganese tissue binding capacity of the (a) liver and (b) striatum is calibrated to steady-state tissue concentrations (Dorman et al., 2001a). Dietary concentration of 2, 10, and 100 ppm were simulated. The curves represent model predictions and the symbols with standard errors represent data (8 rats/diet). Reprinted with permission from supplementary materials of Nong et al., 2009.
66
Pharmacokinetic Modeling of Manganese – An Essential Element
obtained for the tissue steady-state manganese concentrations in rats fed on each diet by adjusting tissue binding constants (ka, kd) and maximal capacity (Bmax ). Model fits to the dietary studies indicate that, as the dietary manganese level increases, the biliary manganese excretion increases and fractional dietary uptake decreases. These results are consistent with the rise in bile manganese concentration from increasing manganese dietary intake observed from several rodent studies (Teeguarden et al., 2007b). These changes in kinetic constants with dietary manipulations are essential for maintaining steady-state manganese levels in the body over a range of dietary manganese intakes. With increasing dietary intake of manganese, coordinate changes occur to restrict uptake percentage and enhance elimination.
3.2.4 Calibrating the Inhalation Exposures in Rats The second aspect of model fitting was the extension to describe inhalation. Studies were conducted with rats fed a 100 ppm diet that were exposed by inhalation to soluble MnSO4 at 0.03, 0.3, or 3 mg manganese/m3 for six hours per day for 14 consecutive days. This data set provided tissue concentrations of manganese in rats at the end of the exposure as well as tracer kinetics beyond the 14-day exposure period (Dorman et al., 2001b). A study was also conducted with rats fed a 10 ppm manganese diet exposed to MnSO4 at 0.1 and 0.5 mg/m3 for six hours per day, five days per week over a 90-day period (Dorman et al., 2004). This study included evaluation of tissue manganese concentrations of some cohorts midway through the inhalation exposure (i.e., day 45), at the end of the 90-day exposure, and at 45 and 90 days after the cessation of exposure, and included 54 Mn tracer clearance measurements immediately after the 90-day inhalation. Intake by inhalation was estimated from a particle deposition model that calculated the percentage of inhaled manganese that would be deposited in various regions of the respiratory tract. Soluble forms of manganese (MnSO4 and MnCl2 ) were modeled as rapidly dissolving after deposition on the respiratory epithelial surfaces and rapidly transferred into tissue and on to the blood. To represent the olfactory transport of manganese directly to the olfactory bulb along olfactory nerves observed in rodent studies, manganese deposited on the olfactory epithelium in the nose was modeled as being transported directly into the olfactory bulb, where it diffused into tissues within the olfactory tract in the central nervous system. Model simulations of the 14-day inhalation study (Dorman et al., 2001b) produced tissue concentrations consistent with the measured concentration-dependent increases in tissue concentrations (Figure 3.4). The ability to recapitulate the greater uptake of the striatum compared to liver tissue with increasing inhalation exposure to manganese was related to the inclusion of diffusion-limited permeability constants that had larger input than efflux clearance from tissue (kin and kout). Biliary elimination parameters did not have to be changed appreciably at high inhalation exposure of manganese (3 mg/m3 ) in these 14-day studies (Figure 3.4; 3 mg Mn/m3 ). As the inhaled exposure is increased from 0.03 to 3 mg Mn/m3 , the increases in tissue manganese estimated from the model were likely primarily increases in free manganese, since the available binding sites become filled. With the inclusion of saturable tissue manganese binding and differential transport, model predictions for liver and striatum were consistent with the data from the 14-day inhalation studies in rats. The model then predicted the more rapid approach to steady state and rapid
Processes Included In the PBPK Model for Manganese
67
Concentration (µ g/g)
Cerebellum 7
3 mg/m3
6
0.3 mg/m3 0.03 mg/m3
5 4 3 2 1 0 0
2
4
6
8
10
12
14
8
10
12
14
8
10
12
Days
Concentration (µ g/g)
Striatum 7
3 mg/m3
6
0.3 mg/m3 0.03 mg/m3
5 4 3 2 1 0 0
2
4
6 Days
Concentration (µg/g)
Olfactory Bulb 7
3 mg/m3
6
0.3 mg/m3 0.03 mg/m3
5 4 3 2 1 0 0
2
4
6
14
Days
Figure 3.4 Comparison of simulated manganese brain concentrations at various inhaled manganese concentrations during a 14-day exposure versus data collected in Dorman et al., 2001b. It is important to distinguish between data from experiments (symbols with error bars) and modelled results (curves) since they are different entities. Reprinted with permission from supplementary materials of Nong et al., 2009.
68
Pharmacokinetic Modeling of Manganese – An Essential Element
return to basal tissue levels like those observed in experimental studies than it would have if it were only consistent with low intake tracer rate constants. Thus, the characteristics of manganese tissue accumulation over different durations and exposure concentrations were achieved using tissue binding to regulate the daily tissue concentration excursions caused by manganese inhalation. The tissue binding capacity was a major factor in determining tissue manganese accumulation and slow release of tracer manganese. Maximal bound manganese tissue levels are reached once the binding capacities are saturated. The 14-day exposure model was then extrapolated to predict tissue levels following longer duration exposures (Figure 3.5). The simulated liver and striatal manganese concentrations were more consistent with measured levels after slight adjustments of dietary uptake and biliary excretion for the 10 ppm diet (F DietUp = 0.02, kBileC = 0.60 /h/kg). Nonetheless, the parameter set successful in simulating the 14-day studies produced extremely good predictions of the 90-day study, with only a slight over-prediction. A mammillary model lacking saturable tissue binding was not capable of making this extrapolation between these times of exposure and concentrations (Nong et al., 2008; Model A). With overexposure via inhalation, compensatory mechanisms exist to enhance biliary elimination – an observation also seen in the monkey (Dorman et al., 2006b; Nong et al., 2009). However, the gastrointestinal uptake of dietary manganese remains similar at higher inhaled concentrations as at lower inhaled concentrations. 3.2.5 Sensitivity Analysis of Model Parameters The sensitivity coefficients for the parameters controlling total manganese concentration in liver and striatum were generated to determine the influence of tissue binding constants on the tissue manganese concentration at low and high inhaled manganese exposure (Figure 3.6). Parameters related to the tissue binding capacity and tissue clearance were evaluated (i.e., kd, ka, Ptissue:blood , kin, kout, Bmax , Qtissue ). These sensitivity coefficients were estimated for 0.0, 0.03, or 3 mg Mn/m3 concentration exposure scenarios (until near steady-state concentrations were reached) and found to be highly dose dependent. As the inhaled manganese concentration increases, the liver binding capacity saturates and, consequently, the sensitivity of the tissue binding parameters (ka and kd) towards change in liver tissue concentration decreases. Liver free manganese concentration is highly sensitive to the liver partition coefficient and biliary excretion, while bound manganese concentrations are more sensitive to liver binding capacity (not shown). Changes in striatal manganese concentrations are sensitive to changes in brain influx and efflux permeability rate constants (kin, kout) at all manganese concentrations. Sensitivity of brain manganese concentration to binding parameters was high for dietary intake with and without low inhalation exposures and decreased sharply at high inhaled concentrations (Figure 3.6).
3.3
Model Results
3.3.1 Excursions of Free Manganese in Tissues Computer codes for running the manganese model in Berkeley Madonna are provided in the QMT library (Folder: NONG1). This model is adapted from Model B from Nong et al.
Model Results
69
Cerebellum Tissue concentration (µg/g)
4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 0.001 control
0.01 Inhaled Mn concentration
0.1
1
(mg/m3 )
Striatum Tissue concentration (µg/g)
4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 control 0.001
0.01 0.1 Inhaled Mn concentration (mg/m3 )
1
0.01 0.1 Inhaled Mn concentration (mg/m3 )
1
Liver Tissue concentration (µg/g)
4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 control 0.001
Figure 3.5 Comparison of simulated end of exposure manganese brain concentrations at various inhaled manganese concentration during a 90-day exposure versus data collected in Dorman et al., 2004. It is important to distinguish between data from experiments (symbols with error bars) and modelled results (curves) since they are different entities. Long-term changes in hepatobiliary excretion was needed to refine the model results (solid vs dotted lines). Reprinted with permission from supplementary materials of Nong et al., 2009.
70
Pharmacokinetic Modeling of Manganese – An Essential Element Cerebellum 1.00
Normalized sensitivity ratio
0.75 0.50 0.25 0.00 -0.25 -0.50 -0.75 -1.00 Bmax
ka
kd
kin
kout
Qbrn
kbile
fdietup
Bmax
ka
kd
kin
kout
Qbrn
kbile
fdietup
Striatum 1.00
Normalized sensitivity ratio
0.75 0.50 0.25 0.00 -0.25 -0.50 -0.75 -1.00
Liver 1.00
0 mg/m3 0.3 mg/m3 3 mg/m3
Normalized sensitivity ratio
0.75 0.50 0.25 0.00 -0.25 -0.50 -0.75 -1.00 Bmax
ka
kd
kin
kout
Qliv
kbile
fdietup
Figure 3.6 Sensitivity analysis of manganese concentration in the cerebellum, striatum, and liver at 0, 0.3, or 3 mg Mn/m3 for various model parameters. The model parameters analyzed in each tissue are maximal binding capacity (Bmax ), association and dissociation rate constants (ka, kd), influx and efflux permeability diffusion rate constants (kin, kout), tissue blood flow (Qtissue ), biliary elimination rate (kbile), and dietary absorption fraction (fdietup). The tissue with asymmetric diffusion has a more diverse group of factors affecting tissue accumulation. Reprinted with permission from supplementary materials of Nong et al., 2009.
Model Results
71
(2008) and includes saturable binding stores for tissue manganese. In this adaptation, the brain is divided into two equally sized regions. In region I, there is asymmetrical diffusion; in region II diffusional clearances are comparable for intake and efflux. The first exercise examines the alteration in tissue stores of manganese in the rats exposed to 3 mg Mn/m3 for six hours per day, every day for 14-days. The model calculates increases in tissue concentration during inhalation exposures and calculates the percentage of manganese in brain and liver that is free. PCFTissue = 100∗ (Afree, tissue/Atotal, tissue)
(3.7)
The distribution between bound and free manganese in each tissue is mainly determined by the dissociation binding ratio (i.e., kd/ka), binding maximum, and the total amount of manganese at any given time. Tissue levels of bound manganese are constrained by the maximal binding capacity (Bmax ). Model simulation of the 14-day exposure study by Dorman et al. (2001b) after fitting to this revised model was still consistent with the dataset (Figure 3.7). In this example, kbilec and Fdietup were based on values in Table 3.1 for rats fed a 125 ppm manganese diet. Each diffusion influx rate (kinBRx) was adjusted to its respective data (kinBR1 = 14; kinBR2 = 2.1). The simulation was generated for a 14-day exposure (dstop = 14, dstart = 0) at six hours per day (tlen = 6) and seven days per week
90
4
80
3.5
70
PCFBR1
3
3
mg/m3
data 60
2.5 50 2 40 1.5 30 1
Percent Free Mn
Mn Concentration (µg/g)
CTOTBR1
20
0.5
10
0
0 0
8
16
24
32
40
Days
Figure 3.7 Simulation of total manganese concentration in brain region I (CTOTBR1) from a 14-day exposure at 3 mg/m3 for 6 hours/day, 7 days/week. Percentage of manganese in tissue as free manganese capacity (PCFBR1) is also plotted versus time. The simulation for brain region I concentration is compared to a single data point from Dorman et al. (2001b). In this example, kbilec and fdietup were based from values in Table 3.1 for rats fed a 125 ppm manganese diet.
72
Pharmacokinetic Modeling of Manganese – An Essential Element
Table 3.1 Model parameters regulating background manganese levels in rats. Parameter (abbreviation) Manganese diet Daily dietary intakea Fractional gut absorptionb Biliary excretionc
Values Ddiet inFac Fdietup kbilec
2 10 0.05 0.05 0.13 0.040 0.001 6 0.002 2
100 0.05 0.005 8 0.003 6
Units 125 ppm 0.05 kg/day/kg BW 0.005 0 0.010 l/h/kg
a
Dietary intake of manganese is from USEPA, 1986. Daily dose is calculated as Ddiet × inFac × fdietup × BW. c kbilec is allometrically scaled (kbile = kbile × BW). Values were fitted to data from Dorman et al., 2001a, 2001b. b
(dayson = 7). With increasing numbers of inhalation days and increasing tissue manganese concentration, the percentage of free manganese rises after all tissue binding capacity is occupied. Excursions of free manganese above the maximal binding capacity cause proportionately greater rises in free manganese in tissues compared to basal conditions where tissue manganese is mostly in the bound form. The increase in percentage of free manganese is greater in brain region I, the portion of the brain with asymmetric diffusion, compared to region II (Figure 3.7). A parameter plot of the end of exposure brain manganese concentration shows the rapid increase expected after exposure to about 0.1 mg Mn/m3 (Figure 3.8), where the free manganese also begins to increase disproportionately. The incorporation of tissue binding capacity not only allows for a rapid rise of free manganese when the binding maximum is exceeded, but is responsible for the rapid return to the initial basal level of manganese following exposure. 3.3.2 Influence of Diet on Tracer Kinetics and Basal Manganese Levels Initial calibration of the PBPK model consisted of adjusting daily manganese dietary intake (Fdietup) and biliary elimination (kbilec) to correspond with the observed steady-state tissue concentrations in the dietary study by Dorman et al. (2001a). Further refinements of the tissue-specific parameters (e.g., kin, kout, kd, or ka) for each model were determined by fitting each model structure to the 14-day inhalation dataset. The next exercise consists of modeling long-term kinetic data by changing dietary controls from the 100 ppm manganese diet of a 14-day inhalation exposure study to a 10 ppm manganese diet in a 90-day study. The daily dietary dose (ddiet) was first changed to 10 ppm and the exposure conditions were adjusted for a 90-day exposure (dstop = 90, dstart = 0) at six hours per day (tlen = 6) and five days per week (dayson = 5). Afterwards, fractional intake (Fdietup) and biliary elimination (kbilec) were changed according to the values in Table 3.1. The PBPK model parameters were established with the steady-state tissue concentrations and tracer kinetic data in rats fed a defined daily diets containing 2, 10, or 100 ppm manganese (Dorman et al., 2001a). Fractional gastrointestinal absorption (Fdietup) and biliary manganese excretion (kbilec) rate constants were estimated for tracer elimination fitted to the model for each dietary level (Table 3.1). After maintenance on the diet for 13 weeks, kinetic analyses included both tissue steady-state manganese concentrations and elimination kinetics from the iv tracer dose of 54 MnCl2 . In this manner, these kinetic
Model Results
73
3.5
Mn Concentration (µg/g)
3
CTOTBR1 CTOTBR2
2.5
2
1.5
1
0.5 0.01
0.01
0.1 Inhaled Concentration (mg/m3)
1
10
Figure 3.8 Parameter plot of the brain manganese concentration in regions I and II following 14-day exposure over a range of inhaled manganese concentration. In this example, the end of exposure brain regional manganese concentrations were plotted (dstop = stoptime = 14). The brain region with the asymmetric diffusional properties (I) accumulates a larger concentration of manganese than does the second region (II) with all other parameters similar, except kin and kout from the tissue.
data served for calibration of the model estimates of daily manganese dietary intake and manganese elimination by biliary excretion. The biliary manganese excretion rate was consistent with the tracer elimination kinetics following an iv injection (Figure 3.9a). Fractional gastrointestinal absorption was then determined to correspond with the steady-state tissue manganese concentration for each dietary level (Figure 3.9b). Preliminary fits were obtained for tissue steady-state manganese concentrations in rats fed on each diet by adjusting tissue binding constants (ka, kd) and maximal capacity (Bmax ). Model fits to the dietary studies indicated that, as the dietary manganese level rises, the manganese biliary rate constant for excretion increases and fractional dietary uptake decreases. The results are consistent with the increases in bile manganese concentration from increasing manganese diet observed from several rodent studies (Teeguarden et al., 2007b). These small changes in kinetic constants with dietary manipulations are important for maintaining steady-state manganese levels in the body from gradual changes of dietary manganese intake. Model simulations for liver manganese concentrations from the 90-day inhalation data (Figure 3.10) were predicted from the 14-day study parameters. This simulation overestimated the tissue manganese levels. A better fit was obtained by adjusting the kbilec (0.0022 l/h/kg) and fdietup (0.040) to the 10 ppm diet and making small changes in
74
(a)
Pharmacokinetic Modeling of Manganese – An Essential Element 25
2 ppm diat 10 ppm diat 100 ppm diat 54 Mn tracer data
54Mn Radioactivity (kBq)
20
15
10
5
0 0
20
40
60
80
100
Days
(b)
4 3.5
Mn Concentration (µg/g)
3 2.5 2
CTOTLIV CTOTBR1 100 ppm diet data
1.5 1 0.5 0 0
20
40
60
80
100
Days
Figure 3.9 (a) Simulation of the whole body 54 Mn elimination (AtotMn54) at different dietary manganese concentrations: (from top to bottom) 2, 10, and 100 ppm. (b) Manganese tissue binding capacity of the liver (top) and brain (bottom) from a dietary concentration of 100 ppm were also compared. Steady-state manganese dietary uptake and biliary excretion is calibrated to data from Dorman et al., 2001a.
Model Results
75
3 2.8
Mn Concentration (µg/g)
2.6
CTOTLIV default CTOTLIV high kbilec 0.5 mg/m3 data
2.4 2.2 2 1.8 1.6 1.4 –10 0
10 20 30 40 50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200 Days
Figure 3.10 Simulation of liver manganese concentration (CTOTLIV) from 90-day exposure at 0.5 mg/m3 for 6 hours/day and 5 days/week. The rats were fed a 10 ppm manganese diet during the study. The lower plot was obtained by increasing the biliary excretion rate constant (kbilec) from 0.0022 to 0.005. The simulation curve is compared to data from Dorman et al., 2004.
the initial condition values for Bmax (1800 µg/kg) and Cliv0 (1600 µg/kg) in liver. The simulation results were more consistent with measured levels after the adjustment of biliary excretion for the long-term exposure (from 0.0022 to 0.005 l/h/kg). The projected increase in biliary excretion with longer-term exposures suggests that the dose dependencies of the hepatobiliary excretion of manganese for inhalation are similar to those seen for dietary uptake of this element. 3.3.3
Asymmetrical Diffusion in Target Tissues
The ability to recapitulate the greater uptake of the striatum compared to liver tissue concentrations at higher inhalation exposure of manganese was related to diffusion-limited permeability constants where influx is larger than efflux in striatal tissue (kin/kout). This next exercise demonstrates regional distribution of manganese in the brain by preferential influx in areas with larger rises of manganese concentration upon inhaled exposure (Figure 3.11). The two brain regions (I and II) in the model represent distinct areas of manganese sequestration. Due to greater affinity of transport in region I, kinBR1 (14) is over five times greater than kinBR2 (2.1). All other constants are equivalent for brain regions and are kept the same in this example. Differences in uptake in different tissues could be due to preferential barrier characteristics or to the presence of specific metal transporters in different tissues.
76
Pharmacokinetic Modeling of Manganese – An Essential Element 4 3.5 CTOTBR1 CTOTBR2 3 mg/m3 data
Mn Concentration (µg/g)
3 2.5 2 1.5 1 0.5 0 0
5
10
15
20 Days
25
30
35
40
Figure 3.11 Simulations of manganese concentrations in different brain regions from 14-day repeated exposure at 3 mg/m3 for 6 hours/day. The high manganese concentration brain region I has a five time greater influx to efflux diffusion ratio than the brain region II with lower manganese levels. The simulation curve for the 14-day study is compared to data from Dorman et al., 2001b.
3.4 Extrapolations to Other Life Stages and Species 3.4.1 Extension of the Adult Rat Model to Pregnancy, Lactation, Fetal, and Neonatal Life Stages The adult rat PBPK model has been extended to describe manganese uptake and tissue distribution in pregnant and lactating dams, fetuses, and neonates during dietary and inhalation exposures (Yoon et al., 2009a; 2009b). This extension incorporated key physiological processes controlling manganese pharmacokinetics during pregnancy/lactation and fetal/neonatal development. After calibration against a variety of studies showing tissue manganese concentrations during inhalation exposures, the model accurately simulated manganese tissue distribution in the dam and fetus following both diet and inhalation exposures to the pregnant rat. Maternal to fetal transfer of manganese through placenta was described using two pathways, a saturable active transport process with high affinity and a simple diffusion process. The active transport dominates under normal dietary and low to moderate inhaled manganese exposure conditions; at higher manganese exposures, the relative contribution of the diffusion pathway increases. To simulate fetal tissue manganese concentrations, tissue binding parameters and preferential influx/efflux rates in the fetal brain were adjusted from the adult model based on differential developmental processes and varying tissue demands for
Extrapolations to Other Life Stages and Species
77
manganese in early life. Model simulations were consistent with observed tissue manganese concentrations in fetal tissues, including brain, for diet alone and for combined diet and inhalation exposure. Simulations of manganese in placenta and other maternal tissues in late gestation correlated well with measured tissue concentrations. The conditions modeled at the end of gestation were then transposed to the early postnatal stage for dams and pups. The adult model was extended to lactating dams and pups by including differential tissue binding capacities in developing pups, increased absorption of dietary manganese in lactating dams, and more efficient gastrointestinal absorption and lower basal biliary excretion in pups. Enhancement of biliary excretion in pups was also required to accurately simulate tissue manganese during early postnatal inhalation. Overall, these changes were concordant with the behavior of manganese and other essential metals during development. The resulting model simulations match a variety of published studies on maternal manganese homeostasis during lactation, milk manganese levels, and changing patterns of neonatal tissue manganese for normal dietary intake and with manganese inhalation. The successful description of manganese kinetics across these life stages suggests that the present model can help describe the relationship between exposure dose and target tissue manganese concentrations across different developmental stages and assist in assessing whether infants and children should be regarded as susceptible populations for manganese inhalation.
3.4.2
Extension of the Rat Models to Primates and Humans
The PBPK model for manganese in rats was scaled to describe manganese tissue accumulation in nonhuman primates exposed to manganese by inhalation and diet (Nong et al., 2009). The extent of manganese accumulation in rat and monkey tissues differs because of a few key physiological and biochemical differences in these species, such as tissue volumes and blood flows between the rat and monkey. The interspecies scaling was based on typical allometric expectations for flows (BW 0.75 ) and volumes (BW). The permeability rate constants (kkin , kout ) were scaled as BW −0.25 because they represent rate constants comprised of a clearance term divided by a tissue volume. Because tissue binding capacity (Bmax ) terms account for observed tissues manganese concentrations in each species, they were simply scaled to the tissue volumes. The tissue binding rate constants (ka and kd) terms represent presumed association and dissociation processes that are likely related to incorporation and degradation of specific macromolecular manganese stores. These parameters were kept essentially constant from the rat to the monkey. After accounting for these physiological differences between rat and monkey, the monkey model parameters were calibrated using steady-state tissue manganese concentration from rhesus monkeys fed a diet containing 133 ppm manganese. The model was then applied to simulate 65 exposure days of weekly (6 h/d; 5 d/wk) inhalation exposures to soluble MnSO4 at 0.03–1.5 mg Mn/m3 (Dorman et al., 2006b). A few additional adjustments were required besides the generic scaling approaches. These changes included dose dependencies in brain uptake rate constants and in biliary elimination of free manganese. While inducible biliary excretion of manganese was suggested by the results in long-term exposure in rats, the need to incorporate dose-dependent uptake mechanisms in the monkey brain is likely indicative of a more complex control of brain
78
Pharmacokinetic Modeling of Manganese – An Essential Element
manganese concentrations in monkeys than in rats. Another significant difference is the 20-fold difference in nasal olfactory surface area between the rat and monkey, with the rat having a much larger nasal olfactory surface area. The difference in surface area of the nasal epithelium influences the amount of manganese delivered to olfactory bulb through the olfactory pathway, which is relatively less in monkeys. Recognition of the differences in factors which control manganese uptake into target tissues between rat and monkey is important since the monkey, with selective increases in mid-brain regions and toxic responses to manganese more like those in humans, appears to be the better animal model for predicting expected behaviors in humans. 3.4.3 Extension of the Animal Models to Humans Sensitivity analyses show that manganese tissue concentrations in the rat and monkey models have dose dependencies in (1) biliary excretion of free manganese from liver, (2) saturable tissue binding in all tissues, and (3) differential influx/efflux rates for tissues that preferentially accumulate manganese. These PBPK models are consistent with the available experimental kinetic data, indicating preferential increases in some brain regions with exposures above 0.2 mg/m3 and fairly rapid return to steady state levels (within several weeks rather than months) after cessation of exposure. The models can now be extended to humans by incorporating human physiological values into the models and comparing the model output with human tissue manganese data. This data will include both direct measurements of human brain manganese levels and the determination of brain manganese content from magnetic resonance imaging (MRI) data of people following various overexposure scenarios, such as occupational cohorts exposed by inhalation or people exposed to high manganese levels in TPN or drinking water. Human PBPK models that account for preferential manganese tissue accumulation from both oral and inhalation exposures will be central to support efforts of tissue dosimetry-based human risk assessments for manganese, described below.
3.5
Discussion and Conclusion
3.5.1 Insights Gained During the Modeling Process for Manganese Manganese is both essential and toxic, and, unlike exogenous compounds typically examined with PBPK models, biological process exist to both ensure adequate tissue concentrations in times of low intake and enhance elimination to prevent toxicity during times of excess intake. The modeling process for manganese revealed insights regarding this control of manganese that were not readily apparent from the data the models were constructed from, such as the importance of tissue binding and free vs bound manganese to the regulation of tissue manganese levels. Initial attempts to construct a mammillary model of manganese based on tracer kinetics failed to reproduce the rapid tissue increases due to inhalation and the rapid return to baseline manganese levels after the cessation of exposure. This deficiency was rectified by the addition of tissue binding that served to maintain tissue levels during normal dietary exposures and low to moderate inhalation exposures but allowed rapid tissue accumulation
Discussion and Conclusion
79
(and subsequent rapid clearance) once a dose-dependent threshold for inhalation exposure was reached. The modeling process highlighted the importance of tissue binding in maintaining relatively constant tissue manganese concentrations across a wide range of low to moderate inhaled concentrations. Only with saturation of these binding capacities do tissue concentrations throughout the body increase in closer proportion to the rate of intake. The elevation occurs preferentially in free manganese that would be more available for excretion, transport, and toxic interactions. The challenge in describing the observed tissue manganese after inhalation is to distinguish those tissues that show relative consistent tissue manganese levels across a wide range of inhalation exposures and those that show some preferential dose-related increases, such as the striatum. The discrepancies between predictions of the earlier mammillary PBPK model (Teeguarden et al., 2007a) and the observed data led to the incorporation of processes that were required in the model to gain consistency with both dietary and inhalation studies, specifically the use of tissue binding that is capacity limited with association and dissociation rate constants that are unusually small. Small dissociation rate constants were also necessary because the terminal phase in tracer studies is correspondingly small. These small association and dissociation rate constants probably reflect processes other than simple bimolecular manganese binding and may be related to organellar storage of manganese.
3.5.2
The Use of PBPK Models in Manganese Risk Assessment
PBPK models reduce uncertainty and improve the scientific basis for determining the relationship among: (a) exposure to the substance of interest; (b) dose to target tissues; and (c) toxicity and other biological responses (USEPA, 2006). PBPK models are typically used for inter-species extrapolation, estimating intra-species variability, route-to-route extrapolation, high-to-low dose extrapolation, and duration of exposure adjustment in the risk assessment of exogenous chemicals. However, for as essential element such as manganese, the PBPK models will allow for a more sophisticated analysis of normal tissue levels, dietary intake, and homeostatic controls of inhaled manganese than was possible before they were constructed. Previous to the development of PBPK models for manganese, risk assessments for inhaled environmental manganese relied upon extrapolation from occupational studies of workers exposed to relatively high concentrations of manganese. To determine a lifetime exposure level that is likely to be without risk of deleterious effects to a population (including sensitive subgroups), such as a RfC or Tolerable Daily Intake (TDI), regulators used the traditional risk assessment approach of determining a point of departure, that is, a no (or lowest) observed adverse effect level (i.e., NOAEL or LOAEL) or benchmark concentration (BMC) based on subclinical changes in motor function in workers, and applying uncertainty factors to extrapolate to the entire population. PBPK models may be used in these types of traditional risk assessments to incorporate chemical specific adjustment factors (CSAFs) instead of traditional uncertainty factors (WHO IPCS, 2005; USEPA, 2006). PBPK models allow for a multi-media risk assessment of essential elements such as manganese that simultaneously considers ingestion and inhalation, along with their homeostatic controls, in the derivation of RfCs by quantifying the relative risk of adverse effects from each route. PBPK models quantitatively consider factors which affect the accumulation and excretion
80
Pharmacokinetic Modeling of Manganese – An Essential Element
of manganese and estimate a range of possible internal levels associated with a given exposure for a population. Specifically, the models describe variation in tissue manganese levels during early development or other potentially susceptible life stages. Because rich data sets were used to build and validate the PBPK models, including animal exposures of different durations to different forms of manganese, the models for manganese have the capability to compare the effects of potential differences in bioavailability of different manganese forms due to differing solubilities, the duration of exposure, and other PK factors to aid in setting appropriately protective CSAFs. The ability of PBPK modeling to use numerous studies and evaluate internal doses to target tissues will produce more robust manganese risk assessments. Another key application of PBPK models to risk assessment involved their ability to extrapolate beyond the exposure conditions that were used to establish and validate the model. Thus, the PBPK models may be used to determine air manganese concentrations that do or do not lead to target tissue (i.e., globus pallidus) accumulation during chronic or lifetime exposures. This attribute allows PBPK models to be used in an alternative risk assessment strategy for essential elements such as manganese based on dose to target tissue. An upper safe exposure value might be based on an air concentration that changes brain tissue levels by no more than some fraction of the normal variability within a population (Andersen, Gearhart, and Clewell, 1999; Andersen et al., 2010). This approach requires a PBPK model and some level of confidence in the model across species and dose routes. The current PBPK model recapitulates (1) elevation in tissue manganese with increasing doses, (2) the long half-life of tracer manganese with normal dietary exposures and the shorter half-lives with high concentration inhalation, (3) the preferential increases in specific brain regions, and (4) combined uptake by both oral and inhalation exposures. While the underlying biological processes, especially those determining the capacity of tissues to maintain bound stores of manganese and asymmetric tissue diffusion, remain only partially understood, the consistency of the processes across species and the consistency with expected behavior for a biologically controlled essential element indicate that the important elements of the kinetics of manganese are captured by this PK model. The asymmetry in diffusion likely represents behavior of specific metal ion transporters. In fact, the tissues that show larger increases in manganese in high concentration inhalation exposures – for example, mid-brain, heart, hypothalamus – may have asymmetric transport to ensure maintenance of adequate manganese in times of deficiency. Their ability to preserve manganese at low concentrations may render them at greater risk in conditions of excess once exposures are sufficiently high to overwhelm the body’s homeostatic mechanisms that attempt to regulate tissue levels. With a more complete evaluation of monkey toxicity results using the now-available monkey manganese PBPK model to assess dosimetry, and with applications of the model to human datasets, the current PBPK model (and subsequent human model) should be an important component of future tissue-dose-based approaches for manganese risk assessment. Similar PK model-based dosimetry approaches could also be considered for risk assessments with other essential metals.
References Andersen, M.E., Gearhart, J., and Clewell, H.J. III (1999) The role of pharmacokinetics and tissue dosimetry in risk assessments for inhaled and ingested Manganese. Neurotoxicology, 20, 161–172.
References
81
Andersen, M.E., Dorman, D.C., Clewell, H.J. III, et al. (2010) Multi-dose-route, multi-species pharmacokinetic models for manganese and their use in risk assessment. J. Toxicol. Environ. Health A, 73, 217–234. Aschner, J.L. and Aschner, M. (2005) Nutritional aspects of manganese homeostasis. Mol. Aspects Med., 26, 353–362. Brown, R.P., Delp, M.D., Lindstedt, S.L., et al. (1997) Physiological parameter values for physiologically based pharmacokinetic models. Toxicol. Ind. Health, 13, 407–484. Cartwright, G.E. and Wintrobe, M.M. (1964) Copper metabolism in normal subjects. Am. J. Clin. Nutr., 14, 224–232. Crossgrove, J.S., Allen, D.D., Bukaveckas, B.L., et al. (2003) Manganese distribution across the blood–brain barrier. I. Evidence for carrier-mediated influx of manganese citrate as well as manganese and manganese transferrin. Neurotoxicology, 24, 3–13. Dorman, D.C., Struve M.F., James, A.R., et al. (2001a) Influence of dietary manganese on the pharmacokinetics of inhaled manganese sulfate in male CD Rats. Toxicol. Sci., 60, 242–251. Dorman, D.C., Struve, M.F., James, A.R., et al. (2001b) Influence of particle solubility on the delivery of inhaled manganese to the rat brain: manganese sulfate and manganese tetroxide pharmacokinetics following repeated (14-Day) exposure. Toxicol. Appl. Pharmacol., 170, 79–87. Dorman, D.C., McManus, B.E., Marshall, M.W., et al. (2004) Old age and gender influence the pharmacokinetics of inhaled manganese sulfate and manganese phosphate in rats. Toxicol. Appl. Pharmacol., 197, 113–124. Dorman, D.C., Struve, M.F., Clewell, H.J. III, and Andersen, M.E. (2006a) Application of pharmacokinetic data to the risk assessment of inhaled manganese. Neurotoxicology, 27, 752–764. Dorman, D.C., Struve, M.F., Marshall, M.W., et al. (2006b) Tissue manganese concentrations in young male Rhesus monkeys following subchronic manganese sulfate inhalation. Toxicol. Sci., 92, 201–210. Foster, D.M., Aamodt, R.L., Henkin, R.I., and Berman, M. (1979) Zinc metabolism in humans: a kinetic model. Amer. J. Physiol., 237 (5), R340–R349. Harvey, L.J., Dainty, J.R., Hollands, W.J., et al. (2005). Use of mathematical modeling to study copper metabolism in humans. Am. J. Clin. Nutr., 81, 807–813. Miller, L.V., Krebs, N.F., and Hambidge, K.M. (2000) Development of a compartmental model of human zinc metabolism: identifiability and multiple studies analyses. Am. J. Physiol. Regul. Integr. Comp. Physiol., 279, R1671–R1684. Moos, T. and Morgan, E.H. (2000) Transferrin and transferrin receptor function in brain barrier systems. Cell. Mol. Neurobiol., 20, 77–95. Nong, A., Teeguarden, J.G., Clewell, H.J. III, et al. (2008) Pharmacokinetic modeling of manganese in the rat IV: Assessing factors that contribute to brain accumulation during inhalation exposure. J. Toxicol. Environ. Health A, 71, 413–426. Nong, A., Taylor, M.D., Clewell, H.J. III, et al. (2009) Manganese tissue dosimetry in rats and monkeys: accounting for dietary and inhaled Mn with physiologically based pharmacokinetic modeling. Toxicol. Sci., 108, 22–34. Reddy, M.B., Yang, R.S.H., Andersen, M.E., and Clewell, H.J. III (2005) Physiologically Based Pharmacokinetic Modeling: Science and Applications, John Wiley & Sons, Inc., Hoboken, NJ. Teeguarden, J.G., Dorman, D.C., Covington, T.R., et al. (2007a) Pharmacokinetic modeling of manganese. I. Dose dependencies of uptake and elimination. J. Toxicol. Environ. Health A, 70, 1493–1504. Teeguarden, J.G., Dorman, D.C., Nong, A., et al. (2007b) Pharmacokinetic modeling of manganese. II. Hepatic processing after ingestion and inhalation. J. Toxicol. Environ. Health A, 70, 1505–1514. Teeguarden, J.G., Gearhart, J., Clewell, H.J. III, et al. (2007c) Pharmacokinetic modeling of manganese. III. Physiological approaches accounting for background and tracer kinetics. J. Toxicol. Environ. Health A, 70, 1515–1526. USEPA (US Environmental Protection Agency) (2006) Approaches for the Application of Physiologically Based Pharmacokinetic (PBPK) Models and Supporting Data in Risk Assessment, National Center for Environmental Assessment, Washington, DC; EPA/600/R-05/043F. Available from: National Technical Information Service, Springfield, VA, and at http://epa.gov/ncea (accessed 1 May 2009).
82
Pharmacokinetic Modeling of Manganese – An Essential Element
WHO IPCS (World Health Organization and International Programme on Chemical Safety) (2005) Chemical-specific adjustment factors for Interspecies differences and human variability: Guidance document for use of data in dose/concentration-response assessment. Available at http://www.who.int/ipcs/methods/harmonization/areas/uncertainty/en/index.html (accessed 1 May 2009). Yokel, R.A., Crossgrove, J.S., and Bukaveckas, B.L. (2003) Manganese distribution across the blood–brain barrier. II. Manganese efflux from the brain does not appear to be carrier mediated. Neurotoxicology, 24, 15–22. Yoon, M., Nong, A., Clewell, H.J. III, et al. (2009a) Lactational transfer of manganese in rats: Predicting manganese tissue concentration in the dam and pups from inhalation exposure with a pharmacokinetic model. Toxicol. Sci., 112, 23–43. Yoon, M., Nong, A., Clewell, H.J. III, et al. (2009b). Evaluating placental transfer and tissue concentrations of manganese in the pregnant rat and fetuses after inhalation exposures with a PBPK model. Toxicol. Sci., 112, 44–58.
4 Physiologically Based Modeling of Pharmacokinetic Interactions in Chemical Mixtures Sami Haddad1 , Robert Tardif 2 , Jonathan Boyd3 and Kannan Krishnan2 1
D´epartement des sciences biologiques, Center TOXEN, Universit´e du Qu´ebec a` Montr´eal, Canada 2 Groupe de recherche interdisciplinaire en sant´e et D´epartement de sant´e environnementale et sant´e au travail, Universit´e de Montr´eal, Canada 3 C Eugene Bennett Department of Chemistry, West Virginia University, USA
4.1 Introduction Guideline values for chemicals are developed based on data from toxicity studies of individual chemicals. However, human exposure in occupational and general environments often occurs to a multitude of chemical stressors, concurrently or sequentially. Several chemicals can interact with each other by various mechanisms and, of the many reports on chemical–chemical and drug–drug interactions, the vast majority of these occur at the pharmacokinetic level (Krishnan and Brodeur, 1991). These interactions occur through various mechanisms that are dependent on the dose, dosing regimen (i.e., single or repeated exposure), exposure pattern (i.e., pretreatment, co-administration, or postadministration), and/or exposure route of one or both chemicals (Krishnan and Brodeur, 1991). Most of the interaction studies reported to date have been conducted in laboratory animals by administering high doses of one or both chemicals by routes and scenarios often different from anticipated human exposures (Calabrese, 1991; Krishnan and Brodeur, 1994). Further, information on the toxicological consequences of low-level or chronic exposures to binary Quantitative Modeling in Toxicology C 2010 John Wiley & Sons, Ltd
Edited by Kannan Krishnan and Melvin E. Andersen
84
Physiologically Based Modeling of Pharmacokinetic Interactions in Chemical Mixtures
chemical mixtures, which show significant interactions when administered acutely, is often unavailable (Krishnan and Brodeur, 1991). In order to account for interactions in risk assessment of mixtures, there is a need for tools that can describe and predict the impact of co-exposure on the pharmacokinetics and pharmacodynamics of mixture constituents as well as allow all necessary extrapolations related to differences between toxicity studies and human exposure (i.e., high dose to low dose, route to route, species to species, scenario to scenario, and binary to more complex mixtures). These concerns can be addressed with the use of a physiologically based modeling approach. Physiologically based modeling refers to the process of reconstructing mathematically the anatomic-physiological characteristics of the organism of interest and describing the complex interplay among the critical determinants of pharmacokinetics and pharmacodynamics.
4.2
Pharmacokinetic Interactions and Mathematical Descriptions
Pharmacokinetic interactions occur when a compound alters determinants of absorption, distribution, metabolism or excretion of another chemical. These determinants belong to one of the three types of parameters: physiological, physicochemical, and biochemical. 4.2.1 Interactions Due to Physiological Effects Physiological changes altering the pharmacokinetics of one chemical by another have been characterized largely for binary chemical mixtures. For example, cyanide and hydrogen sulfide at low concentrations increase alveolar ventilation rates (Qalv), and hence change inhalation/exhalation rates of other volatile chemicals (Dreisbach 1977). Cardiac output and tissue blood flows can also be influenced by chemicals which can thereby affect the distribution or the metabolic rates of coexposed chemicals. Ethanol and phenobarbital increase hepatic blood flow, which can increase the extraction ratio of highly metabolized compounds during co-exposure (Krishnan, Clewell, and Andersen 1994). Vasodilators and vasoconstricors may influence the distribution of other chemicals by modifying regional blood flows. Glomerular filtration rates (GFR), an important factor for renally excreted chemicals, can be modified by certain compounds. Chronic exposure to cadmium leads to accumulation of metallothionin-cadmium complexes in kidneys which diminish GFR (Webb, 1986; Goyer et al., 1989; Shigematsu et al., 1989). Some chemicals can modify skin structure or composition, leading to changes in the rate of dermal absorption of other chemicals. An interaction due to skin composition changes is exemplified by the reduction of absorption of m-xylene due to skin dehydration by isobutanol (Riihim¨aki 1979). Dimethyl sulfoxide (DMSO) causes swelling of basal cells of the stratum corneum as well as a disruption of keratin matrices in skin (Kurihara-Bergstrom, Flynn, and Higuchi, 1987; Qiao et al., 1996). This has been shown to positively influence the dermal permeability of coexposed lipophilic compounds (Hayes and Pearce, 1953; Jacob, Bischel, and Herschler 1964; Choi, Flynn, and Amidon, 1990). To date, there are no published pharmacokinetic models incorporating changes in physiological parameters caused by co-exposures.
Pharmacokinetic Interactions and Mathematical Descriptions
4.2.2
85
Physicochemical Interactions
Co-exposures can lead to modification of a chemical’s solubility in lipid or water or even in its permeability across biological membranes, resulting in changes in distribution or rates of absorption. For example, some chemicals, such as antacids, can alter the pH of gastric or intestinal regions and, therefore, influence the ionization state of other acidic or basic chemicals, leading to altered absorption rates. For some chemicals, their presence together leads to formation of complexes which are more lipophilic than either chemical itself, resulting in an increase in their permeability across membranes (e.g., increased permeability across blood–brain barrier of lead-dithiocarbamate complexes (Oskarsson and Lind, 1985)). Much like interactions due to physiological alterations, interactions at the physicochemical level have not yet been described in PBPK models. 4.2.3
Interactions at the Biochemical Level
Interactions at the metabolic and transporter levels are by far the most frequently reported pharmacokinetic interactions. They occur when a chemical alters the binding, the biotransformation or the active transport of another chemical. These types of modifications are either the result of changes in the affinity or maximal velocity. 4.2.3.1
Reversible Protein Binding Interaction
Mechanisms of interactions at the level of protein binding might involve either competition for the binding site or induction of binding protein levels. The modeling of protein induction is discussed elsewhere in this chapter as well as in Chapter 7. Sugita et al. (1982) developed a PBPK model describing the competition between tolbutamide and sulfonamides (sulfaphenazol, sulfadimethoxin or sulfomethoxazol) for binding to plasma proteins. To estimate the free concentration of a chemical (Cf ) that binds to a protein, the following equation can be used: Cb =
n · β · Kd · C f (1 + K d · C f )
(4.1)
where C = Concentration (mg/liter), Kd = dissociation constant (mg/liter), and n β = binding capacity, and the subscripts b and f refer to bound and free forms. In the presence of a competitive inhibitor (I), Kd in the above equation increases by factor α: α =1+
4.2.3.2
[I ] Ki
(4.2)
Reversible Metabolic Inhibition
Among all the mixture PBPK models published to date, reversible metabolic inhibition is by far the most frequently encountered type of interaction (listed in Table 4.1). There are three simple cases of reversible enzyme inhibition: competitive, non-competitive, and uncompetitive (Table 4.2).
Warfarin Sodium tolbutamide
Dibromomethane Trichloroethylene Phenolsulfonphthalein
Luecke and Wosilait (1979) Sugita et al. (1982)
Clewell and Andersen (1985) Andersen et al. (1987) Russel, Wouterse, and van Ginneken (1987) Russel, Wouterse, and van Ginneken (1987) Russel, Wouterse, and Van Ginneken (1989) Purcell et al. (1990) Tardif et al. (1993) Filser et al. (1993) Bond et al. (1994) Bond et al. (1994) Barton et al. (1995) Tardif et al. (1995) Krishnan and Pelekis (1995) el-Masri et al. (1996a, 1996b) Probenecid Toluene m-Xylene Styrene Styrene Benzene Vinyl chloride Xylene Dichloromethane 1,1-Dichloroethylene
Benzene Toluene 1-3 butadiene 1,3-butadiene 1,3-butadiene 1,1-Dichloroethylene Toluene Toluene Trichloroethylene
Bromosulfophthalein Sulfaphenozol Sodium sulfadimethoxazole Sodium Sulfadimethoxine Isofluorane 1,1-Dichloroethylene Probenecid Saliuric acid Phenolsulfonphthalein
Chemical B
Iodopracet
Saliuric acid
Chemical A
Reference
Table 4.1 PBPK models developed to describe reversible inhibition in binary mixtures.
Non-competitive Competitive Competitive Competitive Competitive Competitive Competitive Competitive Competitive
Competitive
Competitive Non-competitive Non-competitive Non-competitive Competitive Competitive Competitive Competitive (2 sites) Non-competitive
Type of inhibition
m-xylene Trichloroethylene Xylenes Itraconazole Trichloroethylene
Toluene Toluene Methyl chloroform Toluene Ethylbenzene Simvastatin Chloroform
Yu et al. (1998) Ali and Tardif (1999)
Tardif and Charest-Tardif (1999) Thrall and Poet (2000) Jang, Droz, and Kim (2001) Ishigam et al. (2001) Isaacs, Evans, and Harris (2004)
Styrene Dichloromethane Cimetidine Probenecid n-Hexane n-Hexane
1-3 butadiene Toluene Ranitidine
Leavens and Bond (1996) Pelekis and Krishnan (1997) Boom et al. (1998)
Competitive Competitive Competitive Competitive
Competitive Competitive Competitive Competitive Non-competitive Uncompetitive or non-competitive Competitive
88
Physiologically Based Modeling of Pharmacokinetic Interactions in Chemical Mixtures
Table 4.2 Descriptions of reversible metabolic inhibition on Vmax , and Km . (Based on Segel,1975).
E + S ES → E + P + + I I
E + S ES → E + P + I
Apparent Km Apparent V max a
Note: α = 1 +
EI αKm V max
EI + S EIS Km V max /α
E + S ES → E + P + I
Uncompetitive
Non-competitive
Equilibrium equation
Competitive
EIS Km /α V max /α
[I ] . Ki
Competitive inhibition occurs when chemicals compete for the enzyme’s active site, resulting in decreased apparent affinity (i.e., increased K m ) and, therefore, reduced rate of metabolism at lower substrate concentration. The competitive inhibitor may either be another substrate or strictly an inhibitor; the K i of a competing substrate is the same as its K m (Segel, 1975). Non-competitive inhibition occurs when a chemical binds to the enzyme (free or complexed with substrate) at a site that is away from the catalytic active site. This binding changes the conformation of the enzyme, resulting in a decreased catalytic activity (i.e., decreased V max ). The less frequently encountered uncompetitive inhibition occurs when a chemical binds to the enzyme-substrate complex. The catalytic function is affected without interfering with substrate binding. The inhibitor causes a structural distortion of the active site and inactivates it (Voet and Voet, 2004). This has the effect of reducing the available enzyme for the reaction (i.e., lowering V max ) and also driving the reaction (E+S→ES) to the right (i.e., decreasing K m ). It is noteworthy to point out that these types of reversible metabolic inhibition can also occur with active transport processes. In fact, Sugita et al. (1982) described non-competitive inhibition as the mechanism of binary interaction between sodium tolbutamide and three other drugs (sulfaphenozol, sodium sulfadimethoxazole, and sodium sulfadimethoxine). Metabolites may also interfere with the biotransfortmation of their parent compound. This phenomenon is called product inhibition and might invoke a competitive, non-competitive or uncompetitive mechanism. For example, n-hexane, which is metabolized to methyl n-butyl ketone (MnBK) and then to 2,5-hexanedione, has been reported to involve multiple interactions (competitive inhibition) occurring among n-hexane and its metabolites (Andersen and Clewell, 1983). 4.2.3.3
Irreversible Metabolic Inhibition
When an inhibitor binds irreversibly to the enzyme at the active site, it decreases the concentration of functional enzyme and thus the V max . This type of inhibition has been described
Pharmacokinetic Interactions and Mathematical Descriptions
89
by interaction-based PBPK models for mixtures of triazolam and erythromycin (Kanamitsu et al., 2000a), 5-fluorouracil and sorovidine (Kanamitsu et al., 2000b), trichloroethylene and its metabolite dichloracetate (Keys et al., 2004). Briefly, the modeling of this type of interaction consists of describing the change in V max of the substrate by taking into account the inactivation of enzyme in relation to the concentration of the inhibitor as follows. Accordingly, the concentration of active enzyme at steady state (i.e., in the absence of inactivator) equals the rate of enzyme synthesis (a zero order process) minus the rate of enzyme degradation (first order process that can be determined experimentally). This steady state is interrupted in the presence of an enzyme inactivator and the levels of enzyme is decreased that is directly related to the concentration of the by a rate of enzyme inactivation dI nact dt inactivating chemicals in the liver (I h ), as follows:
dI nact = dt
kinact ∗ E a ∗ f b ∗ K i,app + f b ∗
Ih Kp
Ih Kp
(4.3)
where kinact represents the maximum inactivation rate constant, K p represents the liver-to blood partition coefficient, f b is the unbound fraction in blood, and I h is the inactivator’s concentration in the liver.
4.2.3.4
Induction
Enzyme induction increases the V max of its substrate, due to increased enzyme synthesis and/or decreased enzyme degradation. Induction of CYP2B1/2 by octamethylcyclotetrasiloxane (Sarangapani et al., 2002) and CYP1A1 and 1A2 by TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin) via interaction with the Ah-receptor (Andersen, 1995; Andersen et al., 1997) have been described quantitatively, as follows: dSyn [R L]n = K syn basal + (K syn max − K syn basal ) × dt [R L]n + K d n
(4.4)
where Ksynbasal represents the basal rate of enzyme synthesis, Ksynmax represents the maximal rate of enzyme synthesis, [R L] is the concentration of the receptor-ligand complex and n is the hill coefficient. The decrease in enzyme degradation has been described by Chien, Thummel, and Slattery (1997) for modeling the induction of CYP2E1 by ethanol, acetone, and isoniazid via enzyme stabilization. Chien, Thummel, and Slattery (1997) described two pools of the enzyme. Accordingly, the first pool arising from synthesis is degraded rapidly in free form but slowly when bound to the stabilizing chemical; on the other hand, the second enzyme pool is described as being degraded slowly in either bound or unbound form (Chien, Thummel, and Slattery, 1997).
90
Physiologically Based Modeling of Pharmacokinetic Interactions in Chemical Mixtures
4.3 PBPK Modeling of Mixtures A key feature of PBPK modeling is that it can be used to integrate information on pharmacokinetic interactions. Mixtures in which chemical components do not interact will not be dealt with in this chapter because constituents can be dealt with as single chemicals. Ideally, to develop mixture PBPK models, one should start with the PBPK models developed and validated for each of the mixture constituents. The interaction-based PBPK model can then be developed by linking together the single chemical models by known or hypothesized mathematical descriptions of their interaction mechanism (see above). For example, chemical A may inhibit the hepatic metabolism of chemical B and vice versa by competing for the enzyme (competitive inhibition) as depicted in Figure 4.1. The rate of metabolism (RAM) of chemicals A and B is then calculated by accounting for the inhibition constant and concentration of the other chemical (i.e., inhibitor) in the liver compartment. There are numerous examples of interaction-based PBPK models for binary mixtures (Krishnan et al., 1994; Reddy et al., 2005) and in all cases the interaction is primarily related to metabolic interference. Following initial work on the modeling of metabolic interactions in binary mixtures (toluene–benzene; toluene and m-xylene; toluene and ethylbenzene), Krishnan and co-workers (Tardif et al., 1993, 1995, 1997; Pelekis and Krishnan, 1997; Haddad et al., 1999, 2000a) extended this approach to more complex chemical mixtures. The hypothesis put forward and tested by this group was that the pharmacokinetics of interacting mixture components may be simulated if all binary level interactions in the mixtures are described in the model. Briefly, the approach consisted of constructing PBPK models for each mixture constituent and then connecting them at the binary level on the
Figure 4.1 Conceptual representation of a PBPK model for a binary mixture for chemicals A and B that compete with each other for metabolism.
PBPK Modeling of Mixtures
B
91
C
A D E Figure 4.2 A representation of a network of binary pharmacokinetic interactions between five chemicals (A, B, C, D, and E). All mixture constituents that interact are connected within this network.
basis of the interaction mechanism. By doing so, a network of binary pharmacokinetic interactions is created (Figure 4.2) and the kinetics of the mixture constituents becomes interdependent. Any change in the concentration of a mixture component will, therefore, necessarily have direct and/or indirect repercussions on the kinetics of other chemicals that are part of the interaction network (Haddad and Krishnan, 1998; Krishnan et al., 2002). Conceptually, this approach can be applied to mixtures of any complexity as long as information on all interacting pairs is taken into account by the model. Using this approach, Tardif et al. (1997) simulated interactions occurring in a ternary mixture of toluene, m-xylene, and ethylbenzene. Subsequently, Haddad et al. (1999, 2000a) demonstrated that additional mixture components could be modeled by simply incorporating mechanistic information on the new binary interactions. This led to the development, and validation of interaction-based PBPK models for mixtures of four chemicals (benzene, toluene, m-xylene, and ethylbenzene) and even of five chemicals (benzene, toluene, m-xylene, ethylbenzene, and dichloromethane) (Figure 4.3). Applying the same approach, the interactions occurring in a ternary mixture of trichloroethylene (TCE), tetrachloroethylene (PERC), and 1,1,1-trichloroethane (methyl chloroform, MC) in rats and humans have been modeled (Dobrev, Andersen, and Yang, 2001, 2002). Although all these studies dealt strictly with metabolic interactions, there is no reason to believe that the approach based on binary interaction network may not apply to other types of pharmacokinetic interactions. To use this mixture modeling approach, a priori studies on all binary interactions in the mixture must be characterized. This is a major limitation for the construction of mixture PBPK models, since the number of binary interactions (N) increases greatly with the number of mixture components (n) (i.e., N = n (n − 1)/2). Accordingly, for mixture of 5 and 10 chemicals, 10 and 45 binary interactions must be characterized. Considering the complexity of some of the mixtures to which humans and other species are exposed, the characterization of all binary interactions will be tedious or even impossible. In this regard, some alternative mixture modeling methods have been proposed. 4.3.1
Modeling Maximal Impact of Interactions
A pragmatic alternative approach, when there is insufficient information on mechanism of binary interactions or on the mixture composition, would be to focus on the modeling of maximal impact of interactions on the kinetics of the chemicals (Haddad, Charest-Tardif, and Krishnan, 200b). Although this approach does not allow the exact predictions of the
exhaled
Lungs
Lungs
Dichloromethane
Benzene
exhaled
Slowly perfused tissues
Slowly perfused tissues
inhaled
Richly perfused tissues
Richly perfused tissues
exhaled
Fat
Fat
inhaled
Liver
RAM B
RAM E
RAM D =
RAM B =
RAM E =
RAM X =
RAM T =
Liver
Slowly perfused tissues
Richly perfused tissues
Fat
Lungs
exhaled
Ethylbenzene inhaled
Liver
RAM D
RAM T
RAM X
Liver
Slowly perfused tissues
Richly perfused tissues
Fat
Lungs
exhaled
V max T ⋅ Cvl T
X ⋅
Cvl X
V max E ⋅ Cvl E
Cvl T Cvl E Cvl B Cvl D ⎞⎟⎟ + + + + Cvl X KiTX Ki EX Ki BX Ki DX ⎟⎠⎟
V max
Cvl X Cvl E Cvl B Cvl D ⎞⎟⎟ + + + + Cvl T Ki XT Ki ET Ki BT Ki DT ⎟⎟⎠
V max B ⋅ Cvl B
V max D ⋅ Cvl D Cvl T Cvl X Cvl E Cvl B ⎞⎟⎟ Km 1 + + + + + Cvl D KiTD Ki XD Ki ED Ki BD ⎟⎟⎠ ⎛ ⎜ ⎜ D⎜ ⎜ ⎝
Cvl T Cvl X Cvl E Cvl D ⎞⎟⎟ Km 1 + + + + + Cvl B KiTB Ki XB Ki EB Ki DB ⎟⎟⎠ ⎛ ⎜ ⎜ B⎜ ⎜ ⎝
Cvl T Cvl X Cvl B Cvl D ⎞⎟⎟ Km 1 + + + + + Cvl E KiTE Ki XE Ki BE Ki DE ⎟⎟⎠
⎛ ⎜ ⎜ E⎜ ⎜ ⎝
⎜ ⎝
⎛ ⎜
Km X ⎜⎜1 +
⎜ ⎝
⎛ ⎜
KmT ⎜⎜1 +
Figure 4.3 Representation of the PBPK model for a mixture of five VOCs (X: m-xylene, T: toluene, E: ethylbenzene, B: benzene, and D: dichloromethane) All binary interactions which occur at the level of the rate of metabolism (RAM) are taken into account. Modification of Km due to competitive inhibition among all mixture constituents is captured in the RAM equations. Figure adapted from Krishnan et al. (2002).
Liver
Slowly perfused tissues
Richly perfused tissues
Richly perfused tissues
Fat
Lungs
inhaled
Toluene
m-Xylene inhaled
PBPK Modeling of Mixtures
93
altered kinetics, it does permit the prediction of the upper or lower bound concentrations that could occur in the presence of interacting chemicals. The authors demonstrated the applicability of such an approach for mixtures of VOCs (m-xylene, ethylbenzene, benzene, toluene, dichloromethane, perchloroethylene, p-xylene, o-xylene, styrene, and trichloroethylene) of up to 10 constituents. For these chemicals, they assumed that interactions would occur only at the level of hepatic metabolism and described the rate of metabolism (RAM) as a function of the extraction ratio (E), as follows: R AM = Q l · E · Ca
(4.5)
where Ca is the arterial concentration and Ql is the blood flow to liver. Knowing that the values of E can only vary between 0 (i.e., maximal effect of inhibition) and 1 (maximal effect of induction), they simulated the concentration versus time profiles for defined exposure conditions of 10 chemicals in various mixtures. The modeling results showed that the limits were well predicted for nine chemicals out of ten (Figure 4.4). This approach produces a “prediction envelope” reflective of the maximal impact of interactions and is particularly useful in data-poor situations for inhaled volatile organics and has potential applications in screening-level risk assessments. 4.3.2
Lumping Chemicals
Another approach particularly applicable for very large or undefined mixtures is the “lumping” of chemicals. Dennison et al. (2003, 2004) modeled the pharmacokinetics of the constituents of two mixtures of gasoline (i.e., gasolines of summer blend and winter blend). In these studies, the mixture was treated as a composite of six chemicals, namely, benzene, toluene, ethylbenzene, o-xylene, n-hexane, and a pseudo-chemical which is an aggregate or lumping of all the other chemicals in the mixture (e.g., aromatics, isoparaffins, naphthalenes, olefins, paraffins, oxygenates, 4–10 carbon alkanes). The authors used the binary interaction-based approach to model the pharmacokinetics of all “six” components. Competitive inhibition was the principal mechanism of pharmacokinetic interactions among these “six” chemicals. Computer simulation results from the “six” chemical interaction model matched well with gas uptake pharmacokinetic experimental data from single chemicals, the five chemical mixture, and the two blends of gasoline. The kinetics of the pseudochemical was well predicted, partly due to the fact that interactions had very little impact on the mixed venous blood concentration. This lumping approach, likely to be more useful for modeling mixtures containing similar chemicals, would allow the reduction of the number of binary interaction studies for identifying interaction mechanisms and related parameters required for modeling. 4.3.3
Using Km as Ki for Competing Substrates
Price and Krishnan (2005) developed PBPK models for mixtures of chemical competing for metabolism, on the basis that K m values of substrates are sufficient for simulating competitive interactions within a multichemical mixture, in the absence of knowledge on binary inhibition constants. They validated this hypothesis with a mixture of VOCs (dichloromethane, toluene, ethylbenzene, m-xylene, o-xylene, p-xylene, trichloroethylene,
94
Physiologically Based Modeling of Pharmacokinetic Interactions in Chemical Mixtures TOLUENE
Venous concentration (mg/l)
10
1
0.1
0.01 0
1
2
3
4
5
6
7
Time (h) ETHYLBENZENE
Venous concentration (mg/l)
10
1
0.1
0.01 0
1
2
3
4
5
6
7
Time (h)
Figure 4.4 Simulations of venous blood concentrations of toluene and ethylbenzene during maximal impact of inhibition (E = 0; solid thick line) and maximal impact of induction (E = 1; dotted line) in rats exposed by inhalation for a duration of four hours to 100 ppm. Experimental data (symbols) are shown for toluene and ethylbenzene obtained in rats exposed alone and to mixtures of increasing complexity (2–10 volatile organic chemicals). The thin line represents the kinetic profile associated with the single chemical exposure scenario. Adapted from Haddad, Charest-Tardif, and Krishnan (2000b). Reprinted by permission of Taylor & Francis Group, http://www.informaworld.com.
Modeling and Simulations of Binary to Higher Order Interactions in Chemical Mixtures
95
and styrene) in rats. The V max and K m for these chemicals, in turn, were estimated by QSAR methods, which could prove useful for PBPK modeling of chemical mixtures in data-poor situations. The resulting simulations yielded predictions of pharmacokinetics within a factor of 1.5). Using such approaches in mixture PBPK modeling should greatly reduce the number of binary interaction studies for the development of multichemical PBPK models. The approach of Price and Krishnan (2005) is suitable in cases where chemicals compete for metabolism and do not interact in any other way. This approach could be used as a first step in identifying/validating the assumption of competitive inhibition as the mechanism of binary interaction in mixtures.
4.3.4
Fitting Parameter Values to Data Obtained During Exposures to Mixtures
When the kinetic data are available for all components of a mixture for relevant combined exposure scenarios, it becomes relatively straightforward to characterize the apparent rates and affinities of metabolism. In such cases, there is no need to individually characterize the behavior of each inhibitor, its concentration or its inhibition potency with regard to all other mixture components. Using this strategy, Emond, Charbonneau, and Krishnan (2005) modeled the pharmacokinetics of mixtures of PCB congeners (118, 138, 153, 170, 180, and 187) in rats. Because these compounds are highly lipophilic, the kinetics of these compounds were modeled by simply considering the lipid content of the tissue compartments and lipid flow via systemic circulation. Instead of characterizing every binary metabolic interaction in the mixture (i.e., 15 binary combinations), the authors used pharmacokinetic data for these compounds, determined following administration as mixtures, to optimize the metabolic rates on day 41 or 90 of repeated exposures by gavage. Using this approach, the values for metabolic rates generally increased in function of dose, which is consistent with CYP induction in rats following repeated exposures to PCBs. Although, this mixture modeling approach allows the simulation a posteriori of the kinetics of mixture constituents without the use of binary interaction data, it is only likely to be of value in conducting interpolations covering the range of doses and exposure scenarios for which the metabolic rates were optimized.
4.4 Modeling and Simulations of Binary to Higher Order Interactions in Chemical Mixtures Several commercially available simulation or programming software packages can be used for conducting PBPK model simulations (Krishnan and Andersen, 2007). Thy can also R R , QuattroPro be accomplished using simple spreadsheet programs (e.g., Lotus 1-2-3 R and Microsoft Excel ) as demonstrated by Haddad, Pelekis, and Krishnan (1996), particularly when models are relatively simple. The “internal mechanics” of computer simulation in such cases can be visualized if the user can reconstruct the way in which the simulation software (i) solves each equation in the model, and (ii) takes the output of one equation and provides it as input to other equations of the model. Therefore, this approach is appropriate for individuals who do not have sufficient knowledge of numerical integration algorithms and simulation software. As an example, it is possible to view the
96
Physiologically Based Modeling of Pharmacokinetic Interactions in Chemical Mixtures
Figure 4.5 Computer screen display of the spreadsheet PBPK model of the binary mixture of toluene and m-xylene.
implementation of the PBPK model for the binary mixture of toluene (TOL) and m-xylene (XYL) (Tardif et al., 1995) on an Excel spreadsheet (see QMT Model Library folder HADDAD). In this example, all model parameters are introduced onto a table in a sheet called Parameters (Figure 4.5). The top portion of this sheet has a table containing the values of physiological parameters (tissues blood flows in column C and tissue volumes in column D), tissue:blood and blood:air partition coefficients (column E and G for TOL and XYL, respectively) and biochemical parameters (column F and H for TOL and XYL, respectively). Exposure conditions are located in the table located below to the left where inhaled concentrations (Cinh) and exposure duration (Length) are specified for each chemical. The length of the simulation and the integration time step are given in
Modeling and Simulations of Binary to Higher Order Interactions in Chemical Mixtures
97
the lower left table. Experimental values are also given on the lower right table (columns F–H; rows 23–30) for a six hour exposure to a mixture of TOL 100 ppm and XYL 200 ppm. In this example, a second sheet entitled Simulations (a part of the same EXCEL file) is used to integrate all mass balance differential equations (Figure 4.6). Each column is dedicated to calculate and display the results of a single equation at each integration interval. The progression through time is made by repeating the calculation in subsequent lines using the current values for the variables. To write this binary mixture model, a single chemical PBPK model is first written (Figure 4.6a), where column B corresponds to time progression during simulation, column C is the inhaled chemical concentration, column D is the arterial blood concentration (Ca), and column U is the venous blood concentration resulting from the venous blood leaving each tissue (Cvt). All equations referring to each tissue are grouped together (liver: columns E–H; Fat: columns I–L; richly perfused tissues: columns M–P; and slowly perfused tissues: columns Q–T). The first column corresponding to each tissue contains the mass balance differential equation (dAt/dt), the second calculates the amount of chemical in tissue at a given time (At), the third has the tissue concentration (Ct), and the fourth contains the Cvt. Once all columns required for simulating the kinetics of one chemical are created, these columns (C–U) are then copied and pasted onto columns V to AN (Figure 4.6b), and all references to TOL parameters found in equations are changed to those of XYL. The metabolic interaction between both chemicals is then introduced into the differential equation for liver (columns E and X), as follows: Cell E5 = (Ql∗ (D5 − H4)) − ((Vmax t∗ H4)/(Kmt∗ (1 + AA4/Kixt) + H4)) Cell X5 = (Ql∗ (W5 − AA4)) − ((Vmax x∗ AA4)/(Kmx∗ (1 + H4/Kitx) + AA4))
(4.6) (4.7)
where parameters Ql, V max , K m , and K i are the liver blood flow, the maximal rate of metabolism, the Michaelis affinity constant, and the inhibition constant, respectively, and the suffixes t and x refer to the chemicals, toluene (TOL) and xylene (XYL). The inhibition constant (K i ) xt signifies the inhibitory effect of XYL on TOL and tx the inhibitory effect of TOL on XYL. Variables D5 and W5 are the arterial blood concentrations for TOL and XYL, respectively. And, variables H4 and AA4 in the above equations refer to Cvl for TOL and XYL, respectively. When writing the model, only the first two lines (lines 4 and 5 of the sheet) need to be written, and then the second line can be copied onto the number of lines desired. The number of lines will depend on the integration step and the desired duration of simulation. In this example, line 5 is copied up to line 1303 to simulate kinetics during 6.5 hours (Figure 4.7). It does become tedious to conduct such simulations with increasingly complex mixtures. In this regard, the use of simulation software is needed to be efficient and pragmatic. This aspect is illustrated with the PBPK model for a quaternary mixture model, namely BTEX (benzene, toluene, ethylbenzene, and m-xylene) in rats (Haddad et al., 1999), written in a specialized simulation software ACSLXtreme (Aegis Technologies, Huntsville AL). This BTEX PBPK model (see folder HADDAD in the QMT Model Library) can be used to simulate exposures to any mixture combinations existing in BTEX (i.e., six binary mixtures, four ternary mixtures and one quaternary mixture) and it can, therefore, be used to reproduce simulations found in a number of previous publications (Tardif et al., 1993,
Figure 4.6 (a) Visual snapshot of the spreadsheet PBPK model of the binary mixture of toluene and xylene. The sheet presented in this screen is the one that has model equations and computational results for toluene (TOL). (b) Visual snapshot of the spreadsheet PBPK model of the binary mixture of toluene and xylene. The sheet presented in this screen is the one that has model equations and computational results for m-xylene (XYL).
Modeling and Simulations of Binary to Higher Order Interactions in Chemical Mixtures
99
Figure 4.7 Visual snapshot of the spreadsheet PBPK model of the binary mixture of toluene and m-xylene. The sheet presented in this screen captures the graphical output of the 6.5 hour simulation of venous blood concentrations in rats simultaneously exposed to 100 ppm toluene and 200 ppm m-xylene for four hours.
1997, Haddad et al., 1999). The use of this model for conducting simulations associated with mixed exposures is illustrated below with examples. The number of interacting chemicals in a mixture can have a great impact on the blood kinetics a given chemical. The BTEX PBPK model is used here to illustrate this point, as well as to show the impact of exposure concentrations on the magnitude of interactions. Figure 4.8 shows PBPK model simulations of blood toluene concentrations following exposure of a rat to toluene alone or with increasing number of chemicals (up to four). As the level of complexity of the mixture is increased, the mathematical description of the rate of metabolism of chemicals is complicated by the introduction of an additional binary interaction term (i.e., Cvlinhibitor /K i ) (Table 4.3). The addition of a third chemical, ethylbenzene (E), will affect the liver venous blood concentration of toluene (T) and mxylene (X). The addition E to the binary mixture affects the magnitude of the existing binary interaction of T–X by increasing the Cvl of T and that of X (Table 4.3). Similarly, the addition of E to the ternary mixture affects the kinetics of all three solvents. The magnitude of the modulation of interactions invoked upon the addition of another chemical to an existing “network” of binary interactions depends on its inhibition potency (reflected by its inhibition constant, K i ), and also on its Cvl. With increasing complexity of mixtures, the K i for binary
Physiologically Based Modeling of Pharmacokinetic Interactions in Chemical Mixtures Venous blood concentration (mg/l)
100
1.4 1.2 1 0.8
Cvt (T alone)
0.6
Cvt (TX)
0.4
Cvt (TEX) Cvt (BTEX)
0.2 0
0
1
2
3
4
5
6
7
Time (h)
Figure 4.8 Simulations of rat venous blood concentrations (Cvt) of toluene alone (T alone) or in mixtures of increasing complexity with m-xylene (TX), ethylbenzene (TEX) and benzene (BTEX). Inhaled concentrations of mixture constituents are 100 ppm each.
Venous blood concentrtaion (mg/l)
interactions is not modified; rather the Cvl is increased according to the potency and number of the inhibitors. The increasing effective concentration of chemicals in a mixture is due to cascade of inhibitory events at the binary level which are all interconnected within the PBPK model framework (Table 4.3). This is the reason why the tendency is to see a more marked inhibitory effect with increasing number of inhibitors on the metabolism of a substrate at a specific exposure concentration. The level of increase is also dependent on their exposure levels, as shown by the difference between Figures 4.8 and 4.9, where the number of constituents are similar but their exposure concentrations differ by 10-fold (10 ppm each vs 100 ppm each). To obtain
0.12 0.1 0.08 Cvt (T alone)
0.06
Cvt (TX) 0.04
Cvt (TEX) Cvt (BTEX)
0.02 0
0
1
2
3
4
5
6
7
Time (h)
Figure 4.9 Simulations of rat venous blood concentrations (Cvt) of toluene alone (T alone) or in mixtures of increasing complexity with m-xylene (TX), ethylbenzene (TEX) and benzene (BTEX). Inhaled concentrations of mixture constituents are 10 ppm each (B).
Modeling and Simulations of Binary to Higher Order Interactions in Chemical Mixtures
101
Table 4.3 Mathematical description of the (rate of metabolism) (RAM) of toluene (T) present alone or along with other chemicals (i.e., m-xylene (X), ethylbenzene (E), benzene (B)) that compete for the same but saturable enzyme catalytic sites.a Number of chemicals in mixture
Chemical
RAM equation
1
T
V maxT ·Cvl T K mT + Cvl T
2
T
V maxT ·Cvl T X + Cvl T K mT 1 + KCvl iXT
X
V max X ·Cvl X T + Cvl X K mX 1 + KCvl iT X
3
T
X
E
4
T
X
E
B
V maxT ·Cvl T
K mT 1 +
Cvl E K iE T
Cvl T K iT X
+
Cvl E K iE X
V max E ·Cvl E
K mE 1 +
K mT 1 +
Cvl T K iT E
Cvl X K iX E
+ Cvl T
+ Cvl X
+ Cvl E
+
Cvl E K iE T
+
Cvl B K i BT
V max X ·Cvl X
K mX 1 + K mE 1 +
Cvl T K iT E
K mB 1 +
+
V maxT ·Cvl T Cvl X K iXT
Cvl T K iT X
+
V max X ·Cvl X
K mX 1 +
Cvl X K iXT
+
Cvl E K iE X
+
Cvl B K iBX
V max E ·Cvl E +
Cvl X K iX E
+
Cvl B K iBE
V max B ·Cvl B Cvl T K iT B
+
Cvl X K iX B
+
Cvl E K iE B
+ Cvl T
+ Cvl X
+ Cvl E
+ Cvl B
α KiXY = inhibition constant, for the effect of chemical X on chemical Y. Cvlx = concentration of chemical x in venous blood leaving liver.
these simulations, only the exposure concentrations of mixture constituents were changed during the modeling exercises. As the exposure concentrations of co-occurring chemicals decrease, the magnitude of interaction and change in toluene concentration in the venous blood also decrease (Figure 4.9 versus Figure 4.8). Due to the fact that the binary interaction terms are influenced by the Cvl of inhibitors and their inhibitory potency K i , it is obvious that as the chemical exposure levels decrease (yielding blood levels well below K i ), there is little impact on the overall rate of metabolism of toluene (Table 4.3).
102
Physiologically Based Modeling of Pharmacokinetic Interactions in Chemical Mixtures
4.5
Conclusions
Pharmacokinetic interactions result when one chemical alters the determinants of absorption, distribution, metabolism or excretion of another chemical during co-exposures. The quantitative information on the interaction mechanism can be integrated within PBPK models to conduct simulations of kinetics of chemicals in mixtures. The binary interactionbased PBPK model can then be developed by linking together the single chemical models on the basis of known or hypothesized mathematical description of their interaction mechanism. These models have been shown to be able to simulate the kinetics of chemicals in increasingly complex mixtures. A number of alternative modeling approaches are also available and these do not require the knowledge of all binary level interactions in a given mixture. These approaches include: modeling maximal impact of interactions, lumping of mixture constituents, using K m as K i for competing substrates, as well as fitting parameter values to data obtained during exposures to mixtures.
References Ali, N. and Tardif, R. (1999) Toxicokinetic Modeling of the Combined Exposure to Toluene and n-Hexane in Rats and Humans. J. Occup. Health, 41 (2), 95–103. Andersen, M.E. and Clewell, H.J. III (1983) Pharmacokinetic Interaction of Mixtures. Proceedings of the 14th Annual Conference on Environmental Toxicology, Dayton, Ohio. AFAMRL-TR-83-099, pp. 226–238. Andersen, M.E., Gargas, M.L., Clewell, H.J. III and Severyn, K.M. (1987) Quantitative evaluation of the metabolic interactions between trichloroethylene and 1,1-dichloroethylene in vivo using gas uptake methods. Toxicol. Appl. Pharmacol., 89 (2), 149–157. Andersen, M.E. (1995) Development of physiologically based pharmacokinetic and physiologically based pharmacodynamic models for applications in toxicology and risk assessment. Toxicol. Lett., 79 (1–3), 35–44. Andersen, M.E., Birnbaum, L.S., Barton, H.A., and Eklund, C.R. (1997) Regional hepatic CYP1A1 and CYP1A2 induction with 2,3,7,8-tetrachlorodibenzo-p-dioxin evaluated with a multicompartment geometric model of hepatic zonation. Toxicol. Appl. Pharmacol., 144 (1), 145–155. Barton, H.A., Creech, J.R., Godin, C.S. et al. (1995) Chloroethylene mixtures: pharmacokinetic modeling and in vitro metabolism of vinyl chloride, trichloroethylene, and trans-1,2-dichloroethylene in rat. Toxicol. Appl. Pharmacol., 130 (2), 237–247. Bond, J.A., Csanady, G.A., Gargas, M.L. et al. (1994) 1,3-Butadiene: linking metabolism, dosimetry, and mutation induction. Environ. Health Perspect., 102 (Suppl 9), 87–94. Boom, S.P., Meyer, I., Wouterse, A.C., and Russel, F.G. (1998) A physiologically based kidney model for the renal clearance of ranitidine and the interaction with cimetidine and probenecid in the dog. Biopharm. Drug Dispos., 19 (3), 199–208. Calabrese, E.J. (1991) Multiple Chemical Interactions, Lewis Publishers, Chelsea, MI. Clewell, H.J. III and Andersen, M.E. (1985) Risk assessment extrapolations and physiological modeling. Toxicol. Ind. Health., 1 (4) 111–131. Chien, J.Y., Thummel, K.E., and Slattery, J.T. (1997) Pharmacokinetic consequences of induction of CYP2E1 by ligand stabilization. Drug Metab. Dispos., 25 (10), 1165–1175. Choi, H.K., Flynn, G.L., and Amidon, G.L. (1990) Transdermal delivery of bioactive peptides: The effect of n-decylmethyl sulfoxide, pH, and inhibitors on enkephalin metabolism and transport. Pharm. Res., 7 (11), 1099–1106. Dennison, J.E., Andersen, M.E., and Yang, R.S. (2003) Characterization of the pharmacokinetics of gasoline using PBPK modeling with a complex mixtures chemical lumping approach. Inhal. Toxicol., 15 (10), 961–986.
References
103
Dennison, J.E., Andersen, M.E., Clewell, H.J., and Yang, R.S. (2004) Development of a physiologically based pharmacokinetic model for volatile fractions of gasoline using chemical lumping analysis. Environ. Sci. Technol., 38 (21), 5674–5681. Dobrev, I.D., Andersen, M.E., and Yang, R.S. (2001) Assessing interaction thresholds for trichloroethylene in combination with tetrachloroethylene and 1,1,1-trichloroethane using gas uptake studies and PBPK modeling. Arch. Toxicol., 75 (3), 134–144. Dobrev, I.D., Andersen, M.E., and Yang, R.S. (2002) In silico toxicology: simulating interaction thresholds for human exposure to mixtures of trichloroethylene, tetrachloroethylene, and 1,1,1trichloroethane. Environ. Health Perspect., 110 (10), 1031–1039. Dreisbach, R.H. (1977) Cyanides, sulfides and cobalt, in Handbook of Poisoning, 9th edn, Lange Medical Publishing Co, Los Altos, CA, p. 241. el-Masri, H.A., Constan, A.A., Ramsdell, H.S., and Yang, R.S. (1996a) Physiologically based pharmacodynamic modeling of an interaction threshold between trichloroethylene and 1,1dichloroethylene in Fischer 344 rats. Toxicol. Appl. Pharmacol., 141 (1), 124–132. el-Masri, H.A., Tessari, J.D., and Yang, R.S. (1996b) Exploration of an interaction threshold for the joint toxicity of trichloroethylene and 1,1-dichloroethylene: utilization of a PBPK model. Arch. Toxicol., 70 (9), 527–539. Emond, C., Charbonneau, M., and Krishnan, K. (2005) Physiologically based modeling of the accumulation in plasma and tissue lipids of a mixture of PCB congeners in female SpragueDawley rats. J. Toxicol. Environ. Health A, 68 (16), 1393–1412. Filser, J.G., Johanson, G., Kessler, W. et al. (1993) A pharmacokinetic model to describe toxicokinetic interactions between 1,3-butadiene and styrene in rats: predictions for human exposure. IARC Sci. Publ., 127, 65–78. Goyer, R.A., Miller, C.R., Zhu, S.-Y., and Victery, W. (1989) Non-metallothionein-bound cadmium in the pathogenesis of cadmium nephrotoxicity in the rat. Toxicol. Appl. Pharmacol., 101, 49–54. Haddad, S., Pelekis, M., and Krishnan, K. (1996) A methodology for solving physiologically based pharmacokinetic models without the use of simulation softwares. Toxicol. Lett., 85, 113–126. Haddad, S., and Krishnan, K. (1998) Physiological modeling of toxicokinetic interactions: implications for mixture risk assessment. Environ. Health Perspect., 106 (Suppl 6), 1377–1384. Haddad, S., Tardif, R., Charest-Tardif, G., and Krishnan, K. (1999) Physiological modeling of the toxicokinetic interactions in a quaternary mixture of aromatic hydrocarbons. Toxicol. Appl. Pharmacol., 161 (3), 249–257. Haddad, S., Charest-Tardif, G., Tardif, R., and Krishnan, K. (2000a) Validation of a physiological modeling framework for simulating the toxicokinetics of chemicals in mixtures. Toxicol. Appl. Pharmacol., 167 (3), 199–209. Haddad, S., Charest-Tardif, G., and Krishnan, K. (2000b) Physiologically based modeling of the maximal effect of metabolic interactions on the kinetics of components of complex chemical mixtures. J. Toxicol. Environ. Health A, 61 (3), 209–223. Hayes, W.J. and Pearce, G.W. (1953) Pesticide formulation: relation to safety in use. J. Agr. Food Chem., 1, 466. Isaacs, K.K., Evans, M.V., and Harris, T.R. (2004) Visualization-based analysis for a mixed-inhibition binary PBPK model: determination of inhibition mechanism. J. Pharmacokinet. Pharmacodyn., 31 (3), 215–242. Ishigam, M., Uchiyama, M., Kondo, T. et al. (2001) Inhibition of in vitro metabolism of simvastatin by itraconazole in humans and prediction of in vivo drug–drug interactions. Pharm. Res., 18 (5), 622–631. Jacob, S.W., Bischel, M., and Herschler, R.J. (1964) Dimethyl sulfoxide: effects on the permeability of biologic membranes. Curr. Ther. Re., 6, 193. Jang, J.Y., Droz, P.O., and Kim, S. (2001) Biological monitoring of workers exposed to ethylbenzene and co-exposed to xylene. Int. Arch. Occup. Environ. Health, 74 (1), 31–37. Kanamitsu, S., Ito, K., Green, C.E. et al. (2000a) Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4. Pharm. Res., 17 (4), 419–426.
104
Physiologically Based Modeling of Pharmacokinetic Interactions in Chemical Mixtures
Kanamitsu, S.I., Ito, K., Okuda, H. et al. (2000b) Prediction of in vivo drug-drug interactions based on mechanism-based inhibition from in vitro data: inhibition of 5-fluorouracil metabolism by (E)-5-(2-Bromovinyl)uracil. Drug Metab. Dispos., 28 (4), 467–474. Keys, D.A., Schultz, I.R., Mahle, D.A., and Fisher, J.W. (2004) A quantitative description of suicide inhibition of dichloroacetic acid in rats and mice. Toxicol. Sci., 82 (2), 381–393. Krishnan, K. and Brodeur, J. (1991) Toxicological consequences of combined exposure to environmental pollutants. Arch. Complex Environ. Studies, 3 (3), 1–106. Krishnan, K. and Brodeur, J. (1994) Toxic interactions among environmental pollutants: corroborating laboratory observations with human experience. Environ. Health Perspect., 102 (Suppl 9), 11–17. Krishnan, K., Clewell, H.J. III and Andersen, M.E. (1994) Physiologically based pharmacokinetic analyses of simple mixtures. Environ. Health Persp., 102 (Suppl 9), 151–155. Krishnan, K., Andersen, M.E., Clewell, H.J. III et al. (1994) Physiologically Based Pharmacokinetic Modeling of Chemical Mixtures, Academic Press, New York, pp. 399–346. Krishnan, K., Haddad, S., Beliveau, M., and Tardif, R. (2002) Physiological modeling and extrapolation of pharmacokinetic interactions from binary to more complex chemical mixtures. Environ. Health Perspect., 110 (Suppl 6), 989–994. Krishnan, K. and Andersen, M.E. (2007) Physiologically based pharmacokinetic modeling in toxicology, in Principles and Methods of Toxicology, 5th edn (ed. A.W. Hayes), Taylor and Francis, Philadelphia, pp. 231–292. Krishnan, K. and Pelekis, M. (1995) Hematotoxic interactions: occurrence, mechanisms and predictability. Toxicology, 105 (2–3), 355–364. Kurihara-Bergstrom, T., Flynn, G.L., and Higuchi, W.L. (1987) Physicochemical study of percutaneous absorption enhancement by dimethyl sulfoxide: Dimethyl sulfoxide mediation of vidarabine (ara-A) permeation of hairless mouse skin. J. Invest. Dermatol., 89, 274–280. Leavens, T.L. and Bond, J.A. (1996) Pharmacokinetic model describing the disposition of butadiene and styrene in mice. Toxicology, 113 (1–3), 310–313. Luecke, R.H. and Wosilait, W.D. (1979) Drug elimination interactions: analysis using a mathematical model. J. Pharmacokinet. Biopharm., 7 (6), 629–641. Oskarsson, A. and Lind, B. (1985) Increased lead levels in brain after long term treatment with lead and dithiocarbamate or thirum derivatives in rats. Acta Pharmacol. Toxicol., 56, 309–315. Pelekis, M. and Krishnan, K. (1997) Assessing the relevance of rodent data on chemical interactions for health risk assessment purposes: a case study with dichloromethane-toluene mixture. Regul. Toxicol. Pharmacol., 25 (1), 79–86. Price, K. and Krishnan, K. (2005) An Integrated QSAR-PBPK Model for Simulating Pharmacokinetics of Chemicals in Mixtures. 44rd Annual Meeting of the Society of Toxicology, New Orleans, LA. March 6–10, 2005. Purcell, K.J., Cason, G.H., Gargas, M.L. et al. (1990) In vivo metabolic interactions of benzene and toluene. Toxicol. Lett., 52 (2), 141–152. Qiao, G.L., Brooks, J.D., Baynes, R.E., and Monteiro-Riviere, N.A. (1996) The use of mechanistically defined chemical mixtures (MDCM) to assess component effects on the percutaneous absoption and cutaneous disposition of topically exposed chemicals. Toxicol. Appl. Pharmacol., 141, 473–486. Reddy, M.B., Yang, R.S., Andersen, M.E., and Clewell, H.J. III (2005) Physiologically Based Pharmacokinetic Modeling: Science and Applications, John Wiley & Sons, Inc, Hoboken, NJ. Riihim¨aki, V. (1979) Percutaneous absorption of m-xylene from a mixture of m-xylene and isobutanolin man. Scand. J. Work Environ. Health, 5, 143–150. Russel, F.G., Wouterse, A.C., and van Ginneken, C.A. (1987) Physiologically based pharmacokinetic model for the renal clearance of salicyluric acid and the interaction with phenolsulfonphthalein in the dog. Drug Metab. Dispos., 15 (5), 695–701. Russel, F.G., Wouterse, A.C., and Van Ginneken, C.A. (1989) Physiologically based pharmacokinetic model for the renal clearance of iodopyracet and the interaction with probenecid in the dog. Biopharm. Drug Dispos., 10 (2), 137–152. Sarangapani, R., Teeguarden, J., Plotzke, K.P. et al. (2002) Dose-response modeling of cytochrome p450 induction in rats by octamethylcyclotetrasiloxane. Toxicol. Sci., 67 (2), 159–172.
References
105
Segel, I.H. (1975) Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems, John Wiley & Sons Canada Ltd, Toronto, Canada, pp. 992. Shigematsu, I., Kikuchi, T., Nogawa, K. et al. (1989) Critical Review on Critical Concentration of Cadmium in the Kidney, International Lead Zinc Research Organization, Research Triangle Park, NC. Sugita, O., Sawada, Y., Sugiyama, Y. et al. (1982) Physiologically based pharmacokinetics of drugdrug interaction: a study of tolbutamide-sulfonamide interaction in rats. J. Pharmacokinet. Biopharm., 10 (3), 297–316. Tardif, R. and Charest-Tardif, G. (1999) The importance of measured end-points in demonstrating the occurrence of interactions: a case study with methylchloroform and m-xylene. Toxicol. Sci., 49 (2), 312–317. Tardif, R., Lapare, S., Krishnan, K., and Brodeur, J. (1993) Physiologically based modeling of the toxicokinetic interaction between toluene and m-xylene in the rat. Toxicol. Appl. Pharmacol., 120 (2), 266–273. Tardif, R., Lapare, S., Charest-Tardif, G. et al. (1995) Physiologically-based pharmacokinetic modeling of a mixture of toluene and xylene in humans. Risk Anal., 15 (3), 335–342. Tardif, R., Charest-Tardif, G., Brodeur, J., and Krishnan, K. (1997) Physiologically based pharmacokinetic modeling of a ternary mixture of alkyl benzenes in rats and humans. Toxicol. Appl. Pharmacol., 144 (1), 120–134. Thrall, K.D., and Poet, T.S. (2000) Determination of biokinetic interactions in chemical mixtures using real-time breath analysis and physiologically based pharmacokinetic modeling. J. Toxicol. Environ Health A, 59 (8), 653–670. Voet, D. and Voet, J.G. (2004) Biochemistry, 3rd edn, John Wiley & Sons Canada Ltd, Toronto, Canada, pp. 1616. Webb, M. (1986) Role of metallothionein in cadmium metabolism, in Cadmium (ed. E.C. Foulkes), Springer Verlag, Berlin, pp. 281–337. Yu, X., Johanson, G., Ichihara, G. et al. (1998) Physiologically Based Pharmacokinetic Modeling of Metabolic Interactions between n-Hexane and Toluene in Humans. J. Occup. Health, 40 (4), 293–301.
5 Physiological Parameters and Databases for PBPK Modeling* Douglas O. Johns1 , Elizabeth Oesterling Owens1 , Chad M. Thompson2 , Babasaheb Sonawane2 , Dale Hattis3 , and Kannan Krishnan4 1
National Center for Environmental Assessment, US Environmental Protection Agency, Research Triangle Park, NC, USA 2 National Center for Environmental Assessment, US Environmental Protection Agency, Washington, DC, USA 3 Marsh Institute, Center for Technology, Environment and Development, Clark University, USA 4 Groupe de Recherche Interdisciplinaire en Sant´e et D´epartement de Sant´e Environnementale et Sant´e au Travail, Universit´e de Montr´eal, Canada
5.1 Introduction One of the key issues in the development of physiologically based pharmacokinetic (PBPK) models involves the choice of values of various physiological parameters used to represent animal and human physiological processes. These parameters include, among others, body weight and body surface area, alveolar ventilation, blood flow to specific organs and tissues, organ and tissue volumes, and glomerular filtration rate. Physiological parameters must be well characterized both in terms of measures of central tendency as well as variability in order for a PBPK model to accurately simulate the absorption, distribution, metabolism, and excretion of environmental chemicals or drugs in a given population. The sensitivity of a model to changes in a given physiological parameter will vary depending in part on ∗ The views expressed in this chapter are those of the authors and do not necessarily reflect the views or policies of the US Environmental Protection Agency.
Quantitative Modeling in Toxicology C 2010 John Wiley & Sons, Ltd
Edited by Kannan Krishnan and Melvin E. Andersen
108
Physiological Parameters and Databases for PBPK Modeling
chemical specific physiochemical and biochemical parameters such as partition coefficients and hepatic clearance. As evaluations of PBPK models have gained support for use in human health risk assessments (Chiu et al., 2007), a greater emphasis has been placed on reducing uncertainty and better characterizing variability within and between models by eliminating inconsistencies in the information sources used to establish appropriate physiological parameter values for model development. Initial efforts were undertaken by Arms and Travis (1988) as well as Davies and Morris (1993) to create a compendium of reference values of physiological parameters for use in PBPK modeling. However, these publications presented only single reference values for physiological parameters in humans and various animal species, with no measures of variability provided. In a more recent and comprehensive review, Brown et al. (1997) provided summary values of physiological parameters that were derived by averaging mean values reported in individual studies. The variability of these parameter values was also presented as the standard deviations of the reported means. Although this work did provide very useful information related to the variability of physiological parameters, no individuallevel data were presented or used in deriving reference values. In addition, data on tissue volumes and blood flow rates were often grouped without stratification by age or gender. Age-related differences in physiological function can significantly affect the pharmacokinetics of environmental chemicals in various subpopulations of interest, namely young children and older adults (Ginsberg et al., 2002, 2005). Values of physiological parameters from these subpopulations have been assimilated from the scientific literature of both humans and experimental animals. Gentry et al. (2004) developed an extensive dataset of physiological parameter values relevant to PBPK modeling among neonate and young (<60 days old) mice and Sprague-Dawley rats. This database has recently been made available to the public (http://www.epa.gov/ncct/parameters.html). Thompson et al. (2009) have recently published a review of physiological parameters in older adult humans, as well as a description of a database containing parameter values from adults over the age of 65 years. This database (http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=188288) is an extension of earlier work involving early human life stage physiological parameters, which was conducted by the International Life Sciences Institute (ILSI) under a cooperative agreement with the US Environmental Protection Agency (International Life Sciences Institute, 2008). In the databases described above, values of body weight, tissue volumes, tissue flows, and so on, have been stratified by species, strain, age, and gender, with individual data presented where available. The National Center for Environmental Assessment and the National Center for Computational Toxicology of the US Environmental Protection Agency’s Office of Research and Development are currently in the process of developing publicly available physiological parameters databases for both humans and experimental laboratory animals that will be continually updated as additional data become available. The initial steps in populating these databases have involved evaluating the data contained within the databases developed for the early life stages of humans and animals (Gentry et al., 2004; International Life Sciences Institute, 2008) as well as older humans (Thompson et al., 2009). A current project is underway to expand these databases to include available data on physiological parameters in adult humans and rodents, in what is essentially an update to the work of Brown et al. (1997). In this undertaking, all of the articles cited in Brown et al. (1997) have been
Introduction
109
collected and evaluated, and an additional literature search and review conducted to identify other physiological parameter data for humans aged 19–64 years, and rats and mice 60 days of age and older. Literature searches were conducted in both PubMed and Current Contents databases using search terms specific to species (human, rat, mouse), in combination with physiological parameter-specific terms related to body weight and body mass index, cardiac output, alveolar ventilation, tissue volumes, tissue blood flow rates, tissue composition, and clearance parameters including glomerular filtration rate. Clinical, toxicological, and in vivo pharmacokinetic studies with various drugs and environmental chemicals were excluded except in cases where the study reported measurements of physiological parameters in untreated humans or animals. Data presented in figures or without appropriate units were also excluded from consideration. Values were entered in the databases as either group or individual data and all entries were independently evaluated by two scientists. The structure of these databases is similar to that used by Thompson et al. (2009) with fields for age, gender, body weight, specific parameter evaluated, value of parameter, group or individual data, parameter variability, and number evaluated. The combined efforts to compile quantitative information on physiological parameters described in this chapter will ultimately be harmonized to produce two comprehensive databases representing parameters from across life stages, one for experimental animals and one for humans. In addition to physiological data taken from individual studies, the animal database will contain the suggested reference or summary values of tissue volumes and blood flow rates for rats and mice presented in Brown et al. (1997). Similarly, for comparison purposes, the human database will contain summary values for tissue volumes, tissue blood volumes, tissue density, tissue composition, and tissue blood flow rates which are presented in ICRP (2003), Leggett and Williams (1991), ICRP (1975), Woodard and White (1986), and Williams and Leggett (1989), respectively. These databases will serve as an evolving central repository of physiological parameter data, which will enable more consistent PBPK development within the scientific community. For the purpose of this chapter, the recently developed adult human physiological parameters database described above has been merged with the database described in Thompson et al. (2009), which contains parameters for older adults as well as developing infants and children (International Life Sciences Institute, 2008). This allows for a more comprehensive description of data availability and variability in physiological parameters across life stages. Database entries include both individual and grouped data, with grouped data typically representing physiological parameter values across a range of ages. In the analyses presented below, parameter values have been stratified by age, using the age of the individual, or, for grouped data, the average age or midpoint of the range of ages. The majority of the data have been collected from cross-sectional studies, with data collected at one time point from an individual or group of individuals. However, in some cases data were collected longitudinally, with parameters measured from the same individual(s) on multiple occasions over time. The availability and variability of data has not been stratified by gender or ethnicity, as the majority of available data comes from males and the ethnicity of individuals is frequently not reported. Although the database does include a limited number of parameter values from health-compromised individuals, only data from relatively healthy individuals are included in the analyses. Parameter units were not consistent across studies, with studies reporting both absolute and relative tissue weights and flows. To allow
110
Physiological Parameters and Databases for PBPK Modeling
for the utilization of the maximum amount of data available, entries presenting relative tissue weights or flows were normalized to body or tissue weight.
5.2 Data Availability The data collected were sorted by tissue weights and volumes, flows, and intake values for healthy humans. Flow data included values such as tissue blood flows, creatinine clearance, glomerular filtration rates, bile flow, cardiac index, and cardiac output. Intake values were comprised of parameters such as energy intake, alveolar ventilation, tidal volume, minute ventilation, and vital capacity. The values were further stratified by age into the following categories: <1, 1–10, 11–20, 21–35, 36–50, 51–60, 61–70, 71–80, and >80 years of age. This age grouping classification was created as a matter of convenience in presenting the data and does not necessarily reflect breakpoints of ages where differences in physiological function have been demonstrated. Tables 5.1–5.3 present the data availability for healthy individuals in each age group. The information was analyzed based on the number of data points and time points (individual, midpoint, or average age) available for each age-stratified parameter and grouped into datarich (≥20 entries) to data-poor (1-2 entries) categories. Parameters that lacked sufficient individual level data were labeled as data gaps. Both individual and group level data were included in these analyses. The majority of physiological parameters available were tissue weights and volumes. Humans lacked a number of tissue weights in young individuals, including values for heart, kidney, lung, and spleen (Table 5.1). With increasing age, the number of tissues with available values increased, but the replication of these values decreased, such that few to no parameters were considered data rich. Tissue flow rates were data rich in some age groups, but in some cases were extremely limited, particularly in early life stages (Table 5.2). Human intake data were extremely limited in the older age populations (Table 5.3).
5.3 Data Variability Values of physiological parameters used in PBPK models are inherently variable and uncertain. The variability of these values represents, in part, the degree to which the parameters differ across a population. It is important to recognize and, to the extent possible, characterize this variability in order to better understand and characterize the variability in the overall model in which the parameters are used. The figures presented below illustrate this variability and range in the parameter measurements. The data include measured values from both males and females, and were not separated by ethnicity. This inclusive approach could account for some of the spread about the values, since both factors are known to influence physiological parameters. 5.3.1 Body Weight Body weight was provided for a majority of the studies compiled (Figure 5.1). The plotted graph only represents healthy individuals and excludes individuals classified as obese, which will likely result in an underestimation of the variability in this parameter. The large
Data Variability
111
Table 5.1 Individual healthy human data availability – Tissue Volume/Weight (data points–time points). Age (years)
Data rich
<1
Brain (23–11) Liver (25–13)
1–10
Brain (20–10)
11–20
21–35
36–50
Fat-free mass (27–10) Fat-mass (27–10) Total body water (24–9)
Data moderate
Data poor
Data gap
Fat volume (2–2) Protein volume (2–2) Water volume (2–2)
Adrenals Blood Fat mass Fat-free mass Heart Kidney Lung Spleen Adrenals Blood Fat mass Fat-free mass Heart Kidney Lung Spleen Adrenals Blood Fat mass Fat-free mass Heart Kidney Lung Spleen
Liver (19–10)
Fat volume (1–1) Protein volume (1–1) Water volume (1–1)
Brain (16–8) Liver (16–8)
Fat mass (1–1) Fat-free mass (1–1) Total body water (1–1)
Blood (10–4) Heart (10–3) Kidney (17–7) Liver (5–4) Lung (3–2) Plasma (10–4) Pulmonary blood volume (6–5) Spleen (4–4) Thyroid (6–4) Blood (21–10) Adrenals (4–3) Bone (25–3) Arm (3–3) Kidney Body fat (12–9) (56–17) Body water (5–5) Lung (27–8) Bone marrow (4–1) Thyroid Brain (9–8) (23–10) Colon (4–1) Eyes (4–3) Fat-free mass (13–10) Fat mass (6–4) Gall bladder (4–3) Heart (16–10) Lean body mass (3–3) Leg (3–3)
Adrenals (1–1) Body fat (1–1) Body water (2–2) Brain (2–2) Pancreas (1–1) Pituitary (1–1) Prostate (1–1)
Adipose tissue (2–1) Body fat mass index (2–1) Breasts (2–1) Cartilage (2–1) Epididymis (1–1) Fallopian tubes (1–1) Fat (2–1) Fat-free mass index (2–1) Larynx (2–1) Esophagus (2–1) Ovaries (1–1) Rectosigmoid (2–1) (Continued)
112
Physiological Parameters and Databases for PBPK Modeling
Table 5.1 (Continued) Age (years)
Data rich
51–60
61–70
Fat-free mass (22–7) Fat mass (44–15)
Data moderate
Data poor
Liver (19–10) Muscle (6–4) Pancreas (14–7) Pituitary (4–3) Plasma (19–10) Prostate (3–3) Pulmonary blood volume (3–3) Spleen (16–9) Stomach (4–3) Thymus (3–2) Urinary bladder (4–3) Blood (6–4) Body fat (3–3) Kidney (12–5) Liver (5–4) Plasma (6–4)
Salivary glands (2–1) Skin (2–1) Small intestine (2–1) Teeth (2–1) Testes (2–1) Tongue (2–1) Total body water (1–1) Trachea (2–1) Ureters (2–1) Urethra (2–1) Uterus (2–1)
Adipose tissue (3–2) Blood (3–2) Body water (10–3) Brain (4–2) Extracellular water (3–2) Fat volume (6–4) Heart (4–2) Intracellular water (3–2) Kidney (16–6) Lean body mass (7–5) Liver (14–3) Muscle (7–3) Skin (3–2) Spleen (5–2) Thyroid (3–1)
Adipose tissue (1–1) Adrenals (1–1) Arm (1–1) Body water (2–2) Bone (1–1) Brain (1–1) Fat-free mass (2–2) Fat mass (1–1) Heart (1–1) Leg (1–1) Lung (2–1) Muscle (2–2) Pancreas (1–1) Pituitary (1–1) Prostate (1–1) Pulmonary blood volume (1–1) Skin (1–1) Spleen (2–2) Thyroids (5–3) Adrenal (1–1) Body fat (1–1) Bone (3–2) Gall bladder (1–1) Lean tissue mass (1–1) Lung (2–1) Pancreas (1–1) Pituitary (1–1) Plasma (1–1) Prostate (1–1) Testes (1–1)
Data gap
Data Variability
113
Table 5.1 (Continued) Age (years)
Data rich
Data moderate
Data poor
71–80
Fat-free mass (35–10) Fat mass (65–21)
Body fat (4–1) Body water (12–6) Bone free lean mass (3–2) Brain (4–3) Fat volume (7–3) Heart (4–3) Kidney (9–3) Lean body mass (7–6) Liver (5–3) Spleen (5–3)
Adrenals (1–1) Blood (2–2) Body fat index (2–1) Bone free mass (1–1) Extracellular water (1–1) Fat-free mass index (2–1) Intracellular water (1–1) Lung (2–1) Muscle (2–1) Pancreas (1–1) Pituitary (1–1) Prostate (1–1) Testes (1–1) Thyroid (1–1) Adrenals (1–1) Lean tissue mass (1–1) Prostate (1–1) Testes (1–1)
>80
Adipose (3–3) Body water (4–3) Bone (3–3) Brain (7–5) Extracellular water (4–3) Fat-free mass (12–5) Fat mass (11–6) Heart (6–4) Intracellular water (4–3) Kidney (17–8) Liver (13–10) Lung (4–2) Muscle (7–5) Skin (3–3) Spleen (9–6) Thyroid (3–3)
Data gap
Blood
Thomas, 1962; Shock et al., 1963; Young et al., 1963; Calloway, Foley, and Lagerbloom, 1965; Lesser and Deutsch, 1967; Malina, 1969; Forbes and Reina, 1970; Kjellberg and Reizenstein, 1970; Sato, Miwa, and Tauchi, 1970; Parizkova et al., 1971; Tauchi, Tsuboi, and Okutomi, 1971; Novak, 1972; Chien et al., 1975; Rasmussen et al., 1978; Swift et al., 1978; Bach et al., 1981; Hegedus et al., 1983; Clarys, Martin, and Drinkwater, 1984; Fulop et al., 1985; Pankow, Michalak, and McGee, 1985; Berghout et al., 1987; Inoue and Otsu, 1987; Deurenberg et al., 1989; Wynne et al., 1989; Hanzlick and Rydzewski, 1990; Schmitz, Nyengaard, and Bendtsen, 1990; Schwartz et al., 1990; Garby et al., 1993; Goldberg et al., 1993; Brudin et al., 1994; Kenney and Zappe, 1994; Khosla et al., 1996; Gallagher et al., 1997; Ogiu et al., 1997; Sprogoe-Jakobsen and Sprogoe-Jakobsen, 1997; Visser et al., 1997; Dinenno et al., 1999; Andersen et al., 2000; Gillette-Guyonnet et al., 2000; Hagberg et al., 2000; Bedogni et al., 2001; de la Grandmaison, Clairand, and Durigon, 2001; Dinenno et al., 2001; Frankenfield et al., 2001; Ito et al., 2001; Kyle et al., 2001a, b, c; Santana et al., 2001; Wang et al., 2001; Yee et al., 2001; Chumlea et al., 2002; Pedersen et al., 2002; Puggaard et al., 2002; Schutz, Kyle, and Pichard, 2002; Visser et al., 2002; International Commission of Radiological Protection, 2003; Alcorn and McNamara, 2003; Boito et al., 2003; Dey et al., 2003; Kyle et al., 2003; Movsesyan et al., 2003; Proctor et al., 2003; Zamboni et al., 2003; Chouker et al., 2004; Kanaya et al., 2004; Kwan, Woo, and Kwok, 2004; Kyle et al., 2004a, b; Nies, Chen, and Vander Wal, 2004; Strotmeyer et al., 2004; Goodpaster et al., 2005; Kyle et al., 2005; Chirachariyavej et al., 2006; Park et al., 2006.
114
Physiological Parameters and Databases for PBPK Modeling
Table 5.2 Individual healthy human data availability – Human blood flow (data points–time points). Age (years)
Data rich
Data moderate
Data poor
Data gap
<1
Creatinine (18–7) Glomerular filtration rate (66–26)
Cutaneous (1–1) Diastolic blood pressure (2–1) Liver (1–1) Muscle (1–1) Subcutaneous (1–1) Systolic blood pressure (2–1) Umbilical artery pulsality index (1–1) Umbilical venous area (1–1) Umbilical venous flow (1–1) Umbilical venous velocity (1–1) Urinary albumin excretion (1–1)
Brain Cardiac index Cardiac output Kidney Lung
1–10
Glomerular filtration rate (26–9)
Cystatin C (9–4) Filtered beta-2-microglobin (6–6) Fraction urine flow rate (6–6) Fractional reabsorption of beta-2-microglobin (6–6) Fractional reabsorption of sodium (6–6) Hematocrit (6–6) Plasma beta-2-microglobulin concentration (6–6) Plasma flow (7–5) Plasma osmolality (6–6) Reabsorption of beta-2-microglobin (6–6) Serum Creatinine (9–4) Urine beta-2-microglobin (12–6) Urine flow rate (6–6) Creatinine (5–3) Cystatin C (5–3) Liver (7–2) Plasma flow (5–2) Serum Creatinine (5–5)
Urinary albumin excretion (1–1)
Cardiac index (3–3) Creatinine (2–2) Cystatin (2–2) Glomerular filtration rate (5–6) Liver (4–2)
Absolute distal re-absorption (1–1) Absolute proximal re-absorption (1–1) Distal Delivery (1–1) Renal plasma flow (1–1) Tubular creatinine secretion (1–1)
Brain Cardiac index Cardiac output Kidney Lung Brain Cardiac output Kidney Lung
11–20
Data Variability
115
Table 5.2 (Continued) Age (years)
Data rich
Data moderate
Data poor
21–35
Brain (35–9) Effective renal plasma flow (115–10) Glomerular filtration rate (133–14) Liver (28–13) Portal (28–13)
Adipose tissue (4–2) Bone marrow (10–2) Cardiac index (17–17) Cardiac output (17–10) Forearm (16–2) Leg (4–3) Large intestine (4–1) Muscle (3–2) Renal plasma flow (4–2)
36–50
Brain (22–8)
Calf (3–1) Cardiac index (16–16) Cardiac output (7–5) Effective renal plasma flow (10–2) Forearm (3–1) Glomerular filtration rate (16–5) Liver (7–3) Portal (6–5)
Adrenals (2–1) Bone (2–1) Creatinine excretion (1–1) GI tract (2–2) Heart (2–1) Hepatic artery (2–1) Iliac (2–1) Kidney (2–1) Lung (2–1) Lymph node (2–1) Pancreas (2–1) Skin (2–1) Small intestine (2–1) Spleen (2–1) Stomach and esophagus (2–1) Thyroid (2–1) Uterine (1–1) Adipose (1–1) Arm (2–1) Creatinine excretion (2–2) Muscle (1–1) Pancreas (1–1) Renal plasma flow (2–1) Skeleton (2–2) Skin (1–1) Thigh (1–1) Creatinine excretion (1–1) Forearm (2–2) Leg (1–1) Muscle (1–1) Skin (1–1) Splanchnic (2–1) Creatinine excretion (1–1) Femoral (1–1) Liver (1–1) Muscle (1–1)
51–60
61–70
Brain (23–8) Glomerular filtration rate (23–11)
Brain (17–5) Cardiac index (11–11) Cardiac output (4–4) Glomerular filtration rate (4–2) Liver (4–3) Portal (8–4) Adipose (4–3) Cardiac index (14–12) Cardiac output (10–5) Forearm (4–2) Portal flow (4–2) Renal (15–10) Splanchnic (8–6)
Data gap
Kidney Lung
Kidney Lung
Lung
(Continued)
116
Physiological Parameters and Databases for PBPK Modeling
Table 5.2 (Continued) Age (years) 71–80
Data rich
Data moderate
Data poor
Data gap
Brain (26–6) Glomerular filtration rate (38–12)
Adipose tissue (3–2) Bone marrow (3–1) Cardiac index (12–11) Cardiac output (4–3) Renal (15–7)
Calf (1–1) Foot (1–1) Muscle (1–1) Portal (1–1) Skin (1–1) Splanchnic (1–1) Forearm (1–1) Portal (2–1)
Liver Lung
>80
Brain (9–5) Cardiac index (3–2) Cardiac output (3–2) Glomerular filtration rate (13–9) Liver (5–1) Renal (6–4)
Lung
Bradley et al., 1945; Bolomey et al., 1949; Davies and Shock, 1950; Olbrich et al., 1950; Sherlock et al., 1950; Fazekas, Alman, and Bessman, 1952; Fazekas, Kleh, and Witkin, 1953; Scheinberg et al., 1953; Schieve and Wilson, 1953; Brandfonbrener, Landowne, and Shock, 1955; Allwood, 1958; Hellon and Clarke, 1959; Fazekas et al., 1960; Granat